View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2018	Feb. 19, 2019	Jun. 30, 2018
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Entity Registrant Name	Jazz Pharmaceuticals plc
Entity Central Index Key	0001232524
Trading Symbol	jazz
Entity Filer Category	Large Accelerated Filer
Current Fiscal Year End Date	--12-31
Smaller Reporting Company	false
Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		57,055,731
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	Yes
Entity Public Float			$ 7,515,311,963

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 309,622	$ 386,035
Investments	515,000	215,000
Accounts receivable, net of allowances of $534 and $4,162 at December 31, 2018 and 2017, respectively	263,838	224,129
Inventories	52,956	43,245
Prepaid expenses	25,017	23,182
Other current assets	67,572	76,686
Total current assets	1,234,005	968,277
Property, plant and equipment, net	200,358	170,080
Intangible assets, net	2,731,334	2,979,127
Goodwill	927,630	947,537
Deferred tax assets, net	57,879	34,559
Deferred financing costs	9,589	7,673
Other non-current assets	42,696	16,419
Total assets	5,203,491	5,123,672
Current liabilities:
Accounts payable	40,602	24,368
Accrued liabilities	264,887	198,779
Current portion of long-term debt	33,387	40,605
Income taxes payable	1,197	21,577
Deferred revenue	5,414	8,618
Total current liabilities	345,487	293,947
Deferred revenue, non-current	9,581	16,115
Long-term debt, less current portion	1,563,025	1,540,433
Deferred tax liabilities, net	309,097	383,472
Other non-current liabilities	218,879	176,608
Commitments and contingencies (Note 12)
Shareholders’ equity:
Ordinary shares, nominal value $0.0001 per share; 300,000 shares authorized; 57,504 and 59,898 shares issued and outstanding at December 31, 2018 and 2017, respectively	6	6
Non-voting euro deferred shares, €0.01 par value per share; 4,000 shares authorized, issued and outstanding at both December 31, 2018 and 2017	55	55
Capital redemption reserve	472	472
Additional paid-in capital	2,113,630	1,935,486
Accumulated other comprehensive loss	(197,791)	(140,878)
Retained earnings	841,050	917,956
Total shareholders’ equity	2,757,422	2,713,097
Total liabilities and shareholders’ equity	$ 5,203,491	$ 5,123,672

Consolidated Balance Sheets (Parenthetical) $ in Thousands	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2018 € / shares	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2017 € / shares
Current assets:
Accounts receivable, allowances \| $	$ 534		$ 4,162
Shareholders’ equity:
Ordinary shares, nominal value (in dollars per share) \| $ / shares	$ 0.0001		$ 0.0001
Ordinary shares, authorized (in shares)	300,000,000		300,000,000
Ordinary shares, issued (in shares)	57,504,000		58,898,000
Ordinary shares, outstanding (in shares)	57,504,000		58,898,000
Nonvoting Euro Deferred shares, par value (in euros per share) \| € / shares		€ 0.01		€ 0.01
Nonvoting Euro Deferred shares, authorized (in shares)	4,000,000		4,000,000
Nonvoting Euro Deferred shares, issued (in shares)	4,000,000		4,000,000
Nonvoting Euro Deferred shares, outstanding (in shares)	4,000,000		4,000,000

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenues:
Total revenues	$ 1,890,922	$ 1,618,693	$ 1,487,973
Operating expenses:
Cost of product sales (excluding amortization of intangible assets)	121,544	110,188	105,386
Selling, general and administrative	683,530	544,156	502,892
Research and development	226,616	198,442	162,297
Intangible asset amortization	201,498	152,065	101,994
Impairment charges	42,896	0	0
Acquired in-process research and development	0	85,000	23,750
Total operating expenses	1,276,084	1,089,851	896,319
Income from operations	614,838	528,842	591,654
Interest expense, net	(77,075)	(77,756)	(61,942)
Foreign exchange gain (loss)	(6,875)	(9,969)	3,372
Loss on extinguishment and modification of debt	(1,425)	0	(638)
Income before income tax provision (benefit) and equity in loss of investees	529,463	441,117	532,446
Income tax provision (benefit)	80,162	(47,740)	135,236
Equity in loss of investees	2,203	1,009	379
Net income	$ 447,098	$ 487,848	$ 396,831
Net income per ordinary share:
Basic (in dollars per share)	$ 7.45	$ 8.13	$ 6.56
Diluted (in dollars per share)	$ 7.30	$ 7.96	$ 6.41
Weighted-average ordinary shares used in per share calculations - basic (in shares)	59,976	60,018	60,500
Weighted-average ordinary shares used in per share calculations - diluted (in shares)	61,221	61,317	61,870
Product sales, net
Revenues:
Total revenues	$ 1,869,473	$ 1,601,399	$ 1,477,261
Royalties and contract revenues
Revenues:
Total revenues	$ 21,449	$ 17,294	$ 10,712

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Statement of Comprehensive Income [Abstract]
Net income	$ 447,098	$ 487,848	$ 396,831
Other comprehensive income (loss):
Foreign currency translation adjustments	(58,988)	174,973	(49,861)
Unrealized gain on hedging activities, net of income tax provision of $289, $212 and $0, respectively	2,022	1,482	0
Other comprehensive income (loss)	(56,966)	176,455	(49,861)
Comprehensive income attributable to Jazz Pharmaceuticals plc	$ 390,132	$ 664,303	$ 346,970

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Statement of Comprehensive Income [Abstract]
Unrealized gain on hedging activities, income tax provision	$ 289	$ 212	$ 0

Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Ordinary Shares	Non-voting Euro Deferred	Capital Redemption Reserve	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Cumulative effect adjustment from adoption of new accounting standards	$ 107,687				$ 0		$ 107,687
Beginning balance (in shares) at Dec. 31, 2015		61,305	4,000
Beginning balance at Dec. 31, 2015	1,598,646	$ 6	$ 55	$ 471	1,562,900	$ (267,472)	302,686
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Issuance of ordinary shares in conjunction with exercise of share options (in shares)		399
Issuance of ordinary shares in conjunction with exercise of share options	16,880				16,880
Issuance of ordinary shares under employee stock purchase plan (in shares)		70
Issuance of ordinary shares under employee stock purchase plan	7,294				7,294
Issuance of ordinary shares in conjunction with vesting of restricted stock units (in shares)		289
Shares withheld for payment of employee's withholding tax liability	(21,234)				(21,234)
Share-based compensation	99,392				99,392
Shares repurchased (in shares)		(2,243)
Shares repurchased	(278,296)			1			(278,297)
Other comprehensive loss	(49,861)					(49,861)
Net income	396,831						396,831
Ending balance (in shares) at Dec. 31, 2016		59,820	4,000
Ending balance at Dec. 31, 2016	1,877,339	$ 6	$ 55	472	1,665,232	(317,333)	528,907
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Issuance of Exchangeable Senior Notes	149,767				149,767
Issuance of ordinary shares in conjunction with exercise of share options (in shares)		428
Issuance of ordinary shares in conjunction with exercise of share options	22,683				22,683
Issuance of ordinary shares under employee stock purchase plan (in shares)		104
Issuance of ordinary shares under employee stock purchase plan	9,141				9,141
Issuance of ordinary shares in conjunction with vesting of restricted stock units (in shares)		250
Shares withheld for payment of employee's withholding tax liability	(18,589)				(18,589)
Share-based compensation	107,252				107,252
Shares repurchased (in shares)		(704)
Shares repurchased	(98,799)						(98,799)
Other comprehensive loss	176,455					176,455
Net income	487,848						487,848
Ending balance (in shares) at Dec. 31, 2017		59,898	4,000
Ending balance at Dec. 31, 2017	2,713,097	$ 6	$ 55	472	1,935,486	(140,878)	917,956
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Cumulative effect adjustment from adoption of new accounting standards	(279)					53	(332)
Issuance of ordinary shares in conjunction with exercise of share options (in shares)		772
Issuance of ordinary shares in conjunction with exercise of share options	82,918				82,918
Issuance of ordinary shares under employee stock purchase plan (in shares)		111
Issuance of ordinary shares under employee stock purchase plan	10,419				10,419
Issuance of ordinary shares in conjunction with vesting of restricted stock units (in shares)		253
Shares withheld for payment of employee's withholding tax liability	(17,925)				(17,925)
Share-based compensation	102,732				102,732
Shares repurchased (in shares)		(3,530)
Shares repurchased	(523,672)						(523,672)
Other comprehensive loss	(56,966)					(56,966)
Net income	447,098						447,098
Ending balance (in shares) at Dec. 31, 2018		57,504	4,000
Ending balance at Dec. 31, 2018	$ 2,757,422	$ 6	$ 55	$ 472	$ 2,113,630	$ (197,791)	$ 841,050

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Operating activities
Net income	$ 447,098	$ 487,848	$ 396,831
Adjustments to reconcile net income to net cash provided by operating activities:
Intangible asset amortization	201,498	152,065	101,994
Share-based compensation	102,441	106,900	98,771
Impairment charges	42,896	0	0
Depreciation	15,233	13,089	11,786
Acquired in-process research and development	0	85,000	23,750
Loss on disposal of assets	655	473	47
Deferred tax benefit	(88,815)	(225,591)	(41,163)
Provision for losses on accounts receivable and inventory	4,728	2,190	2,209
Loss on extinguishment and modification of debt	1,425	0	638
Amortization of debt discount and deferred financing costs	43,960	30,026	22,133
Other non-cash transactions	4,499	14,321	(3,741)
Changes in assets and liabilities:
Accounts receivable	(40,132)	12,278	(25,603)
Inventories	(18,512)	(8,667)	(17,024)
Prepaid expenses and other current assets	6,697	(26,874)	(15,700)
Other non-current assets	(320)	119	267
Accounts payable	17,040	214	361
Accrued liabilities	71,208	(6,578)	11,989
Income taxes payable	(19,735)	16,331	2,962
Deferred revenue	(7,497)	21,009	(1,315)
Other non-current liabilities	14,537	18,934	23,199
Net cash provided by operating activities	798,904	693,087	592,391
Investing activities
Acquisition of investments	(1,165,915)	(385,000)	(132,181)
Proceeds from maturity of investments	855,000	230,000	66,906
Acquired in-process research and development	0	(85,000)	(23,750)
Purchases of property, plant and equipment	(20,370)	(28,950)	(9,687)
Acquisitions, net of cash acquired	0	0	(1,502,443)
Acquisition of intangible assets	(111,100)	0	(150,000)
Net proceeds from sale of assets	47,898	0	0
Net cash used in investing activities	(394,487)	(268,950)	(1,751,155)
Financing activities
Net proceeds from issuance of debt	0	559,393	994,647
Proceeds from employee equity incentive and purchase plans	93,337	31,824	24,174
Share repurchases	(523,672)	(98,799)	(278,296)
Payment of employee withholding taxes related to share-based awards	(17,925)	(18,589)	(21,234)
Repayments of long-term debt	(25,717)	(36,094)	(28,304)
Payment of debt modification costs	(6,406)	0	0
Repayments under revolving credit facility	0	(850,000)	(150,000)
Proceeds from tenant improvement allowance on build-to-suit lease	1,253	3,154	0
Net cash provided by (used in) financing activities	(479,130)	(409,111)	540,987
Effect of exchange rates on cash and cash equivalents	(1,700)	5,046	(5,045)
Net increase (decrease) in cash and cash equivalents	(76,413)	20,072	(622,822)
Cash and cash equivalents, at beginning of period	386,035	365,963	988,785
Cash and cash equivalents, at end of period	309,622	386,035	365,963
Supplemental disclosure of cash flow information:
Cash paid for interest	42,706	44,609	39,898
Cash paid for income taxes	164,217	174,124	160,306
Non-cash investing activities:
Amounts capitalized in connection with facility lease obligations	$ 27,747	$ 40,970	$ 23,799

Organization and Description of Business

12 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Description of Business

Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing life-changing medicines for people with limited or no options. As a leader in sleep medicine and with a growing hematology/oncology portfolio, we have a diverse portfolio of products and product candidates in development.

Our lead marketed products are:


•	Xyrem^® (sodium oxybate) oral solution, the only product approved by the U.S. Food and Drug Administration, or FDA, and marketed in the U.S. for the treatment of both cataplexy and excessive daytime sleepiness, or EDS, in adult and pediatric patients with narcolepsy;


•	Erwinaze^® (asparaginase Erwinia chrysanthemi), a treatment approved in the U.S. and in certain markets in Europe (where it is marketed as Erwinase^®) for patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase;

•

Defitelio^®(defibrotide sodium), a product approved in the U.S. for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, or VOD, also known as sinusoidal obstruction syndrome, with renal or pulmonary dysfunction following hematopoietic stem cell transplantation, or HSCT, and in Europe (where it is marketed as Defitelio^®(defibrotide)) for the treatment of severe VOD in adults and children undergoing HSCT therapy; and


•	Vyxeos^®(daunorubicin and cytarabine) liposome for injection, a product approved in the U.S. and in Europe (where it is marketed as Vyxeos^® 44 mg/100 mg powder for concentrate for solution for infusion) for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes.

We are also seeking approval in the U.S. and Europe for solriamfetol as a treatment to improve wakefulness and reduce EDS in adult patients with narcolepsy or obstructive sleep apnea.

We are developing JZP-258, an oxybate product candidate that contains 90% less sodium than Xyrem, for the treatment of both cataplexy and EDS in narcolepsy as well as for other conditions.

Our strategy to create shareholder value is focused on:


•	Strong financial execution through growth in sales of our current lead marketed products;


•	Building a diversified product portfolio and development pipeline through a combination of our internal research and development efforts and obtaining rights to clinically meaningful and differentiated on- or near-market products and early- to late-stage product candidates through acquisitions, collaborations, licensing arrangements, partnerships and venture investments; and


•	Maximizing the value of our products and product candidates by continuing to implement our comprehensive global development plans, including through generating additional clinical data and seeking regulatory approval for new indications.

Throughout this report, unless otherwise indicated or the context otherwise requires, all references to “Jazz Pharmaceuticals,” “the registrant,” “we,” “us,” and “our” refer to Jazz Pharmaceuticals plc and its consolidated subsidiaries. Throughout this report, all references to “ordinary shares” refer to Jazz Pharmaceuticals plc’s ordinary shares.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Basis of Presentation

The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, and include the accounts of Jazz Pharmaceuticals plc and our subsidiaries and intercompany transactions and balances have been eliminated. Our consolidated financial statements include the results of operations of businesses we have acquired from the date of each acquisition for the applicable reporting periods.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.

Adoption of New Accounting Standards

In May 2014, the Financial Accounting Standards Board, or FASB, issued ASU No. 2014-09. The standard states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this, an entity will need to identify the contract with a customer; identify the separate performance obligations in the contract; determine the transaction price; allocate the transaction price to the separate performance obligations in the contract; and recognize revenue when (or as) the entity satisfies each performance obligation. We adopted ASU No. 2014-09 on January 1, 2018 on a modified retrospective basis and applied the standard to all contracts as of this date. The adoption of ASU No. 2014-09 did not have a material impact on our results of operations and financial position as the timing of revenue recognition for product sales, net, which is our primary revenue stream, did not change. Refer to Note 17, Revenues, for revenue-related disclosures.

In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments” which addresses how certain cash receipts and cash payments are presented and classified in the statement of cash flows. We adopted this standard on January 1, 2018 and adoption did not have a material impact on our consolidated financial statements.

In October 2016, the FASB issued ASU No. 2016-16, “Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory” which requires an entity to recognize the income tax consequences of an intra-entity asset transfer, other than an intra-entity asset transfer of inventory, when the transfer occurs. We adopted this standard on January 1, 2018 on a modified retrospective basis and adoption did not have a material impact on our consolidated financial statements.

In January 2017, the FASB issued ASU No. 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business” which provides clarification on the definition of a business and adds guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. We adopted this standard on January 1, 2018. In the second quarter of 2018, we entered into an asset purchase agreement, or APA, with TerSera Therapeutics LLC, or TerSera, whereby TerSera agreed to purchase substantially all of our assets related to the manufacture, marketing and sale of Prialt^®(ziconotide) intrathecal infusion. We entered into an amendment to the APA, and the transaction closed on September 27, 2018. We determined that the disposal group did not constitute a business under the new guidance. Refer to Note 3, Business Combination, Asset Acquisitions and Disposition, for further information on the sale of our rights to Prialt.

In August 2017, the FASB issued ASU No. 2017-12, “Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities” which amends and simplifies existing guidance in order to allow companies to more accurately present the economic effects of risk management activities in their financial statements. ASU No. 2017-12 is effective for reporting periods beginning after December 15, 2018, with early adoption permitted. We elected to early adopt this standard on January 1, 2018 on a modified retrospective basis. Adoption of this standard did not have a material impact on our consolidated financial statements.

The cumulative effect of the changes made to our consolidated balance sheet as of January 1, 2018 for the adoption of the above accounting standards was as follows (in thousands):



	Balance at December 31, 2017			Transition Adjustments			Balance at January 1, 2018
Assets:
Deferred tax assets, net	$	34,559		$	595		$	35,154
Liabilities:
Deferred revenue	8,618			(1,120		)	7,498
Deferred revenue, non-current	16,115			(1,120		)	14,995
Deferred tax liabilities, net	383,472			3,114			386,586
Shareholders' Equity:
Accumulated other comprehensive loss	(140,878		)	53			(140,825		)
Retained earnings	917,956			(332		)	917,624

Significant Risks and Uncertainties

Our financial results are significantly influenced by sales of Xyrem. Our ability to maintain or increase Xyrem product sales is subject to a number of risks and uncertainties, including, without limitation, the introduction of new products in the U.S. market that compete with, or otherwise disrupt the market for, Xyrem in the treatment of cataplexy and/or EDS in narcolepsy; the introduction of a generic version of Xyrem in the U.S. market before the entry dates specified in our settlements with the abbreviated new drug application, or ANDA, filers or on terms that are different from those contemplated by the settlement agreements; increased pricing pressure from, changes in policies by, or restrictions on reimbursement imposed by, third party payors, including pressure to agree to discounts, rebates or other restrictive pricing terms for Xyrem; changes in healthcare laws and policy, including changes in requirements for patient assistance programs, rebates, reimbursement and coverage by federal healthcare programs, and changes resulting from increased scrutiny on pharmaceutical pricing and risk evaluation and mitigation strategy, or REMS, programs by government entities; changes to or uncertainties around our Xyrem REMS, or any failure to comply with our REMS obligations to the satisfaction of the FDA; challenges to our intellectual property around Xyrem, including the possibility of new ANDA or new drug application, or NDA, filers or new post-grant patent review proceedings; operational disruptions at the Xyrem central pharmacy; any supply or manufacturing problems, including any problems with our sole source Xyrem active pharmaceutical ingredient, or API, provider; continued acceptance of Xyrem by physicians and patients, including as a result of negative publicity that surfaces from time to time; and changes to our label, including new safety warnings or changes to our boxed warning, that further restrict how we market and sell Xyrem.

In addition to risks related specifically to Xyrem, we are subject to other challenges and risks specific to our business and our ability to execute on our strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: effectively commercializing our other products; competition; obtaining and maintaining adequate coverage and reimbursement for our products; increasing scrutiny of pharmaceutical product pricing and resulting changes in healthcare laws and policy; market acceptance; delays or problems in the supply of our products, loss of single source suppliers or failure to comply with manufacturing regulations; regulatory approval and successful launch of our late-stage product candidates; identifying, acquiring or in-licensing additional products or product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; the regulatory approval process; the challenges of protecting and enhancing our intellectual property rights; complying with applicable regulatory requirements; and possible restrictions on our ability and flexibility to pursue certain future opportunities as a result of our substantial outstanding debt obligations.

Concentrations of Risk

Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and derivative contracts. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and investments to the extent recorded on the balance sheet.

We manage our foreign currency transaction risk and interest rate risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes. As of December 31, 2018 and 2017, we had foreign exchange forward contracts with notional amounts totaling $271.5 million and $511.4 million, respectively. As of December 31, 2018 and 2017, the outstanding foreign exchange forward contracts had a net liability fair value of $0.3 million and a net asset fair value of $10.5 million, respectively. As of December 31, 2018 and 2017, we had interest rate swap contracts with notional amounts totaling $300.0 million. These outstanding interest rate swap contracts had a net asset fair value of $4.1 million and $1.7 million as of December 31, 2018 and 2017, respectively. The counterparties to these contracts are large multinational commercial banks, and we believe the risk of nonperformance is not significant.

We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the U.S., and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable. As of December 31, 2018, two customers accounted for 89% of gross accounts receivable, Express Scripts Specialty Distribution Services, Inc. and its affiliates, or Express Scripts, which accounted for 74% of gross accounts receivable, and McKesson Corporation and affiliates, or McKesson, which accounted for 15% of gross accounts receivable. As of December 31, 2017, two customers accounted for 86% of gross accounts receivable, Express Scripts, which accounted for 71% of gross accounts receivable, and McKesson, which accounted for 15% of gross accounts receivable.

We depend on single source suppliers for most of our products, product candidates and their active pharmaceutical ingredients, or APIs. With respect to Xyrem, the API is manufactured for us by a single source supplier and the finished product is manufactured both by us in our facility in Athlone, Ireland and by our U.S.-based Xyrem supplier.

Business Acquisitions

Our consolidated financial statements include the results of operations of an acquired business from the date of acquisition. We account for acquired businesses using the acquisition method of accounting. The acquisition method of accounting for acquired businesses requires, among other things, that assets acquired, liabilities assumed and any noncontrolling interests in the acquired business be recognized at their estimated fair values as of the acquisition date, with limited exceptions, and that the fair value of acquired in-process research and development, or IPR&D, be recorded on the balance sheet. Also, transaction costs are expensed as incurred. Any excess of the acquisition consideration over the assigned values of the net assets acquired is recorded as goodwill. Contingent consideration is included within the acquisition cost and is recognized at its fair value on the acquisition date. A liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved and changes in fair value are recognized in earnings.

Cash Equivalents and Investments

We consider all highly liquid investments, readily convertible to cash, that mature within three months or less from date of purchase to be cash equivalents.

Investments consist of time deposits with initial maturities of greater than three months. Collectively, cash equivalents and investments are considered available-for-sale and are recorded at fair value. Unrealized gains and losses, net of tax, are recorded in accumulated other comprehensive loss in shareholders’ equity. We use the specific-identification method for calculating realized gains and losses on securities sold. Realized gains and losses and declines in value judged to be other than temporary on investments are included in interest expense, net in the consolidated statements of income.

Derivative Instruments and Hedging Activities

We record the fair value of derivative instruments as either assets or liabilities on the consolidated balance sheets. Changes in the fair value of derivative instruments are recorded each period in current earnings or other comprehensive income (loss), depending on whether a derivative instrument is designated as part of a hedging transaction and, if it is, the type of hedging transaction. For a derivative to qualify as a hedge at inception and throughout the hedged period, we formally document the nature and relationships between the hedging instruments and hedged item. We assess, both at inception and on an on-going basis, whether the derivative instruments that are used in cash flow hedging transactions are highly effective in offsetting the changes in cash flows of hedged items. Gains or losses on cash flow hedges are reclassified from other comprehensive income (loss) to earnings when the hedged transaction occurs. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting and any related unrealized gain or loss on the derivative instrument is recognized in current earnings. Derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings.

Inventories

Inventories are valued at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method for all inventories. Our policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected requirements. The estimate of excess quantities is subjective and primarily dependent on our estimates of future demand for a particular product. If our estimate of future demand changes, we consider the impact on the reserve for excess inventory and adjust the reserve as required. Increases in the reserve are recorded as charges in cost of product sales.

We capitalize inventory costs associated with our products prior to regulatory approval when, based on management's judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. The determination to capitalize inventory costs is based on various factors, including status and expectations of the regulatory approval process, any known safety or efficacy concerns, potential labeling restrictions, and any other impediments to obtaining regulatory approval. We had no pre-approval inventory on our consolidated balance sheet as of December 31, 2018 or 2017.

Property, Plant and Equipment

Property, plant and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Estimated useful lives are as follows:



Buildings	40 years
Manufacturing equipment and machinery	5-10 years
Computer software and equipment	3 years
Furniture and fixtures	5 years

Leasehold improvements and the build-to-suit facility are amortized over the shorter of the noncancelable term of our leases or their economic useful lives. Maintenance and repairs are expensed as incurred.

Operating Leases and Financing Obligations

We recognize rent expense under operating leases on a straight-line basis over the term of the lease with the difference between the expense and cash payments recorded as deferred rent on the consolidated balance sheets.

For certain build-to-suit lease arrangements where we have concluded that we are the “deemed owner” of the building, for accounting purposes only, during the construction period, we are required to record an asset with a corresponding financing obligation for the construction costs incurred by the landlord. The financing obligation is recorded within accrued liabilities and other non-current liabilities in the consolidated balance sheets. We increase the asset and financing obligation as additional building costs are incurred by the landlord during the construction period. Once construction is complete, we evaluate whether the asset qualifies for sale-leaseback accounting treatment. If the lease meets the sale-leaseback criteria, we remove the asset and the related liability from the consolidated balance sheets and treat the lease as either an operating or capital lease based on an assessment of the accounting guidance. If the arrangement does not qualify for sale-leaseback treatment, we reduce the financing obligation over the lease term as payments are made and depreciate the asset over its estimated useful life or lease term, whichever is shorter. Future lease payments associated with build-to-suit leases where we are the deemed owner are allocated between the land and building components. The portion of the lease payments allocated to the land is treated for accounting purposes as operating lease payments, and therefore is recorded as rent expense in the consolidated statements of income. The portion of the lease payments allocated to the building is further bifurcated into a portion allocated to interest expense and a portion allocated to reduce the build-to-suit financing obligation.

Goodwill

Goodwill represents the excess of the acquisition consideration over the fair value of assets acquired and liabilities assumed. We have determined that we operate in a single segment and have a single reporting unit associated with the development and commercialization of pharmaceutical products. The annual test for goodwill impairment is a two-step process. The first step is a comparison of the fair value of the reporting unit with its carrying amount, including goodwill. If this step indicates impairment, then, in the second step, the loss is measured as the excess of recorded goodwill over its implied fair value. Implied fair value is the excess of the fair value of the reporting unit over the fair value of all identified assets and liabilities. We test goodwill for impairment annually in October and when events or changes in circumstances indicate that the carrying value may not be recoverable.

Acquired In-Process Research and Development

The initial costs of rights to IPR&D projects acquired in an asset acquisition are expensed as IPR&D unless the project has an alternative future use. The fair value of IPR&D projects acquired in a business combination are capitalized and accounted for as indefinite-lived intangible assets until the underlying project receives regulatory approval, at which point the intangible asset will be accounted for as a finite-lived intangible asset, or discontinued, at which point the intangible asset will be written off. Development costs incurred after an acquisition are expensed as incurred.

Intangible Assets

Intangible assets with finite useful lives consist primarily of purchased developed technology and are amortized on a straight-line basis over their estimated useful lives, which range from two to 18 years. The estimated useful lives associated with finite-lived intangible assets are consistent with the estimated lives of the associated products and may be modified when circumstances warrant. Such assets are reviewed for impairment when events or circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset and its eventual disposition are less than its carrying amount. The amount of any impairment is measured as the difference between the carrying amount and the fair value of the impaired asset.

Intangible assets with finite useful lives also includes a Priority Review Voucher, or PRV, which we can use to obtain priority review by the FDA for one of our future regulatory submissions or may sell or transfer to a third party. The PRV is measured at cost and reviewed for impairment when events or circumstances indicate that the carrying value may not be recoverable. At the time we commit to using the PRV to accelerate the review of a drug application, the cost of the PRV will be expensed to the consolidated statement of income. Alternatively, if the PRV is sold, the asset would be derecognized from the consolidated balance sheet.

Revenue Recognition

Our revenue comprises product sales, net and royalty and contract revenues. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Prior to recognizing revenue, we make estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.

Product Sales, Net

Product sales revenue is recognized when control has transferred to the customer, which occurs at a point in time, which is typically on delivery to the customer or, in the case of products that are subject to consignment agreements, when the customer removes product from our consigned inventory location for shipment directly to a patient.

Reserves for Variable Consideration

Revenues from sales of products are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established and which relate to returns, specialty distributor fees, wholesaler fees, prompt payment discounts, government rebates, government chargebacks, coupon programs and rebates under managed care plans. Calculating certain of these reserves involves estimates and judgments and we determine their expected value based on sales or invoice data, contractual terms, historical utilization rates, new information regarding changes in these programs’ regulations and guidelines that would impact the amount of the actual rebates, our expectations regarding future utilization rates for these programs and channel inventory data. These reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. We reassess our reserves for variable consideration at each reporting date. Historically, adjustments to estimates for these reserves have not been material.

Reserves for returns, specialty distributor fees, wholesaler fees, government rebates, coupon programs and rebates under managed care plans are included within current liabilities in our consolidated balance sheets. Reserves for government chargebacks and prompt payment discounts are shown as a reduction in accounts receivable.

Royalties and Contract Revenues

We enter into out-licensing agreements under which we license certain rights to our products or product candidates to third parties. If a licensing arrangement includes multiple goods or services, we consider whether the license is distinct. If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If the license to our intellectual property is determined not to be distinct, it is combined with other goods or services into a combined performance obligation. We consider whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. We evaluate the measure of progress each reporting date and, if necessary, adjust the measure of performance and related revenue recognition.

At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or that of the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.

For arrangements that include sales-based royalties and milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties and sales-based milestones relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty or sales-based milestone has been allocated has been satisfied (or partially satisfied).

Cost of Product Sales

Cost of product sales includes manufacturing and distribution costs, the cost of drug substance, royalties due to third parties on product sales, product liability and cargo insurance, FDA user fees, freight, shipping, handling and storage costs and salaries and related costs of employees involved with production. Excluded from cost of product sales shown on the consolidated statements of income is amortization of acquired developed technology of $201.3 million, $149.1 million and $99.0 million in 2018, 2017 and 2016, respectively.

Research and Development

Research and development expenses consist primarily of costs related to clinical studies and outside services, personnel expenses and other research and development costs, including milestone payments incurred prior to regulatory approval of products. Clinical study and outside services costs relate primarily to services performed by clinical research organizations, clinical studies performed at clinical sites, materials and supplies, and other third party fees. Personnel expenses relate primarily to salaries, benefits and share-based compensation. Other research and development expenses primarily include overhead allocations consisting of various support and facilities-related costs. Research and development costs are expensed as incurred. For product candidates that have not been approved by the FDA, inventory used in clinical trials is expensed at the time of production and recorded as research and development expense. For products that have been approved by the FDA, inventory used in clinical trials is expensed at the time the inventory is packaged for the trial.

Advertising Expenses

We expense the costs of advertising, including promotional expenses, as incurred. Advertising expenses were $37.4 million, $36.6 million and $29.5 million in 2018, 2017 and 2016, respectively.

Income Taxes

We use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amount and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more-likely-than-not that some portion or all of a deferred tax asset will not be realized. We recognize the benefits of a tax position if it is “more-likely-than-not” of being sustained. A recognized tax benefit is then measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon settlement. Interest and penalties related to unrecognized tax benefits are included in the income tax provision and classified with the related liability on the consolidated balance sheets.

Foreign Currency

Our functional and reporting currency is the U.S. dollar. The assets and liabilities of our subsidiaries that have a functional currency other than the U.S. dollar are translated into U.S. dollars at the exchange rate prevailing at the balance sheet date with the results of operations of subsidiaries translated at the average exchange rate for the reporting period. The cumulative foreign currency translation adjustment is recorded as a component of accumulated other comprehensive income (loss) in shareholders’ equity.

Transactions in foreign currencies are translated into the functional currency of the relevant subsidiary at the rate of exchange prevailing at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the relevant functional currency at exchange rates prevailing at the balance sheet date or on settlement. Resulting gains and losses are recorded in foreign exchange gain (loss) in our consolidated statements of income.

Deferred Financing Costs

Deferred financing costs are reported at cost, less accumulated amortization and are presented in the consolidated balance sheets as a direct deduction from the carrying value of the associated debt, with the exception of deferred financing costs associated with revolving-debt arrangements which are presented as assets. The related amortization expense is included in interest expense, net in our consolidated statements of income.

Contingencies

From time to time, we may become involved in claims and other legal matters arising in the ordinary course of business. We record accruals for loss contingencies to the extent that we conclude that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. Legal fees and other expenses related to litigation are expensed as incurred and included in selling, general and administrative expenses.

Share-Based Compensation

We account for compensation cost for all share-based awards at fair value on the date of grant. The fair value is recognized as expense over the service period, net of estimated forfeitures, using the straight-line method. The estimation of share-based awards that will ultimately vest requires judgment, and, to the extent actual results or updated estimates differ from current estimates, such amounts will be recorded as a cumulative adjustment in the period estimates are revised. We primarily consider historical experience when estimating expected forfeitures.

Recent Accounting Pronouncements

In August 2018, the FASB issued ASU No. 2018-15, “Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract”, which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The standard is effective for us beginning January 1, 2020 and early adoption is permitted. The new guidance is not expected to have a material impact on our results of operations and financial position.

In January 2017, the FASB issued ASU No. 2017-04, “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” which simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. The standard is effective for us beginning January 1, 2020. Early adoption is permitted for any impairment tests performed after January 1, 2017. The new guidance is not expected to have a material impact on our results of operations and financial position.

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”, or ASU No. 2016-02. Under the new guidance, lessees will be required to recognize a right-of-use asset, which represents the lessee’s right to use, or control the use of, a specified asset for the lease term, and a corresponding lease liability, which represents the lessee’s obligation to make lease payments under a lease, measured on a discounted basis. ASU No. 2016-02 is effective beginning January 1, 2019 and early adoption is permitted. We will adopt ASU No. 2016-02 on a modified retrospective basis at the adoption date of January 1, 2019. The adoption of ASU No. 2016-02 will result in the recognition of right-of-use assets and lease liabilities of approximately $150 million and $170 million, respectively, on the consolidated balance sheet as of January 1, 2019, and the de-recognition of the build-to-suit assets and related financing obligations on the consolidated balance sheet as of December 31, 2018 of $95 million and $110 million, respectively, with the balance impacting retained earnings and deferred rent. The right-of-use assets and lease liabilities primarily relate to real estate leases. We will provide additional lease-related disclosures in the notes to the consolidated financial statements commencing with our consolidated financial statements for the quarter ending March 31, 2019.

Business Combination, Asset Acquisitions, and Disposition

12 Months Ended

Dec. 31, 2018

Business Combinations [Abstract]

Business Combination, Asset Acquisitions, and Disposition

Business Combination, Asset Acquisitions and Disposition

Celator Acquisition

On May 27, 2016, we entered into a definitive merger agreement with Celator Pharmaceuticals Inc., or Celator, pursuant to which we made a cash tender offer of $30.25 per share for all of the outstanding shares of Celator’s common stock. As of the expiration of the offer period on July 12, 2016, 36,516,173 shares, which represented approximately 81% of Celator’s then outstanding common stock, were properly tendered and not withdrawn in the tender offer. The condition to the tender offer that more than 50% of Celator’s outstanding common stock be validly tendered and not withdrawn prior to the expiration of the tender offer was satisfied. In addition, notices of guaranteed delivery were delivered with respect to 2,016,237 additional shares, representing approximately 4% of Celator’s outstanding common stock as of the expiration of the tender offer. On July 12, 2016, we completed the acquisition of Celator, or the Celator Acquisition, under the terms of the merger agreement, pursuant to which Celator became an indirect wholly owned subsidiary of Jazz Pharmaceuticals plc and each share of Celator common stock then outstanding (other than shares owned by us or Celator) was converted into the right to receive $30.25, the same price per share offered in the tender offer. The aggregate cash consideration for the Celator Acquisition was $1.5 billion.

On July 12, 2016, we entered into the amended credit agreement that provides for a revolving credit facility of $1.25 billion, which replaced our prior revolving credit facility of $750.0 million, and a $750.0 million term loan facility. Please see Note 11, Debt, for further information regarding the 2015 credit agreement and the amended credit agreement. We used the proceeds of $1.0 billion of loans under the revolving credit facility, together with cash on hand, to fund the Celator Acquisition.

Celator was an oncology-focused biopharmaceutical company seeking to transform the science of combination therapy and develop products to improve patient outcomes in cancer. The Celator Acquisition broadened our hematology/oncology portfolio with the acquisition of worldwide development and commercialization rights to Vyxeos. In addition, the Celator Acquisition provided us with Celator’s proprietary technology platform, CombiPlex, which enables the rational design and rapid evaluation of optimized combinations of additional anti-cancer drugs.

The Celator Acquisition was accounted for as a business combination using the acquisition method under which assets and liabilities of Celator were recorded at their respective estimated fair values as of the closing date of the Celator Acquisition and added to the assets and liabilities of Jazz Pharmaceuticals plc, including an amount for goodwill representing the difference between the acquisition consideration and the estimated fair value of the identifiable net assets. The results of operations of Celator and the estimated fair values of the assets acquired and liabilities assumed have been included in our consolidated financial statements since the closing date of the Celator Acquisition.

In 2016, we incurred $10.0 million in acquisition-related costs related to the Celator Acquisition, which primarily consisted of banking, legal, accounting and valuation-related expenses. These expenses were recorded in selling, general and administrative expense in the accompanying consolidated statements of income. We did not recognize any revenues from the acquired Celator business in 2016. The portion of total expenses and net loss associated with the acquired Celator business was not separately identifiable due to the integration with our operations.

The fair values of assets acquired and liabilities assumed at the closing date of the Celator Acquisition are summarized below (in thousands):



Cash and cash equivalents	$	26,137
Other receivables	386
Prepaid expenses and deposits	151
Property, plant and equipment	767
Intangible assets	1,811,250
Goodwill	252,825
Other non-current assets	43
Accrued liabilities	(19,076		)
Deferred tax liability, net, non-current	(542,901		)
Other non-current liabilities	(1,002		)
Total acquisition consideration - cash paid	$	1,528,580

Identifiable intangible assets acquired comprised IPR&D, which represented incomplete research and development projects at Celator related to Vyxeos. Management estimated the fair value of Vyxeos IPR&D to be approximately $1.8 billion. The fair value of acquired IPR&D was determined using the income approach, including the application of probability factors related to the likelihood of success of Vyxeos reaching final development and commercialization. This approach also took into consideration information and certain program-related documents and forecasts prepared by management. The fair value of acquired IPR&D was capitalized as of the closing date of the Celator Acquisition. After receiving FDA approval of our new drug application, or NDA, for Vyxeos in August 2017, we reclassified the IPR&D balance of $1.8 billion from an indefinite-lived intangible asset to an acquired developed technology finite-lived intangible asset. This acquired developed technology asset is being amortized over its estimated useful life of 18 years.

The excess of the total acquisition consideration over the fair value amounts assigned to the assets acquired and the liabilities assumed represents the goodwill amount resulting from the Celator Acquisition. We believe that the factors that contributed to goodwill included the Celator workforce, which will complement our clinical experience in hematology/oncology and our expertise in reaching targeted physicians who treat serious medical conditions, and the deferred tax consequences of intangible assets recorded for financial statement purposes. We do not expect any portion of this goodwill to be deductible for tax purposes.

Pro Forma Financial Information (Unaudited)

The following unaudited supplemental pro forma information presents our combined historical results of operations with pro forma adjustments as if the Celator Acquisition had been completed on January 1, 2015. The primary pro forma adjustments include:


•	The exclusion of acquisition-related and integration expenses of $13.6 million in 2016.


•	An increase in interest expense of $13.7 million in 2016 incurred on additional borrowings made to partially fund the Celator Acquisition as if the borrowings had occurred on January 1, 2015.

The unaudited pro forma results do not assume any operating efficiencies as a result of the consolidation of operations and are as follows (in thousands, except per share data):



	Year Ended December 31, 2016
Revenues	$	1,488,118
Net income attributable to Jazz Pharmaceuticals plc	$	386,342
Net income attributable to Jazz Pharmaceuticals plc per ordinary share - basic	$	6.39
Net income attributable to Jazz Pharmaceuticals plc per ordinary share - diluted	$	6.24

Disposition

On June 29, 2018, we entered into an APA with TerSera, pursuant to which TerSera agreed to purchase substantially all of our assets related to the manufacture, marketing and sale of Prialt, but excluding accounts receivable, and to assume certain related liabilities as set forth in the APA. We entered into an amendment to the APA, and the transaction closed, on September 27, 2018. The total sales price was $80.0 million, of which we received $50.0 million at closing, and, subject to certain conditions, we are entitled to receive $15.0 million payable on December 31, 2019 and $15.0 million payable on December 31, 2020, or earlier under certain circumstances.

The related assets met the assets held for sale criteria and were reclassified to assets held for sale as of June 30, 2018. We adjusted the carrying value of the assets held for sale to fair value less costs to sell, which resulted in an impairment charge of $42.9 million in our consolidated statements of income in 2018, primarily related to the carrying balances of intangible assets. Upon closing, we recognized a loss on disposal of $0.5 million within selling, general and administrative expenses in our consolidated statements of income in 2018.

We determined that the disposal of these assets does not qualify for reporting as a discontinued operation since it does not represent a strategic shift that has or will have a major effect on our operations and financial results.

Collaboration and Option Agreement

In August 2017, we entered into a collaboration and option agreement with ImmunoGen, Inc., or ImmunoGen, granting us rights to opt into exclusive, worldwide licenses to develop and commercialize two hematology-related antibody-drug conjugate, or ADC, programs, as well as an additional program to be designated during the term of the agreement. The programs covered under the agreement include IMGN779, a CD33-targeted ADC for the treatment of AML in Phase 1 testing, and IMGN632, a CD123-targeted ADC for hematological malignancies expected to enter clinical testing before the end of 2017.

Under the terms of the agreement, ImmunoGen will be responsible for the development of the three ADC programs prior to any potential opt-in by us. Following any opt-in, we would be responsible for any further development as well as for potential regulatory submissions and commercialization.

As part of the agreement, we paid ImmunoGen a non-refundable upfront payment of $75.0 million, which was charged to acquired IPR&D expense upon closing of the transaction. Additionally, we will pay ImmunoGen up to $100 million in development funding over seven years to support the three ADC programs. For each program, we may exercise our opt-in right at any time prior to a pivotal study or any time prior to a biologics license application upon payment of an option exercise fee. The option exercise fee depends on the timing of exercise and certain other conditions. For each program to which we elect to opt-in, ImmunoGen would be eligible to receive milestone payments based on receiving regulatory approval of the applicable product, plus tiered royalties as a percentage of commercial sales. After opt-in, we will share with ImmunoGen the costs associated with developing and obtaining regulatory approvals of the applicable product in the U.S. and the European Union, or EU. ImmunoGen has the right to co-commercialize one product (or two products, under certain limited circumstances) with us in the U.S. with U.S. profit-sharing in lieu of our payment of applicable U.S. milestone and royalties to ImmunoGen.

License and Option Agreement

In July 2016, we entered into an agreement with Pfenex Inc., or Pfenex, that granted us worldwide rights to develop and commercialize multiple early-stage hematology product candidates and an option for us to negotiate a license for a recombinant pegaspargase product candidate. This agreement was amended in December 2017. Under the amended agreement, Pfenex received upfront, option and development milestone payments totaling $35.3 million and may be eligible to receive additional payments of up to $189 million based on the achievement of certain development, regulatory and sales milestones. In 2017, we recognized expense of $19.5 million within research and development expenses. In 2016, we recognized expenses of $15.8 million, of which $15.0 million was charged to acquired IPR&D expense upon closing of the transaction and $0.8 million was charged to research and development expenses.

Acquisition of Alizé Pharma II S.A.S.

In March 2016, we acquired all of the outstanding shares of Alizé Pharma II S.A.S., a privately held biotechnology company, for an upfront payment of $8.8 million. In connection with the acquisition, we obtained intellectual property and know-how related to recombinant crisantaspase. The transaction includes contingent regulatory milestone payments of up to €10 million. The transaction was accounted for as an asset acquisition and the upfront payment was charged to acquired IPR&D expense upon closing of the transaction.

Cash and Available-for-Sale Securities

12 Months Ended

Dec. 31, 2018

Cash and Cash Equivalents [Abstract]

Cash and Available-for-Sale Securities

Cash and cash equivalents and investments consisted of the following (in thousands):



	December 31, 2018
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value		Cash and Cash Equivalents		Investments
Cash	$	215,606	$	—	$	—	$	215,606	$	215,606	$	—
Time deposits	515,000		—		—		515,000		—		515,000
Money market funds	94,016		—		—		94,016		94,016		—
Totals	$	824,622	$	—	$	—	$	824,622	$	309,622	$	515,000



	December 31, 2017
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value		Cash and Cash Equivalents		Investments
Cash	$	225,235	$	—	$	—	$	225,235	$	225,235	$	—
Time deposits	235,000		—		—		235,000		20,000		215,000
Money market funds	140,800		—		—		140,800		140,800		—
Totals	$	601,035	$	—	$	—	$	601,035	$	386,035	$	215,000

Cash equivalents and investments are considered available-for-sale securities. We use the specific-identification method for calculating realized gains and losses on securities sold and include them in interest expense, net in the consolidated statements of income. Our investment balances represent time deposits with original maturities of greater than three months and less than one year.

Fair Value Measurement

12 Months Ended

Dec. 31, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurement

The following table summarizes, by major security type, our available-for-sale securities and derivative contracts that were measured at fair value on a recurring basis and were categorized using the fair value hierarchy (in thousands):



	December 31, 2018						December 31, 2017
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Total Estimated Fair Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Total Estimated Fair Value
Assets:
Available-for-sale securities:
Time deposits	$	—	$	515,000	$	515,000	$	—	$	235,000	$	235,000
Money market funds	94,016		—		94,016		140,800		—		140,800
Interest rate contracts	—		4,070		4,070		—		2,138		2,138
Foreign exchange forward contracts	—		1,194		1,194		—		15,495		15,495
Totals	$	94,016	$	520,264	$	614,280	$	140,800	$	252,633	$	393,433
Liabilities:
Interest rate contracts	$	—	$	—	$	—	$	—	$	392	$	392
Foreign exchange forward contracts	—		1,460		1,460		—		5,017		5,017
Totals	$	—	$	1,460	$	1,460	$	—	$	5,409	$	5,409

As of December 31, 2018, our available-for-sale securities included time deposits and money market funds and their carrying values were approximately equal to their fair values. Time deposits were measured at fair value using Level 2 inputs and money market funds were measured using quoted prices in active markets, which represent Level 1 inputs. Level 2 inputs, obtained from various third party data providers, represent quoted prices for similar assets in active markets, or these inputs were derived from observable market data, or if not directly observable, were derived from or corroborated by other observable market data.

Our derivative assets and liabilities include interest rate and foreign exchange derivatives that are measured at fair value using observable market inputs such as forward rates, interest rates, our own credit risk as well as an evaluation of our counterparties’ credit risks. Based on these inputs, the derivative assets and liabilities are classified within Level 2 of the fair value hierarchy.

There were no transfers between the different levels of the fair value hierarchy in 2018 or in 2017.

As of December 31, 2018, the carrying amount of investments measured using the measurement alternative for equity investments without a readily determinable fair value was $4.5 million. The carrying amount, which is recorded within other non-current assets, represents the purchase price paid in 2018.

As of December 31, 2018, the estimated fair values of our 1.875% exchangeable senior notes due 2021, or the 2021 Notes, and our 1.50% exchangeable senior notes due 2024, or the 2024 Notes, were approximately $558 million and $521 million, respectively. The fair values of the Exchangeable Senior Notes were estimated using quoted market prices obtained from brokers (Level 2). The estimated fair value of our borrowings under our term loan was approximately equal to its book value based on the borrowing rates currently available for variable rate loans (Level 2).

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Derivatives Instruments and Hedging Activities

12 Months Ended

Dec. 31, 2018

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivatives and Hedging Activities

Derivative Instruments and Hedging Activities

We are exposed to certain risks arising from operating internationally, including fluctuations in interest rates on our outstanding term loan borrowings and fluctuations in foreign exchange rates primarily related to the translation of euro-denominated net monetary liabilities, including intercompany balances, held by subsidiaries with a U.S. dollar functional currency. We manage these exposures within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes.

To achieve a desired mix of floating and fixed interest rates on our variable rate debt, we entered into interest rate swap agreements in March 2017 which are effective until July 2021. These agreements hedge contractual term loan interest rates. As of December 31, 2018 and 2017, the interest rate swap agreements had a notional amount of $300.0 million. As a result of these agreements, the interest rate on a portion of our term loan borrowings was fixed at 1.895%, plus the borrowing spread, until July 12, 2021.

The effective portion of changes in the fair value of derivatives designated as and that qualify as cash flow hedges is recorded in accumulated other comprehensive loss and is subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings. The impact on accumulated other comprehensive loss and earnings from derivative instruments that qualified as cash flow hedges was as follows (in thousands):



	Year Ended December 31,
Interest Rate Contracts:	2018			2017
Gain (loss) recognized in accumulated other comprehensive loss, net of tax	$	2,274		$	(213	)
Loss (gain) reclassified from accumulated other comprehensive loss to interest expense, net of tax	$	(252	)	$	1,695

Assuming no change in LIBOR-based interest rates from market rates as of December 31, 2018, $1.7 million of gains recognized in accumulated other comprehensive loss will be reclassified to earnings over the next 12 months.

We enter into foreign exchange forward contracts, with durations of up to 12 months, designed to limit the exposure to fluctuations in foreign exchange rates related to the translation of certain non-U.S. dollar denominated liabilities, including intercompany balances. Hedge accounting is not applied to these derivative instruments as gains and losses on these hedge transactions are designed to offset gains and losses on underlying balance sheet exposures. As of December 31, 2018 and 2017, the notional amount of foreign exchange contracts where hedge accounting was not applied was $271.5 million and $511.4 million, respectively.

The foreign exchange gain (loss) in our consolidated statements of income included the following gains and losses associated with foreign exchange contracts not designated as hedging instruments (in thousands):



	Year Ended December 31,
Foreign Exchange Forward Contracts:	2018			2017
Gain (loss) recognized in foreign exchange gain (loss)	$	(14,648	)	$	17,902

We did not enter into foreign exchange forward contracts in 2016.

The cash flow effects of our derivative contracts are included within net cash provided by operating activities in the consolidated statements of cash flows.

The following table summarizes the fair value of outstanding derivatives (in thousands):



	December 31, 2018
	Asset Derivatives			Liability Derivatives
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments:
Interest rate contracts	Other current assets	$	1,929	Accrued liabilities	$	—
	Other non-current assets	2,141
Derivatives not designated as hedging instruments:
Foreign exchange forward contracts	Other current assets	1,194		Accrued liabilities	1,460
Total fair value of derivative instruments		$	5,264		$	1,460



	December 31, 2017
	Asset Derivatives			Liability Derivatives
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments:
Interest rate contracts	Other non-current assets	$	2,138	Accrued liabilities	$	392
Derivatives not designated as hedging instruments:
Foreign exchange forward contracts	Other current assets	15,495		Accrued liabilities	5,017
Total fair value of derivative instruments		$	17,633		$	5,409

Although we do not offset derivative assets and liabilities within our consolidated balance sheets, our International Swap and Derivatives Association agreements provide for net settlement of transactions that are due to or from the same counterparty upon early termination of the agreement due to an event of default or other termination event. The following table summarizes the potential effect on our consolidated balance sheets of offsetting our interest rate contracts and foreign exchange forward contracts subject to such provisions (in thousands):



	December 31, 2018
	Gross Amounts of Recognized Assets/ Liabilities			Gross Amounts Offset in the Consolidated Balance Sheet		Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet			Gross Amounts Not Offset in the Consolidated Balance Sheet
Description	Gross Amounts of Recognized Assets/ Liabilities			Gross Amounts Offset in the Consolidated Balance Sheet					Derivative Financial Instruments			Cash Collateral Received (Pledged)		Net Amount
Derivative assets	$	5,264		$	—	$	5,264		$	(935	)	$	—	$	4,329
Derivative liabilities	$	(1,460	)	$	—	$	(1,460	)	$	935		$	—	$	(525	)



	December 31, 2017
	Gross Amounts of Recognized Assets/ Liabilities			Gross Amounts Offset in the Consolidated Balance Sheet		Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet			Gross Amounts Not Offset in the Consolidated Balance Sheet
Description	Gross Amounts of Recognized Assets/ Liabilities			Gross Amounts Offset in the Consolidated Balance Sheet					Derivative Financial Instruments			Cash Collateral Received (Pledged)		Net Amount
Derivative assets	$	17,633		$	—	$	17,633		$	(5,409	)	$	—	$	12,224
Derivative liabilities	$	(5,409	)	$	—	$	(5,409	)	$	5,409		$	—	$	—

Inventories

12 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Inventories

Inventories consisted of the following (in thousands):



	December 31,
	2018		2017
Raw materials	$	2,774	$	3,542
Work in process	28,864		15,692
Finished goods	21,318		24,011
Total inventories	$	52,956	$	43,245

Property, Plant and Equipment

12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

Property and Equipment

Property, Plant and Equipment

Property, plant and equipment consisted of the following (in thousands):



	December 31,
	2018			2017
Build-to-suit facility	$	52,067		$	51,721
Construction-in-progress	51,243			21,738
Land and buildings	46,650			46,729
Leasehold improvements	33,273			28,779
Manufacturing equipment and machinery	25,837			23,586
Computer software	19,062			19,969
Computer equipment	13,679			12,814
Furniture and fixtures	8,155			5,947
Subtotal	249,966			211,283
Less accumulated depreciation and amortization	(49,608		)	(41,203		)
Property, plant and equipment, net	$	200,358		$	170,080

Depreciation and amortization expense (including amortization expense related to a facility lease) on property, plant and equipment amounted to $15.2 million, $13.1 million and $11.8 million for the years ended December 31, 2018, 2017 and 2016, respectively.

Goodwill and Intangible Assets

12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

The gross carrying amount of goodwill was as follows (in thousands):



Balance at December 31, 2017	$	947,537
Foreign exchange	(19,907		)
Balance at December 31, 2018	$	927,630

The gross carrying amounts and net book values of our intangible assets were as follows (in thousands):



	December 31, 2018								December 31, 2017
	Remaining Weighted- Average Useful Life (In years)	Gross Carrying Amount		Accumulated Amortization			Net Book Value		Gross Carrying Amount		Accumulated Amortization			Net Book Value
Acquired developed technologies	13.9	$	3,110,641	$	(632,413	)	$	2,478,228	$	3,392,832	$	(562,473	)	$	2,830,359
Priority review voucher		111,101		—			111,101		—		—			—
Manufacturing contracts	—	12,256		(12,256		)	—		12,824		(12,634		)	190
Trademarks	—	2,896		(2,896		)	—		2,910		(2,910		)	—
Total finite-lived intangible assets		3,236,894		(647,565		)	2,589,329		3,408,566		(578,017		)	2,830,549
Acquired IPR&D assets		142,005		—			142,005		148,578		—			148,578
Total intangible assets		$	3,378,899	$	(647,565	)	$	2,731,334	$	3,557,144	$	(578,017	)	$	2,979,127

The decrease in the gross carrying amount of intangible assets as of December 31, 2018 compared to December 31, 2017 reflects the sale of the Prialt acquired developed technology asset to TerSera in September 2018 and the negative impact of foreign currency translation adjustments, which was due to the weakening of the euro against the U.S. dollar, partially offset by our purchase of a rare pediatric disease PRV from Spark Therapeutics, Inc. As we may use the PRV to obtain priority review by the FDA for one of our future regulatory submissions or may sell or transfer the PRV to a third party, we capitalized the acquisition cost, including direct transaction costs, as a finite-lived intangible asset upon closing of the transaction in May 2018.

The assumptions and estimates used to determine future cash flows and remaining useful lives of our intangible and other long-lived assets are complex and subjective. They can be affected by various factors, including external factors, such as industry and economic trends, and internal factors such as changes in our business strategy and our forecasts for specific product lines. We reduced the estimated remaining useful life of the Erwinaze intangible asset due to the receipt of a contract termination notice from Porton Biopharma Limited in February 2019.

Based on finite-lived intangible assets recorded as of December 31, 2018, and assuming the underlying assets will not be impaired and that we will not change the expected lives of any other assets, future amortization expenses were estimated as follows (in thousands):



Year Ending December 31,	Estimated Amortization Expense
2019	242,953
2020	246,870
2021	198,956
2022	153,105
2023	153,105
Thereafter	1,483,239
Total	$	2,478,228

Accrued Liabilities

12 Months Ended

Dec. 31, 2018

Payables and Accruals [Abstract]

Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):



	December 31,
	2018		2017
Rebates and other sales deductions	$	86,495	$	81,368
Employee compensation and benefits	58,543		54,930
Estimated loss contingency	58,154		—
Inventory-related accruals	8,753		3,002
Accrued interest	7,407		7,297
Selling and marketing accruals	6,780		3,189
Clinical trial accruals	5,904		2,181
Royalties	2,679		8,058
Sales returns reserve	2,510		3,651
Professional fees	2,333		3,213
Derivative instrument liabilities	1,460		5,409
Other	23,869		26,481
Total accrued liabilities	$	264,887	$	198,779

Debt

12 Months Ended

Dec. 31, 2018

Debt Disclosure [Abstract]

Debt

The following table summarizes the carrying amount of our indebtedness (in thousands):



	December 31,
	2018			2017
2021 Notes	$	575,000		$	575,000
Unamortized discount and debt issuance costs on 2021 Notes	(60,910		)	(81,627		)
2021 Notes, net	514,090			493,373

2024 Notes	575,000			575,000
Unamortized discount and debt issuance costs on 2024 Notes	(138,914		)	(158,680		)
2024 Notes, net	436,086			416,320

Term loan	646,236			671,345
Total debt	1,596,412			1,581,038
Less current portion	33,387			40,605
Total long-term debt	$	1,563,025		$	1,540,433

Credit Agreement

On June 18, 2015, Jazz Pharmaceuticals plc, as guarantor, and certain of our wholly owned subsidiaries, as borrowers, entered into a credit agreement, or the 2015 credit agreement, that provided for a $750.0 million principal amount term loan, which was drawn in full at closing, and a $750.0 million revolving credit facility, of which $160.0 million was drawn at closing and subsequently repaid. We used the proceeds from initial borrowings under the 2015 credit agreement to repay in full the $893.1 million principal amount of term loans outstanding under the credit agreement that we entered into in June 2012, as subsequently amended, which we refer to as the previous credit agreement, and to pay related fees and expenses. The previous credit agreement was terminated upon repayment of the term loans outstanding thereunder.

On July 12, 2016, we amended the 2015 credit agreement to provide for a revolving credit facility of $1.25 billion and a $750.0 million term loan facility. We used the proceeds of $1.0 billion of loans under the revolving credit facility, together with cash on hand, to fund the Celator Acquisition. Please see Note 3, Business Combination, Asset Acquisitions and Disposition, for additional information regarding the Celator Acquisition.

On June 7, 2018, we entered into the second amendment to the 2015 credit agreement to provide for a revolving credit facility of $1.60 billion, which replaced the existing revolving credit facility of $1.25 billion, and a new $667.7 million term loan facility, which replaced the $750.0 million term loan facility, of which $651.0 million principal amount was outstanding as of December 31, 2018. We refer to the 2015 credit agreement as amended by the first and second amendments as the amended credit agreement. We expect to use the proceeds from future loans under the revolving credit facility, if any, for permitted capital expenditures, permitted acquisitions, to provide for ongoing working capital requirements and for other general corporate purposes.

Under the amended credit agreement, the term loan matures on June 7, 2023 and the revolving credit facility terminates, and any loans outstanding thereunder become due and payable, on June 7, 2023.

Borrowings under the amended credit agreement bear interest, at our option, at a rate equal to either (a) the LIBOR rate, plus an applicable margin ranging from 1.375% to 1.750% per annum, based upon our secured leverage ratio, or (b) the prime lending rate, plus an applicable margin ranging from 0.375% to 0.750% per annum, based upon our secured leverage ratio. The revolving credit facility has a commitment fee payable on the undrawn amount ranging from 0.25% to 0.35% per annum based upon our secured leverage ratio.

As of December 31, 2018, the interest rate on the term loan was 3.90% and the effective interest rate was 3.66%. As of December 31, 2018, we had undrawn revolving credit facilities totaling $1.60 billion.

Jazz Pharmaceuticals plc and certain of our wholly owned subsidiaries are borrowers under the amended credit agreement. The borrowers’ obligations under the amended credit agreement and any hedging or cash management obligations entered into with a lender are guaranteed on a senior secured basis by Jazz Pharmaceuticals plc and certain of our subsidiaries (including the issuer of the Exchangeable Senior Notes as described below) and are secured by substantially all of Jazz Pharmaceuticals plc’s, the borrowers’ and the guarantor subsidiaries’ assets.

We may make voluntary prepayments of principal at any time without payment of a premium. We are required to make mandatory prepayments of the term loan (without payment of a premium) with (1) net cash proceeds from certain non-ordinary course asset sales (subject to other exceptions), (2) net cash proceeds from issuances of debt (other than certain permitted debt), and (3) casualty proceeds and condemnation awards (subject to other exceptions).

Principal repayments of the term loan, which are due quarterly, are equal to 5.0% per annum of the principal amount outstanding on June 7, 2018 of $667.7 million, with any remaining balance payable on the maturity date.

The amended credit agreement contains financial covenants that require Jazz Pharmaceuticals plc and our restricted subsidiaries to not (a) exceed a maximum secured net leverage ratio or (b) fall below a cash interest coverage ratio. As of December 31, 2018, we were in compliance with these financial covenants.

In connection with our entry into the amendments to the 2015 credit agreement, we recorded a loss on extinguishment and modification of debt of $1.4 million and $0.6 million in 2018 and 2016, respectively.

Exchangeable Senior Notes Due 2024

In the third quarter of 2017, we completed a private placement of $575.0 million principal amount of 2024 Notes. We used the net proceeds from this offering to repay $500.0 million in outstanding loans under the revolving credit facility and to pay related fees and expenses. We used the remainder of the net proceeds for general corporate purposes. Interest on the 2024 Notes is payable semi-annually in cash in arrears on February 15 and August 15 of each year, beginning on February 15, 2018, at a rate of 1.50% per year. In certain circumstances, we may be required to pay additional amounts as a result of any applicable tax withholding or deductions required in respect of payments on the 2024 Notes. The 2024 Notes mature on August 15, 2024, unless earlier exchanged, repurchased or redeemed.

The holders of the 2024 Notes have the ability to require us to repurchase all or a portion of their 2024 Notes for cash in the event we undergo certain fundamental changes, such as specified change of control transactions, our liquidation or dissolution or the delisting of our ordinary shares from The Nasdaq Global Select Market. Prior to August 15, 2024, we may redeem the 2024 Notes, in whole but not in part, subject to compliance with certain conditions, if we have, or on the next interest payment date would, become obligated to pay to the holder of any 2024 Notes additional amounts as a result of certain tax-related events. We also may redeem the 2024 Notes on or after August 20, 2021, in whole or in part, if the last reported sale price per ordinary share has been at least 130% of the exchange price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide the notice of redemption.

The 2024 Notes are exchangeable at an initial exchange rate of 4.5659 ordinary shares per $1,000 principal amount of 2024 Notes, which is equivalent to an initial exchange price of approximately $219.02 per ordinary share. Upon exchange, the 2024 Notes may be settled in cash, ordinary shares or a combination of cash and ordinary shares, at our election. Our intent and policy is to settle the principal amount of the 2024 Notes in cash upon exchange. The exchange rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain make-whole fundamental changes occurring prior to the maturity date of the 2024 Notes or upon our issuance of a notice of redemption, we will in certain circumstances increase the exchange rate for holders of the 2024 Notes who elect to exchange their 2024 Notes in connection with that make-whole fundamental change or during the related redemption period. Prior to May 15, 2024, the 2024 Notes will be exchangeable only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date.

In accounting for the issuance of the 2024 Notes, we separated the 2024 Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the estimated fair value of a similar liability that does not have an associated exchange feature. The carrying amount of the equity component representing the exchange option was determined by deducting the fair value of the liability component from the face value of the 2024 Notes as a whole. The excess of the principal amount of the liability component over its carrying amount will be amortized to interest expense over the expected life of the 2024 Notes using the effective interest method with an effective interest rate of 6.8% per annum. We have determined the expected life of the 2024 Notes to be equal to the original seven-year term. The equity component is not remeasured as long as it continues to meet the conditions for equity classification. As of December 31, 2018 and 2017, the “if-converted value” did not exceed the principal amount of the 2024 Notes.

We allocated the total issuance costs incurred of $15.6 million to the liability and equity components based on their relative values. Issuance costs attributable to the liability component will be amortized to expense over the term of the 2024 Notes, and issuance costs attributable to the equity component were included with the equity component in our shareholders’ equity.

As of December 31, 2018 and 2017, the carrying value of the equity component of the 2024 Notes, net of equity issuance costs, was $149.8 million.

Exchangeable Senior Notes Due 2021

In August 2014, we completed a private placement of the 2021 Notes. Interest on the 2021 Notes is payable semi-annually in cash in arrears on February 15 and August 15 of each year, beginning on February 15, 2015, at a rate of 1.875% per year. In certain circumstances, we may be required to pay additional amounts as a result of any applicable tax withholding or deductions required in respect of payments on the 2021 Notes. The 2021 Notes mature on August 15, 2021, unless earlier exchanged, repurchased or redeemed.

The holders of the 2021 Notes have the ability to require us to repurchase all or a portion of their 2021 Notes for cash in the event Jazz Pharmaceuticals plc undergoes certain fundamental changes. Prior to August 15, 2021, we may redeem the 2021 Notes, in whole but not in part, subject to compliance with certain conditions, if we have, or on the next interest payment date would, become obligated to pay to the holder of any 2021 Note additional amounts as a result of certain tax-related events. We also may redeem the 2021 Notes on or after August 20, 2018, in whole or in part, if the last reported sale price per ordinary share has been at least 130% of the exchange price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide the notice of redemption.

The 2021 Notes are exchangeable at an initial exchange rate of 5.0057 ordinary shares per $1,000 principal amount of 2021 Notes, which is equivalent to an initial exchange price of approximately $199.77 per ordinary share. Upon exchange, the 2021 Notes may be settled in cash, ordinary shares or a combination of cash and ordinary shares, at our election. Our intent and policy is to settle the principal amount of the 2021 Notes in cash upon exchange. The exchange rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain make-whole fundamental changes occurring prior to the maturity date of the 2021 Notes or upon our issuance of a notice of redemption, we will in certain circumstances increase the exchange rate for holders of the 2021 Notes who elect to exchange their 2021 Notes in connection with that make-whole fundamental change or during the related redemption period. Prior to February 15, 2021, the 2021 Notes will be exchangeable only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date.

In accounting for the issuance of the 2021 Notes, we separated the 2021 Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the estimated fair value of a similar liability that does not have an associated exchange feature. The carrying amount of the equity component representing the exchange option was determined by deducting the fair value of the liability component from the face value of the 2021 Notes as a whole. The excess of the principal amount of the liability component over its carrying amount will be amortized to interest expense over the expected life of the 2021 Notes using the effective interest method with an effective interest rate of 6.4% per annum. We have determined the expected life of the 2021 Notes to be equal to the original seven-year term. The equity component is not remeasured as long as it continues to meet the conditions for equity classification. As of December 31, 2018 and 2017, the “if-converted value” did not exceed the principal amount of the 2021 Notes.

We allocated the total issuance costs incurred of $16.1 million to the liability and equity components based on their relative values. Issuance costs attributable to the liability component will be amortized to expense over the term of the 2021 Notes, and issuance costs attributable to the equity component were included with the equity component in our shareholders’ equity.

As of December 31, 2018 and 2017, the carrying value of the equity component of the 2021 Notes, net of equity issuance costs, was $126.9 million.

The Exchangeable Senior Notes were issued by Jazz Investments I Limited, or the Issuer, a 100%-owned finance subsidiary of Jazz Pharmaceuticals plc. The Exchangeable Senior Notes are senior unsecured obligations of the Issuer and are fully and unconditionally guaranteed on a senior unsecured basis by Jazz Pharmaceuticals plc. No subsidiary of Jazz Pharmaceuticals plc guaranteed the Exchangeable Senior Notes. Subject to certain local law restrictions on payment of dividends, among other things, and potential negative tax consequences, we are not aware of any significant restrictions on the ability of Jazz Pharmaceuticals plc to obtain funds from the Issuer or Jazz Pharmaceuticals plc’s other subsidiaries by dividend or loan, or any legal or economic restrictions on the ability of the Issuer or Jazz Pharmaceuticals plc’s other subsidiaries to transfer funds to Jazz Pharmaceuticals plc in the form of cash dividends, loans or advances. There is no assurance that in the future such restrictions will not be adopted.

For the years ended December 31, 2018, 2017 and 2016, we recognized $56.7 million, $37.8 million and $27.5 million, respectively, in interest expense, net related to the contractual coupon rate and amortization of the debt discount on the Exchangeable Senior Notes.

Scheduled maturities with respect to our long-term debt are as follows (in thousands):



Year Ending December 31,	Scheduled Long-Term Debt Maturities
2019	$	33,387
2020	33,387
2021	608,387
2022	33,387
2023	517,493
Thereafter	575,000
Total	$	1,801,041

Commitments and Contingencies

12 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Indemnification

In the normal course of business, we enter into agreements that contain a variety of representations and warranties and provide for general indemnification, including indemnification associated with product liability or infringement of intellectual property rights. Our exposure under these agreements is unknown because it involves future claims that may be made but have not yet been made against us. To date, we have not paid any claims or been required to defend any action related to these indemnification obligations.

We have agreed to indemnify our executive officers, directors and certain other employees for losses and costs incurred in connection with certain events or occurrences, including advancing money to cover certain costs, subject to certain limitations. The maximum potential amount of future payments we could be required to make under the indemnification obligations is unlimited; however, we maintain insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we believe the fair value of these indemnification obligations is not significant. Accordingly, we did not recognize any liabilities relating to these obligations as of December 31, 2018 and December 31, 2017. No assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations.

Lease and Other Commitments

Facility Leases. In January 2015, we entered into an agreement to lease office space located in Palo Alto, California in a building subsequently constructed by the landlord. The term of this lease is 12 years from the commencement date as defined in the lease agreement and we have an option to extend the term twice for a period of five years each. We are the deemed owner of the building based on applicable accounting guidance for build-to-suit leases. Accordingly, the landlord’s costs of constructing the building were capitalized on our consolidated balance sheets offset by a corresponding financing obligation. We began to occupy this office space in October 2017. As of December 31, 2018 and 2017, the total amount of the related financing obligation was $62.5 million and $62.9 million respectively, which is classified within current liabilities and non-current liabilities in our consolidated balance sheets.

In September 2017, we entered into an agreement to lease office space located in Palo Alto, California in a second building to be constructed by the same landlord. We expect to occupy this office space by the end of 2019. This lease has a term of 12 years from the commencement date as defined in the lease agreement and we have an option to extend the term of the lease twice for a period of five years each. We are the deemed owner of the building during the construction period based on applicable accounting guidance for build-to-suit leases. As of December 31, 2018, we recorded project construction costs of $47.3 million incurred by the landlord as construction-in-progress in property, plant and equipment, net and a corresponding financing obligation in other non-current liabilities on our consolidated balance sheets. We will increase the asset and financing obligation as additional building costs are incurred by the landlord during the construction period.

For the years ended December 31, 2018, 2017 and 2016, we recorded rent expense associated with the ground lease on our facility leases of $4.0 million, $2.4 million and $1.9 million, respectively, in our consolidated statements of income.

Future minimum lease payments under our noncancelable facility leases as of December 31, 2018, were as follows (in thousands):



Year Ending December 31,	Lease Payments
2019	$	9,881
2020	14,474
2021	14,908
2022	15,355
2023	15,816
Thereafter	119,409
Total	$	189,843

Operating Leases. We have noncancelable operating leases for our office buildings and we are obligated to make payments under noncancelable operating leases for automobiles used by our sales force.

Lease expense under our operating leases was as follows (in thousands):



	Year Ended December 31,
	2018		2017		2016
Lease expense	$	11,519	$	14,982	$	11,600

Future minimum lease payments under our noncancelable operating leases as of December 31, 2018, were as follows (in thousands):



Year ending December 31,	Lease Payments
2019	$	8,404
2020	6,269
2021	5,771
2022	5,388
2023	5,168
Thereafter	8,794
Total	$	39,794

In August 2016, we entered into an operating lease agreement for office space in Dublin, Ireland for a term of 20 years, with an option to terminate at the end of eight years with no less than one year’s prior written notice and the payment of a termination fee, and a further option to terminate at the end of 15 years with no less than one year’s prior written notice. We are obligated to make minimum lease payments totaling $16.9 million in connection with this lease.

Other Commitments. As of December 31, 2018, we had $65.1 million of noncancelable purchase commitments due within one year, primarily related to agreements with third party manufacturers.

Legal Proceedings

Xyrem ANDA Litigation and Settlements. In December 2012, we received a notice of Paragraph IV Patent Certification, or Paragraph IV Certification, from Amneal Pharmaceuticals LLC, or Amneal, that it had submitted an ANDA to the FDA requesting approval to market a generic version of Xyrem. In January 2013, we filed a lawsuit against Amneal in the federal district court of New Jersey, or District Court, alleging that our patents covering Xyrem are infringed or will be infringed by Amneal’s ANDA and seeking a permanent injunction to prevent Amneal from introducing a generic version of Xyrem that would infringe these patents. Additional patents covering Xyrem were issued after the date of the original lawsuit against Amneal, and lawsuits we brought against Amneal involving those patents were consolidated into a single case in the District Court.

In October 2018, we entered into a settlement agreement and related agreements resolving our patent infringement litigation against Amneal in the District Court, and the District Court subsequently approved an order dismissing the litigation. We previously settled lawsuits against the eight other companies that have sent us notices that they had filed ANDAs requesting approval to market a generic version of Xyrem. As a result, the settlement with Amneal represents settlement of all outstanding patent infringement litigation related to Xyrem. It is possible that additional companies may file ANDAs seeking to market a generic version of Xyrem or submit new drug applications referencing Xyrem, which could lead to additional patent litigation or challenges with respect to Xyrem.

In our settlement with Amneal, we granted Amneal the right to sell a limited volume of an authorized generic version of Xyrem, or AG Product, in the U.S. beginning on July 1, 2023, or earlier under certain circumstances. Such circumstances include events related to acceleration of the launch date of the AG Product of the first Xyrem ANDA filer, West-Ward Pharmaceuticals Corp., or West-Ward, the earlier launch of another party’s AG Product, the launch of another generic sodium oxybate product, or a final decision that all unexpired claims of the Xyrem patents are not infringed, or are invalid and/or unenforceable. The volume of Amneal’s AG Product is limited to an annual amount equal to a low single-digit percentage of Xyrem sales volume during the calendar year preceding the entry date of its AG Product, and Amneal’s right to sell its AG Product ends on December 31, 2025. We also granted Amneal a license under the Xyrem patents to launch its own generic sodium oxybate product under its ANDA on or after December 31, 2025, or earlier under certain circumstances. Such circumstances include events related to launch of a generic sodium oxybate product by West-Ward or another company under its ANDA, or a final decision that all unexpired claims of the Xyrem patents are not infringed, or are invalid and/or unenforceable. If an acceleration event occurs, then Amneal will have the option to elect to market its AG Product until December 31, 2025, but it will not be entitled to market its AG Product and its own generic sodium oxybate product simultaneously. We are entitled to receive a meaningful royalty on net sales of Amneal’s AG Product, as well as payment for the supply of its AG Product and reimbursement for a portion of the services costs associated with distribution of its AG Product through the Xyrem REMS. The specific terms of the settlement agreement are confidential.

Other Legal Proceedings. From time to time we are involved in legal proceedings arising in the ordinary course of business. We believe there is no litigation pending that could have, individually or in the aggregate, a material adverse effect on our results of operations or financial condition.

Other Contingencies

In May and October 2016 and in February 2017, we received subpoenas from the U.S. Attorney’s Office for the District of Massachusetts requesting documents related to our support of charitable organizations that provide financial assistance to Medicare patients. Other companies have disclosed similar subpoenas and continuing inquiries. We have a comprehensive program intended to ensure our compliance with applicable legal and regulatory requirements for pharmaceutical companies, including guidelines established by the Office of Inspector General of the U.S. Department of Health and Human Services regarding patient assistance programs, and we have been cooperating with the government’s investigation. We have engaged in discussions with the U.S. Department of Justice, or DOJ, about a possible resolution, and in April 2018, we reached an agreement in principle with the DOJ on a proposal for a civil settlement of potential claims by the DOJ in the amount of $57.0 million, subject to accrual of interest on the settlement amount from the date of the agreement in principle, negotiation of a definitive settlement agreement and other contingencies. During 2018, we recorded $58.2 million related to this matter, including related interest, within accrued liabilities on our consolidated balance sheet with the related expense included in selling, general and administrative expenses on our consolidated statement of income. We expect any such settlement will involve entry into a corporate integrity agreement, which will impose significant costs and operational burdens on our business. Moreover, a failure to comply with the terms of a corporate integrity agreement could result in monetary penalties or a reduction or elimination of coverage for our products by federal health care programs such as Medicare and Medicaid and state health care programs. If we do not reach a final settlement, or if we are unable to successfully negotiate and enter into a corporate integrity agreement, the outcome of this investigation could include an enforcement action against us. If the federal government were to file an enforcement action against us as a result of the investigation and could establish the elements of a violation of relevant laws, we could be subject to damages, fines and penalties, which could be substantial, along with other criminal, civil or administrative sanctions, including exclusion from participation in federal health care programs. We would expect to incur significant costs in connection with any enforcement action, regardless of the outcome.

Shareholders' Equity

12 Months Ended

Dec. 31, 2018

Equity [Abstract]

Shareholders' Equity

Shareholders’ Equity

Share Repurchase Program

In November 2015, our board of directors authorized a share repurchase program pursuant to which we were authorized to repurchase a number of ordinary shares having an aggregate purchase price of up to $300.0 million, exclusive of any brokerage commissions. In September 2016, we completed repurchases under the November 2015 share repurchase program. In November 2016, our board of directors authorized a new share repurchase program pursuant to which we were authorized to repurchase a number of ordinary shares having an aggregate purchase price of up to $300.0 million, exclusive of any brokerage commissions. In November and December 2018, our board of directors increased the existing share repurchase program authorization by $320.0 million and $400.0 million, respectively, thereby increasing the total amount authorized to $1.02 billion. Under this program, which has no expiration date, we may repurchase ordinary shares from time to time on the open market. The timing and amount of repurchases will depend on a variety of factors, including the price of our ordinary shares, alternative investment opportunities, restrictions under the amended credit agreement, corporate and regulatory requirements and market conditions. The share repurchase program may be modified, suspended or discontinued at any time without prior notice. In 2018, we spent a total of $523.7 million to repurchase 3.5 million of our ordinary shares at an average total purchase price, including brokerage commissions, of $148.33 per share. In 2017, we spent a total of $98.8 million to repurchase 0.7 million of our ordinary shares at an average total purchase price, including brokerage commissions, of $140.34 per share. All ordinary shares repurchased were canceled. As of December 31, 2018, the remaining amount authorized under the share repurchase program was $379.1 million.

Authorized But Unissued Ordinary Shares

We had reserved the following shares of authorized but unissued ordinary shares (in thousands):



	December 31,
	2018	2017
2011 Equity Incentive Plan	17,729	16,026
2007 Employee Stock Purchase Plan	1,126	339
Amended and Restated 2007 Non-Employee Directors Stock Award Plan	453	481
Amended and Restated Directors Deferred Compensation Plan	178	178
2007 Equity Incentive Plan	13	17
Total	19,499	17,041

Dividends

In 2018 and 2017, we did not declare or pay cash dividends on our common equity. Under Irish law, dividends may only be paid, and share repurchases and redemptions must generally be funded only out of, “distributable reserves.” In addition, the terms of our credit agreement restrict our ability to make certain restricted payments, including dividends and other distributions by us in respect of our ordinary shares, subject to, among other exceptions, (1) a general exception for dividends and restricted payments up to $30 million in the aggregate and (2) an exception that allows for restricted payments, subject to a cap equal to the sum of (i) $100 million plus (ii) so long as our secured leverage ratio (as defined in our credit agreement) does not exceed 3:1 after giving pro forma effect to the restricted payment, a formula-based amount tied to our consolidated net income; provided that such cap applies only if our total leverage ratio (as defined in our credit agreement) exceeds 2:1 after giving pro forma effect to the restricted payment.

Comprehensive Income (Loss)

12 Months Ended

Dec. 31, 2018

Equity [Abstract]

Comprehensive Income (Loss)

Comprehensive income (loss) includes net income and all changes in shareholders’ equity during a period, except for those changes resulting from investments by shareholders or distributions to shareholders.

Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss as of December 31, 2018 and December 31, 2017 were as follows (in thousands):



	Net Unrealized Gain From Hedging Activities			Foreign Currency Translation Adjustments			Total Accumulated Other Comprehensive Loss
Balance at December 31, 2017	$	1,482		$	(142,360	)	$	(140,878	)
Effect of adoption of ASU No. 2017-12	53			—			53
Balance at January 1, 2018	1,535			(142,360		)	(140,825		)
Other comprehensive income (loss) before reclassifications	2,274			(58,988		)	(56,714		)
Amounts reclassified from accumulated other comprehensive loss	(252		)	—			(252		)
Other comprehensive income (loss), net	2,022			(58,988		)	(56,966		)
Balance at December 31, 2018	$	3,557		$	(201,348	)	$	(197,791	)

In 2018, other comprehensive loss reflects foreign currency translation adjustments, primarily due to the weakening of the euro against the U.S. dollar, and the net unrealized gain on derivatives that qualify as cash flow hedges.

Net Income per Ordinary Share

12 Months Ended

Dec. 31, 2018

Earnings Per Share [Abstract]

Net Income per Ordinary Share

Basic net income per ordinary share attributable to Jazz Pharmaceuticals plc is based on the weighted-average number of ordinary shares outstanding. Diluted net income per ordinary share attributable to Jazz Pharmaceuticals plc is based on the weighted-average number of ordinary shares outstanding and potentially dilutive ordinary shares outstanding.

Basic and diluted net income per ordinary share attributable to Jazz Pharmaceuticals plc were computed as follows (in thousands, except per share amounts):



	Year Ended December 31,
	2018		2017		2016
Numerator:
Net income	$	447,098	$	487,848	$	396,831
Denominator:
Weighted-average ordinary shares used in per share calculations - basic	59,976		60,018		60,500
Dilutive effect of employee equity incentive and purchase plans	1,245		1,299		1,370
Weighted-average ordinary shares used in per share calculations - diluted	61,221		61,317		61,870

Net income per ordinary share :
Basic	$	7.45	$	8.13	$	6.56
Diluted	$	7.30	$	7.96	$	6.41

Potentially dilutive ordinary shares from our employee equity incentive and purchase plans, the 2021 Notes and the 2024 Notes are determined by applying the treasury stock method to the assumed exercise of share options, the assumed vesting of outstanding restricted stock units, or RSUs, the assumed issuance of ordinary shares under our employee stock purchase plan, or ESPP, and the assumed issuance of ordinary shares upon exchange of the 2021 Notes and the 2024 Notes, which we refer to together as the Exchangeable Senior Notes. The potential issue of ordinary shares issuable upon exchange of the Exchangeable Senior Notes had no effect on diluted net income per ordinary share because the average price of our ordinary shares in 2018, 2017 and 2016 did not exceed the effective exchange prices per ordinary share of the Exchangeable Senior Notes.

The following table represents the weighted-average ordinary shares that were excluded from the computation of diluted net income attributable to Jazz Pharmaceuticals plc per ordinary share for the years presented because including them would have an anti-dilutive effect (in thousands):



	Year Ended December 31,
	2018	2017	2016
Exchangeable Senior Notes	5,504	3,805	2,878
Options to purchase ordinary shares and RSUs	3,101	3,319	3,010
Ordinary shares under ESPP	12	14	93

Segment and Other Information

12 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

Segment and Other Information

Our operating segment is reported in a manner consistent with the internal reporting provided to the chief operating decision maker or, CODM. Our CODM has been identified as our chief executive officer. We have determined that we operate in one business segment, which is the identification, development and commercialization of meaningful pharmaceutical products that address unmet medical needs.

The following table presents total long-lived assets by location (in thousands):



	December 31,
	2018		2017
United States	$	126,941	$	95,570
Ireland	61,290		64,343
Italy	8,760		8,220
Other	3,367		1,947
Total long-lived assets (1)	$	200,358	$	170,080

_________________________


(1)	Long-lived assets consist of property, plant and equipment.

Revenues

12 Months Ended

Dec. 31, 2018

Revenue from Contract with Customer [Abstract]

Revenues

The following table presents a summary of total revenues (in thousands):



	Year Ended December 31,
	2018		2017		2016
Xyrem	$	1,404,866	$	1,186,699	$	1,107,616
Erwinaze/Erwinase	174,739		197,340		200,678
Defitelio/defibrotide	149,448		133,650		108,952
Vyxeos	100,835		33,790		—
Prialt	20,839		27,361		29,120
Other	18,746		22,559		30,895
Product sales, net	1,869,473		1,601,399		1,477,261
Royalties and contract revenues	21,449		17,294		10,712
Total revenues	$	1,890,922	$	1,618,693	$	1,487,973

The following table presents a summary of total revenues attributed to geographic sources (in thousands):



	Year Ended December 31,
	2018		2017		2016
United States	$	1,727,576	$	1,463,457	$	1,355,921
Europe	125,911		125,624		108,301
All other	37,435		29,612		23,751
Total revenues	$	1,890,922	$	1,618,693	$	1,487,973

The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues:



	Year Ended December 31,
	2018		2017		2016
Express Scripts	74	%	73	%	74	%
McKesson	17	%	16	%	15	%

Financing and payment

Our payment terms vary by the type and location of our customer but payment is generally required in a term ranging from 30 to 45 days.

Contract Liabilities - Deferred Revenue

The deferred revenue balance as of December 31, 2018 primarily related to deferred upfront fees received from Nippon Shinyaku Co., Ltd., or Nippon Shinyaku, in connection with two license, development and commercialization agreements granting Nippon Shinyaku exclusive rights to develop and commercialize each of Defitelio and Vyxeos in Japan. We recognized contract revenues of $7.5 million in 2018 relating to these upfront payments. The deferred revenue balances are being recognized over an average of four years representing the period we expect to perform our research and developments obligations under each agreement.

The following table presents a reconciliation of our beginning and ending balances in contract liabilities from contracts with customers for the year ended December 31, 2018 (in thousands):



	Contract Liabilities
Balance as of December 31, 2017	$	24,733
Effect of adoption of ASU 2014-09	(2,240		)
Amount recognized within royalties and contract revenues	(7,498		)
Balance as of December 31, 2018	$	14,995

Share-Based Compensation

12 Months Ended

Dec. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-Based Compensation

2011 Equity Incentive Plan

On January 18, 2012, the businesses of Jazz Pharmaceuticals, Inc. and Azur Pharma were combined in a merger transaction, or the Azur Merger. In connection with the Azur Merger, Jazz Pharmaceuticals, Inc.’s board of directors adopted the 2011 Equity Incentive Plan, or the 2011 Plan, in October 2011 and its stockholders approved the 2011 Plan at the special meeting of the stockholders held in December 2011 in connection with the Azur Merger. The 2011 Plan became effective immediately before the consummation of the Azur Merger and was assumed and adopted by us upon the consummation of the Azur Merger. The terms of the 2011 Plan provide for the grant of stock options, stock appreciation rights, restricted stock awards, RSUs, other stock awards, and performance awards that may be settled in cash, shares, or other property. All outstanding grants under the 2011 Plan were granted to employees and vest ratably over service periods of four years and expire no more than 10 years after the date of grant. As of December 31, 2018, a total of 24,424,669 of our ordinary shares had been authorized for issuance under the 2011 Plan. In addition, the share reserve under the 2011 Plan will automatically increase on January 1 of each year through January 1, 2022, by the least of (a) 4.5% of the total number of ordinary shares outstanding on December 31 of the preceding calendar year, (b) 5,000,000 shares, or (c) such lesser number of ordinary shares as determined by our board of directors. On January 1, 2019, the share reserve under the 2011 Plan automatically increased by 2,587,659 ordinary shares pursuant to this provision.

2007 Equity Incentive Plan

The 2007 Equity Incentive Plan, or the 2007 Plan, which was initially adopted by the Jazz Pharmaceuticals, Inc. board of directors and approved by the Jazz Pharmaceuticals, Inc. stockholders in connection with its initial public offering, was continued and assumed by us upon consummation of the Azur Merger. The 2007 Plan provided for the grant of stock options, restricted stock awards, RSUs, stock appreciation rights, performance stock awards and other forms of equity compensation to employees, including officers, non-employee directors and consultants. Prior to the consummation of the Azur Merger, all of the grants under the 2007 Plan were granted to employees and vest ratably over service periods of three to five years and expire no more than 10 years after the date of grant. Effective as of the closing of the Azur Merger on January 18, 2012, the number of shares reserved for issuance under the 2007 Plan was set to 1,000,000 ordinary shares. The share reserve under the 2007 Plan will not automatically increase. Since the Azur Merger, all of the new grants under the 2007 Plan were granted to non-employee directors, vest ratably over service periods of one to three years and expire no more than 10 years after the date of grant. The 2007 Plan expired in April 2017, and accordingly, no new grants can be awarded under the 2007 Plan. As of December 31, 2018, the number of shares reserved represents issuable shares from options granted but not yet exercised under the 2007 Plan.

2007 Employee Stock Purchase Plan

In 2007, Jazz Pharmaceuticals, Inc.’s employees became eligible to participate in the ESPP. The ESPP was amended and restated by Jazz Pharmaceuticals, Inc.’s board of directors in October 2011 and approved by its stockholders in December 2011. The amended and restated ESPP became effective immediately prior to the effective time of the Azur Merger and was assumed by us upon the consummation of the Azur Merger. The amended and restated ESPP allows our eligible employee participants (including employees of any of a parent or subsidiary company if our board of directors designates such company as eligible to participate) to purchase our ordinary shares at a discount of 15% through payroll deductions. The ESPP consists of a fixed offering period of 24 months with four purchase periods within each offering period. The number of shares available for issuance under our ESPP during any six-month purchase period is 175,000 shares. As of December 31, 2018, a total of 3,558,471 of our ordinary shares had been authorized for issuance under the ESPP. The share reserve under the ESPP will automatically increase on January 1 of each year through January 1, 2022, by the least of (a) 1.5% of the total number of ordinary shares outstanding on December 31 of the preceding calendar year, (b) 1,000,000 shares, and (c) such lesser number of ordinary shares as determined by our board of directors or a duly-authorized committee thereof. On January 1, 2019, the share reserve under the ESPP automatically increased by 862,553 ordinary shares pursuant to this provision.

Amended and Restated 2007 Non-Employee Directors Stock Award Plan

The Amended and Restated 2007 Non-Employee Directors Stock Award Plan, or the 2007 Directors Award Plan, which was initially adopted by the Jazz Pharmaceuticals, Inc. board of directors and approved by the Jazz Pharmaceuticals, Inc. stockholders in connection with its initial public offering, was continued and assumed by us upon the consummation of the Azur Merger. Until October 2011, the 2007 Directors Award Plan provided for the automatic grant of stock options to purchase shares of Jazz Pharmaceuticals, Inc.’s common stock to its non-employee directors initially at the time any individual first became a non-employee director, which vest over three years, and then annually over their period of service on its board of directors, which vest over one year. On October 24, 2011, Jazz Pharmaceuticals, Inc.’s board of directors amended the 2007 Directors Award Plan to eliminate all future initial and annual automatic grants so that future automatic grants would not be made that would be subject to the excise tax imposed by Section 4985 of the Internal Revenue Code of 1986, as amended, or the Internal Revenue Code, in connection with the Azur Merger. Accordingly, all future stock option grants under the 2007 Directors Award Plan will be at the discretion of our board of directors. Since the Azur Merger, all of the new grants under the 2007 Directors Award Plan were granted to non-employee directors and vest ratably over service periods of one to three years and expire no more than 10 years after the date of grant. In addition, the 2007 Directors Award Plan provides the source of shares to fund distributions made prior to August 15, 2010 under the Directors Deferred Compensation Plan described below. In August 2016, our shareholders approved our proposal to expand the types of stock awards that may be granted to our non-employee directors under the 2007 Directors Award Plan and eliminate the final automatic share reserve increase under the 2007 Directors Award Plan that was scheduled to occur on January 1, 2017. As of December 31, 2018, a total of 903,938 of our ordinary shares had been authorized for issuance under the 2007 Directors Award Plan.

Amended and Restated Directors Deferred Compensation Plan

In May 2007, the Jazz Pharmaceuticals, Inc. board of directors adopted the Directors Deferred Compensation Plan, or the Directors Deferred Plan, which was amended in December 2008 and was then amended and restated in August 2010, and which was continued and assumed by us upon consummation of the Azur Merger. The Directors Deferred Plan allows each non-employee director to elect to defer receipt of all or a portion of his or her annual retainer fees to a future date or dates. Amounts deferred under the Directors Deferred Plan are credited as shares of Jazz Pharmaceuticals, Inc.’s common stock (or our ordinary shares following the Azur Merger) to a phantom stock account, the number of which are based on the amount of the retainer fees deferred divided by the market value of Jazz Pharmaceuticals, Inc.’s common stock (or our ordinary shares following the Azur Merger) on the first trading day of the first open window period following the date the retainer fees are deemed earned. On the 10th business day following the day of separation from the board of directors or the occurrence of a change in control, or as soon thereafter as practical once the non-employee director has provided the necessary information for electronic deposit of the deferred shares, each non-employee director will receive (or commence receiving, depending upon whether the director has elected to receive distributions from his or her phantom stock account in a lump sum or in installments over time) a distribution of his or her phantom stock account, in our ordinary shares (i) reserved under the 2007 Directors Option Plan prior to August 15, 2010 and (ii) from a new reserve of 200,000 shares set up under the Directors Deferred Plan on August 15, 2010. Although we continue to maintain the Directors Deferred Plan, since the consummation of the Azur Merger we have not permitted and will not permit non-employee directors to defer any annual retainer fees under the Directors Deferred Plan. We recorded no expense in 2018, 2017 and 2016 related to retainer fees earned and deferred. As of December 31, 2018, 14,499 of our ordinary shares that were unissued related to retainer fees that were deferred under the Directors Deferred Plan.

Share-Based Compensation

The table below shows, for all share option grants, the weighted-average assumptions used in the Black-Scholes option pricing model and the resulting weighted-average grant date fair value of share options granted in each of the past three years:



	Year Ended December 31,
	2018			2017			2016
Grant date fair value	$	47.17		$	42.72		$	40.45
Volatility	35		%	35		%	39		%
Expected term (years)	4.5			4.3			4.2
Range of risk-free rates	2.2-3.0%			1.6-2.1%			0.8-1.6%
Expected dividend yield	—		%	—		%	—		%

We rely on a blend of the historical and implied volatilities of our own ordinary shares to determine expected volatility for share option grants. In addition, we use a single volatility estimate for each share option grant. The weighted-average volatility is determined by calculating the weighted average of volatilities for all share options granted in a given year.

The expected term of share option grants represents the weighted-average period the awards are expected to remain outstanding and our estimates were based on historical exercise data. The risk-free interest rate assumption was based on zero coupon U.S. Treasury instruments whose term was consistent with the expected term of our share option grants. The expected dividend yield assumption was based on our history and expectation of dividend payouts.

Share-based compensation expense related to share options, RSUs and grants under our ESPP was as follows (in thousands):



	Year Ended December 31,
	2018			2017			2016
Selling, general and administrative	$	76,770		$	83,218		$	79,037
Research and development	19,037			17,870			15,296
Cost of product sales	6,634			5,812			4,438
Total share-based compensation expense, pre-tax	102,441			106,900			98,771
Income tax benefit from share-based compensation expense	(17,230		)	(21,792		)	(30,022		)
Total share-based compensation expense, net of tax	$	85,211		$	85,108		$	68,749

We recognized income tax benefits related to share option exercises of $7.7 million, $8.9 million and $8.3 million in 2018, 2017 and 2016, respectively.

Share Options

The following table summarizes information as of December 31, 2018 and activity during 2018 related to our share option plans:



	Shares Subject to Outstanding Options (In thousands)		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In thousands)
Outstanding at January 1, 2018	5,145		$	121.06
Options granted	1,449		145.03
Options exercised	(772	)	107.45
Options forfeited	(424	)	139.36
Options expired	(118	)	169.18
Outstanding at December 31, 2018	5,280		127.08		6.8	$	78,389
Vested and expected to vest at December 31, 2018	5,027		126.32		6.7	78,332
Exercisable at December 31, 2018	3,070		117.08		5.5	77,725

Aggregate intrinsic value shown in the table above is equal to the difference between the exercise price of the underlying share options and the fair value of our ordinary shares for share options that were in the money. The aggregate intrinsic value changes based on the fair market value of our ordinary shares. The aggregate intrinsic value of share options exercised was $43.4 million, $38.9 million and $36.1 million during 2018, 2017 and 2016, respectively. We issued new ordinary shares upon exercise of share options.

As of December 31, 2018, total compensation cost not yet recognized related to unvested share options was $76.1 million, which is expected to be recognized over a weighted-average period of 2.6 years.

As of December 31, 2018, total compensation cost not yet recognized related to grants under the ESPP was $6.0 million, which is expected to be recognized over a weighted-average period of 1.2 years.

Restricted Stock Units

In 2018, we granted RSUs covering an equal number of our ordinary shares to employees with a weighted-average grant date fair value of $146.36. The fair value of RSUs is determined on the date of grant based on the market price of our ordinary shares as of that date. The fair value of the RSUs is recognized as an expense ratably over the vesting period of four years. In 2018, 374,000 RSUs were released with 253,000 ordinary shares issued and 121,000 ordinary shares withheld for tax purposes. The total fair value of shares vested was $55.8 million, $53.2 million and $59.2 million during 2018, 2017 and 2016, respectively.

As of December 31, 2018, total compensation cost not yet recognized related to unvested RSUs was $94.8 million, which is expected to be recognized over a weighted-average period of 2.5 years.

The following table summarizes information as of December 31, 2018 and activity during 2018 related to our RSUs:



	Number of RSUs (in thousands)		Weighted- Average Grant-Date Fair Value		Weighted- Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In thousands)
Outstanding at January 1, 2018	1,063		$	140.46
RSUs granted	606		146.36
RSUs released	(374	)	145.31
RSUs forfeited	(193	)	140.10
Outstanding at December 31, 2018	1,102		142.13		1.4	$	136,614

Employee Benefit Plans	12 Months Ended
Employee Benefit Plans	Dec. 31, 2018
Retirement Benefits [Abstract]
Employee Benefit Plans	Employee Benefit Plans We operate a number of defined contribution retirement plans. The costs of these plans are charged to the consolidated statements of income in the period they are incurred. We recorded expense related to our defined contribution plans of $6.4 million, $5.5 million and $3.4 million in 2018, 2017 and 2016, respectively. In Ireland, we operate a defined contribution plan in which we contribute up to 8% of an employee’s eligible earnings. We recorded expense of $1.2 million, $1.0 million and $0.8 million in 2018, 2017 and 2016, respectively, in connection with the contributions we made under the Irish defined contribution plan. In the U.S., we provide a qualified 401(k) savings plan for our U.S.-based employees. All U.S.-based employees are eligible to participate, provided they meet the requirements of the plan. In 2013, we elected to match certain employee contributions under the 401(k) savings plan. We recorded expense of $4.2 million, $3.7 million and $1.9 million in 2018, 2017 and 2016, respectively. In the United Kingdom, or UK, we operate a defined contribution plan in which we contribute up to 12% of an employee’s eligible earnings. We recorded expense of $0.8 million, $0.7 million and $0.6 million in 2018, 2017 and 2016, respectively, in connection with contributions we made under the UK defined contribution plan. In France, we accrue for a potential liability which is payable if an employee retires. The accrued liability for France was $0.4 million as of December 31, 2018 and $0.3 million as of December 31, 2017. In Italy, we accrue for a potential liability which is payable if an employee leaves employment. The accrued liability for Italy was $0.3 million as of December 31, 2018 and 2017.

Restructuring

12 Months Ended

Dec. 31, 2018

Restructuring and Related Activities [Abstract]

Restructuring

In 2016, we recorded severance costs of $1.5 million for terminated employees in connection with the reorganization of our operations, primarily in France, Italy and the United Kingdom. These one-time termination benefits were recorded over the remaining service period where employees were required to stay through their termination date to receive the benefits and included within cost of product sales and selling, general and administrative expenses in our consolidated statements of income. As of December 31, 2017, we had incurred total termination benefit costs of $3.0 million in connection with these reorganizations. We completed these restructuring activities in 2017. There were no restructuring activities in 2018.

The following table summarizes the amounts related to total restructuring through December 31, 2017 (in thousands):



	Termination Benefits
Balance at December 31, 2015	$	1,105
Expense	1,516
Payments	(2,590		)
Balance at December 31, 2016	31
Expense	14
Payments	(45		)
Balance at December 31, 2017	$	—

Income Taxes

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Income Taxes

The components of income before the income tax provision (benefit) and equity in loss of investees were as follows (in thousands):



	Year Ended December 31,
	2018		2017		2016
Ireland	$	170,666	$	77,476	$	179,570
United States	294,621		271,440		312,904
Other	64,176		92,201		39,972
Total	$	529,463	$	441,117	$	532,446

The following table sets forth the details of the income tax provision (benefit) (in thousands):



	Year Ended December 31,
	2018			2017			2016
Current
Ireland	$	33,431		$	28,045		$	26,420
United States	95,143			135,608			140,061
Other	40,403			14,198			9,918
Total current tax expense	168,977			177,851			176,399
Deferred, exclusive of other components below
Ireland	(12,408		)	(19,709		)	(7,776		)
United States	(41,337		)	(27,559		)	(9,120		)
Other	(34,545		)	(19,108		)	(13,720		)
Total deferred, exclusive of other components	(88,290		)	(66,376		)	(30,616		)
Deferred, change in tax rates
United States	(538		)	(155,679		)	109
Other	13			(3,536		)	(10,656		)
Total deferred, change in tax rates	(525		)	(159,215		)	(10,547		)
Total deferred tax benefit	(88,815		)	(225,591		)	(41,163		)
Total income tax provision (benefit)	$	80,162		$	(47,740	)	$	135,236

On December 22, 2017, the U.S. Tax Cuts and Jobs Act, or U.S. Tax Act, was signed into law. The legislation significantly changed U.S. tax law by, among other things, lowering corporate income tax rates, implementing a modified territorial tax system, imposing a one-time transition tax on deemed repatriated earnings of foreign subsidiaries and changing the rules which determine whether a U.S. person is a U.S. shareholder of a controlled foreign corporation, or CFC, for 2017 and onwards. The U.S. Tax Act reduced the U.S. corporate income tax rate from a maximum of 35% to a flat 21% rate, effective January 1, 2018.

We use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. As a result of the reduction in the U.S. federal income tax rate from 35% to 21% under the U.S. Tax Act, we remeasured our ending net deferred tax liabilities as of December 31, 2017 and recognized a $155.1 million income tax benefit in our consolidated statement of income in 2017.

On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118, or SAB 118, to address the application of U.S. GAAP in situations when a registrant did not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail as of December 31, 2017 to complete the accounting for certain income tax effects of the U.S. Tax Act. As of December 31, 2017 the Company had recorded provisional amounts in accordance with SAB 118 in relation to certain matters before finalizing its analysis during 2018.

The U.S. Tax Act provided for a one-time transition tax on the mandatory deemed repatriation of post-1986 undistributed foreign subsidiary earnings and profits through the year ended December 31, 2017 and also changed the rules which determine whether a U.S. person is a U.S. shareholder of a CFC for 2017 and onwards. In relation to these changes, we recognized a provisional $6.3 million of income tax provision in our consolidated statement of income in 2017, which was composed of state current tax expense and deferred tax expense. We have now finalized our analysis and recorded an adjusting deferred tax benefit of $7.5 million in our consolidated statement of income during the twelve months ended December 31, 2018 in accordance with SAB 118. This adjustment consisted of a benefit of $10.3 million, primarily due to additional analysis of our ability to utilize foreign tax credits generated by the one-time transition tax following the changes to the rules which determine whether a U.S. person is a U.S. shareholder of a CFC, net of an income tax provision of $2.9 million primarily due to additional analysis on the one-time transition tax on deemed repatriated earnings of foreign subsidiaries.

We had also recognized the provisional tax impact related to changes to the rules regarding the deductibility of certain executive compensation (including the recognition of a related provisional deferred tax asset of $7.5 million) in our consolidated statement of income in 2017. Following further analysis, we determined that this provisional deferred tax asset related to certain executive compensation is recognizable as of December 31, 2018.

While the U.S. Tax Act provides for a territorial tax system, beginning in 2018, it also included two new U.S. tax base erosion provisions, the global intangible low-taxed income, or GILTI, provisions and the base-erosion and anti-abuse tax, or BEAT, provisions. The GILTI provisions require us to include in our U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary’s tangible assets. The GILTI tax expense recognized in our consolidated statement of income in 2018 was not significant. The Company elects to account for tax expenses associated with the GILTI provisions in the period they are incurred.

The BEAT provisions in the U.S. Tax Act eliminate the deduction of certain base-erosion payments made to related foreign corporations, and impose a minimum tax if greater than regular tax. We have completed our analysis of the BEAT provisions and determined that the Company is not subject to BEAT in 2018.

Our income tax provision (benefit) of $80.2 million, $(47.7) million and $135.2 million in 2018, 2017 and 2016, respectively, related to tax arising on income in Ireland, the U.S. and certain other foreign jurisdictions, certain unrecognized tax benefits and various expenses not deductible for income tax purposes. The income tax benefit in 2017 included a provisional benefit of $148.8 million relating to the impact of the enactment of the U.S Tax Act.

The effective tax rates for 2018, 2017 and 2016 were 15.1%, (10.8)% and 25.4%, respectively. The income tax benefit recognized in 2017 in respect of the impact of the enactment of the U.S. Tax Act resulted in a net decrease to our effective tax rate of 33.7%. The effective tax rates for 2018 and 2016 were higher than the Irish statutory rate of 12.5%, primarily due to income taxable at a rate higher than the Irish statutory rate and unrecognized tax benefits, partially offset by the release of reserves related to unrecognized tax benefits from the expiration of a statute of limitation, originating tax credits and the release of a valuation allowance held against certain foreign net operating losses, or NOLs. The effective tax rate for 2017 was lower than the Irish statutory rate of 12.5%, primarily due to the impact of the enactment of the U.S. Tax Act. The increase in the effective tax rate in 2018 compared to 2017 was primarily due to the impact of the enactment of the U.S. Tax Act in 2017. Excluding this effect, the effective tax rate in 2018 would have decreased compared to 2017, primarily due to a decrease in the U.S. corporate income tax rate. The decrease in the effective tax rate in 2017 compared to 2016 was primarily due to the impact of the enactment of the U.S. Tax Act in 2017. Excluding this effect, the decrease in our effective tax rate in 2017 compared to 2016 was primarily due to the release of a valuation allowance held against certain foreign NOLs and the release of reserves related to unrecognized tax benefits upon the expiration of a statute of limitation, partially offset by a reduction in deductions available in relation to subsidiary equity.

The reconciliation between the statutory income tax rate applied to income before the income tax provision (benefit) and equity in loss of investees and our effective income tax rate was as follows:



	Year Ended December 31,
	2018		2017		2016
Statutory income tax rate	12.5	%	12.5	%	12.5	%
Foreign income tax rate differential	11.9	%	20.3	%	16.7	%
Investment in subsidiaries	(5.3	)%	(0.7	)%	(2.4	)%
Financing costs	(4.3	)%	(5.6	)%	(2.9	)%
Research and other tax credits	(3.9	)%	(2.6	)%	(2.8	)%
Change in valuation allowance	3.2	%	(2.8	)%	(0.1	)%
Impact of U.S. Tax Act	(1.4	)%	(33.7	)%	—	%
Non-deductible compensation	1.2	%	2.6	%	1.8	%
Change in unrecognized tax benefits	1.1	%	2.8	%	3.3	%
Change in estimates	(1.1	)%	(2.1	)%	—	%
Non-deductible loss contingency	0.8	%	—	%	—	%
Excess tax benefits from share-based compensation	(0.4	)%	(1.5	)%	(1.5	)%
Change in tax rate	(0.1	)%	(0.4	)%	(1.8	)%
Acquisition-related costs	—	%	—	%	2.1	%
Other	0.9	%	0.4	%	0.5	%
Effective income tax rate	15.1	%	(10.8	)%	25.4	%

Significant components of our net deferred tax assets/(liabilities) were as follows (in thousands):



	December 31,
	2018			2017
Deferred tax assets:
Net operating loss carryforwards	$	106,128		$	125,966
Tax credit carryforwards	156,242			130,782
Intangible assets	23,469			23,536
Share-based compensation	24,592			23,128
Accruals	57,575			45,088
Indirect effects of unrecognized tax benefits	34,349			29,733
Investment in subsidiaries	25,585			—
Other	51,175			63,235
Total deferred tax assets	479,115			441,468
Valuation allowance	(61,237		)	(52,144		)
Net deferred tax assets	417,878			389,324
Deferred tax liabilities:
Intangible assets	(595,746		)	(655,347		)
Other	(73,350		)	(82,890		)
Total deferred tax liabilities	(669,096		)	(738,237		)
Net deferred tax liabilities	$	(251,218	)	$	(348,913	)

The net change in valuation allowance was an increase of $9.1 million and $19.2 million in 2018 and 2016, respectively, and a decrease of $1.0 million in 2017.

The following table presents the breakdown between deferred tax assets and liabilities (in thousands):



	Year Ended December 31,
	2018			2017
Deferred tax assets	$	57,879		$	34,559
Deferred tax liabilities	(309,097		)	(383,472		)
Net deferred tax liabilities	$	(251,218	)	$	(348,913	)

As of December 31, 2018, we had NOL carryforwards and tax credit carryforwards for U.S. federal income tax purposes of approximately $324.8 million and $137.3 million, respectively, available to reduce future income subject to income taxes. These NOL carryforwards are inclusive of $53.6 million from the EUSA Acquisition in 2012 and $211.5 million from the Celator Acquisition in 2016. The U.S. federal NOL carryforwards will expire, if not utilized, in the tax years 2019 to 2035, and the U.S. federal tax credits will expire, if not utilized, in the tax years 2019 to 2038. In addition, we had approximately $83.5 million of NOL carryforwards and $12.7 million of tax credit carryforwards as of December 31, 2018 available to reduce future taxable income for U.S. state income tax purposes. The U.S. state NOL carryforwards will expire, if not utilized, in the tax years 2019 to 2034. In addition, as of December 31, 2018, there were NOL carryforwards for income tax purposes of approximately $80.2 million and $51.9 million available to reduce future income subject to income taxes in Luxembourg and the United Kingdom, respectively. The NOLs generated in Luxembourg and the United Kingdom have no expiration date. We also had excess foreign tax credits, as of December 31, 2018, of $8.7 million, which may only be utilized against certain sources of income. The excess foreign tax credits have no expiration date.

Utilization of certain of our NOL and tax credit carryforwards in the U.S. is subject to an annual limitation due to the ownership change limitations provided by Sections 382 and 383 of the Internal Revenue Code and similar state provisions. Such an annual limitation may result in the expiration of certain NOLs and tax credits before future utilization. We currently estimate that we have an annual limitation on the utilization of certain acquired federal NOLs and credits of $445.6 million, before tax effect, for 2019, $27.8 million, before tax effect, for 2020 and a combined total of $283.2 million, before tax effect, for 2021 to 2032. In addition, as a result of the Azur Merger, until 2022 we are subject to certain limitations under the Internal Revenue Code in relation to the utilization of U.S. NOLs to offset U.S. taxable income resulting from certain transactions.

Valuation allowances require an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction-by-jurisdiction basis. Our valuation allowance was $61.2 million and $52.1 million as of December 31, 2018 and 2017, respectively, for certain Irish, U.S. (federal and state) and foreign deferred tax assets which we maintain until sufficient positive evidence exists to support reversal. During 2018, as part of the overall change in valuation allowance, we recognized a net income tax provision of $11.2 million relating primarily to the creation of a valuation allowance of $25.7 million against certain deferred tax assets primarily associated with temporary differences related to foreign subsidiaries, partially offset by the net release of valuation allowances against certain deferred tax assets primarily associated with NOLs and foreign tax credits. The $11.2 million net income tax provision includes a benefit of $10.9 million relating to a change in judgment leading to the reversal of a valuation allowance against certain deferred tax assets, primarily related to NOLs in the United Kingdom and a benefit of $5.9 million relating to the reversal of a valuation allowance upon completing our analysis of our ability to utilize certain foreign tax credits generated by the one-time transition tax in the U.S. Management determined that valuation allowances were no longer needed on these deferred tax assets based on an assessment of the relative impact of all positive and negative evidence that existed at December 31, 2018, including an evaluation of cumulative income in recent years, future sources of taxable income exclusive of reversing temporary differences, and significant risks and uncertainties related to our business. During 2017, as part of the overall change in valuation allowance, we recognized a net income tax benefit of $6.6 million relating to the net release of a valuation allowance against certain deferred tax assets primarily associated with NOLs, partially offset by the creation of a provisional valuation allowance of $5.9 million against certain deferred tax assets primarily associated with excess foreign tax credits generated during the year as a result of the U.S. Tax Act. The $6.6 million net income tax benefit includes a benefit of $9.1 million relating to the utilization of NOL carryforwards against which a valuation allowance was carried. During 2016, as part of the overall change in valuation allowance, we recognized a net income tax provision of $17.9 million relating to the creation of a valuation allowance against certain deferred tax assets primarily associated with NOLs recognized during the year, partially offset by a release of a valuation allowance due to the impact of the reduction of tax rates in certain jurisdictions and utilization of certain deferred tax assets primarily associated with NOLs. We periodically evaluate the likelihood of the realization of deferred tax assets and will adjust such amounts in light of changing facts and circumstances including, but not limited to, future projections of taxable income, tax legislation, rulings by relevant tax authorities, the progress of tax audits and the regulatory approval of products currently under development. Realization of substantially all the deferred tax assets is dependent on future book income.

Temporary differences related to foreign subsidiaries that are considered indefinitely reinvested totaled approximately $1.2 billion and $1.7 billion as of December 31, 2018 and 2017, respectively. In the event of the distribution of those earnings in the form of dividends, a sale of the subsidiaries, or certain other transactions, we may be liable for income taxes, subject to an adjustment, if any, for foreign tax credits and foreign withholding taxes payable to certain foreign tax authorities. As of December 31, 2018, it was not practicable to determine the amount of the unrecognized deferred tax liability related to these earnings.

We are required to recognize the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. As a result, we have recorded an unrecognized tax benefit for certain tax benefits which we judge may not be sustained upon examination.

A reconciliation of our gross unrecognized tax benefits follows (in thousands):



	December 31,
	2018			2017			2016
Balance at the beginning of the year	$	106,162		$	90,910		$	66,385
Increases related to current year tax positions	22,649			27,875			26,873
Increases related to prior year tax positions	7,584			1,620			1,191
Decreases related to prior year tax positions	—			(1,075		)	(255		)
Lapse of the applicable statute of limitations	(18,182		)	(13,168		)	(3,284		)
Balance at the end of the year	$	118,213		$	106,162		$	90,910

The unrecognized tax benefits were included in other non-current liabilities and deferred tax assets, net, in our consolidated balance sheets. Interest related to our unrecognized tax benefits is recorded in the income tax provision in our consolidated statements of income. As of December 31, 2018 and 2017, our accrued interest and penalties related to unrecognized tax benefits was $6.3 million and $3.6 million, respectively. Included in the balance of unrecognized tax benefits were potential benefits of $78.5 million and $73.5 million at December 31, 2018 and 2017, respectively, that, if recognized, would affect the effective tax rate on income.

We file income tax returns in multiple tax jurisdictions, the most significant of which are Ireland and the U.S. (both at the federal level and in various state jurisdictions). For Ireland we are no longer subject to income tax audits by taxing authorities for the years prior to 2013. The U.S. jurisdictions generally have statute of limitations three to four years from the later of the return due date or the date when the return was filed. However, in the U.S. (at the federal level and in most states), carryforward tax attributes that were generated in 2014 and earlier may still be adjusted upon examination by the tax authorities. Certain of our subsidiaries are currently under examination by the French tax authorities for the years ended December 31, 2012, 2013, 2015, 2016 and 2017. These examinations may lead to ordinary course adjustments or proposed adjustments to our taxes. In December 2015, we received proposed tax assessment notices, and, in October 2018, we received revised tax assessment notices from the French tax authorities for 2012 and 2013 and in December 2018, we received a proposed tax assessment notice for 2015, relating to certain transfer pricing adjustments. The notices propose additional French tax of approximately $43 million for 2012 and 2013 and approximately $4 million for 2015, including interest and penalties through the respective dates of the proposed assessments, translated at the foreign exchange rate at December 31, 2018. We disagree with the proposed assessments and are contesting them vigorously.

Subsequent Event	12 Months Ended
Subsequent Event	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event Collaboration and License Agreement On January 2, 2019, we entered into a strategic collaboration agreement with Codiak BioSciences, Inc., or Codiak, focused on the research, development and commercialization of exosome therapeutics to treat cancer. Codiak granted us an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize therapeutic candidates directed at five targets to be developed using Codiak's engEx™ precision engineering platform for exosome therapeutics. Under the terms of the agreement, Codiak is responsible for the execution of preclinical and early clinical development of therapeutic candidates directed at all five targets through Phase 1/2 proof of concept studies. Following the conclusion of the applicable Phase 1/2 study, we will be responsible for future development, potential regulatory submissions and commercialization for each product. Codiak has the option to participate in co-commercialization and cost/profit-sharing in the U.S. and Canada on up to two products. As part of the agreement, we paid Codiak an upfront payment of $56.0 million in January 2019, which will be recorded as acquired IPR&D expense in our consolidated statements of income in 2019. Codiak is eligible to receive up to $20 million in preclinical development milestone payments across all five programs. Codiak is also eligible to receive milestone payments totaling up to $200 million per target based on investigational new drug application acceptance, clinical and regulatory milestones, including approvals in the U.S., the EU and Japan, and certain sales milestones. Codiak is also eligible to receive tiered royalties on net sales of each approved product.

Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2018

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Data (Unaudited)

The following interim financial information presents our 2018 and 2017 results of operations on a quarterly basis (in thousands, except per share amounts):



	2018
	March 31		June 30		September 30		December 31
Revenues	$	444,613	$	500,479	$	469,373	$	476,457
Gross margin (1)	406,928		461,381		438,623		440,997
Net income	45,991		92,321		149,316		159,470
Net income per ordinary share, basic	0.77		1.53		2.47		2.69
Net income per ordinary share, diluted	0.75		1.50		2.41		2.64



	2017
	March 31		June 30		September 30		December 31
Revenues	$	376,053	$	394,386	$	411,855	$	436,399
Gross margin (1)	348,613		360,983		376,768		404,847
Net income	86,511		105,604		63,526		232,207
Net income per ordinary share, basic	1.44		1.76		1.06		3.87
Net income per ordinary share, diluted	1.41		1.72		1.03		3.79

__________________________


(1)	Gross margin is computed by subtracting cost of product sales (excluding amortization of intangible assets) from product sales, net.

The interim financial information above includes the following items:


•	Estimated loss contingency of $57.0 million in the first quarter of 2018;


•	Impairment charges and disposal costs of $44.0 million in the second quarter of 2018;


•	Upfront and milestone payments of $11.0 million in the first quarter of 2018 and $75.0 million and $26.5 million in the third and fourth quarters of 2017, respectively;


•	Expenses related to certain legal proceedings and restructuring of $6.0 million in the first quarter of 2017; and


•	A net expense of $2.9 million and a net benefit of $10.3 million in the third and fourth quarters of 2018, respectively, and a net benefit of $148.8 million in the fourth quarter of 2017 in respect of the impact of the U.S. Tax Act.

Schedule II Valuation and Qualifying Accounts

12 Months Ended

Dec. 31, 2018

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

Schedule II Valuation and Qualifying Accounts

Schedule II

Valuation and Qualifying Accounts

(In thousands)



		Balance at beginning of period		Additions charged to costs and expenses		Other Additions		Deductions			Balance at end of period
For the year ended December 31, 2018
Allowance for doubtful accounts	(1)	$	396	$	20	$	—	$	(366	)	$	50
Allowance for sales discounts	(1)	103		811		—		(838		)	76
Allowance for chargebacks	(1)	3,663		41,387		—		(44,642		)	408
Deferred tax asset valuation allowance	(2)(3)	52,144		35,500		—		(26,407		)	61,237

For the year ended December 31, 2017
Allowance for doubtful accounts	(1)	$	287	$	231	$	—	$	(122	)	$	396
Allowance for sales discounts	(1)	118		1,087		—		(1,102		)	103
Allowance for chargebacks	(1)	4,749		41,941		—		(43,027		)	3,663
Deferred tax asset valuation allowance	(2)(3)(4)	53,184		7,509		5,581		(14,130		)	52,144

For the year ended December 31, 2016
Allowance for doubtful accounts	(1)	$	489	$	168	$	—	$	(370	)	$	287
Allowance for sales discounts	(1)	181		1,334		—		(1,397		)	118
Allowance for chargebacks	(1)	3,023		41,991		—		(40,265		)	4,749
Deferred tax asset valuation allowance	(2)(3)(4)	33,949		19,328		5,544		(5,637		)	53,184

__________________________


(1)	Shown as a reduction of accounts receivable. Charges related to sales discounts and chargebacks are reflected as a reduction of revenue.


(2)	Additions to the deferred tax asset valuation allowance relate to movements on certain Irish, U.S. (federal and state) and other foreign deferred tax assets where we continue to maintain a valuation allowance until sufficient positive evidence exists to support reversal.


(3)	Deductions to the deferred tax asset valuation allowance include movements relating to utilization of NOLs and tax credit carryforwards, release in valuation allowance and other movements including adjustments following finalization of tax returns.


(4)	Other additions to the deferred tax asset valuation allowance relate to currency translation adjustments recorded directly in other comprehensive income and a valuation allowance recognized in 2016 on purchase accounting.

Summary of Significant Accounting Policies - (Policies)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Basis of Presentation

Use of Estimates

Recent Accounting Pronouncements

Adoption of New Accounting Standards

Significant Risks and Uncertainties

Concentrations of Risk

Business Acquisitions

Cash Equivalents and Investments

We consider all highly liquid investments, readily convertible to cash, that mature within three months or less from date of purchase to be cash equivalents.

Derivative Instruments and Hedging Activities

Inventories

Property and Equipment

Property, Plant and Equipment



Buildings	40 years
Manufacturing equipment and machinery	5-10 years
Computer software and equipment	3 years
Furniture and fixtures	5 years

Operating Leases and Financing Obligations

Goodwill, Acquired In-Process Research and Development, and Intangible Assets

Goodwill

Acquired In-Process Research and Development

Intangible Assets

Revenue Recognition

Product Sales, Net

Reserves for Variable Consideration

Royalties and Contract Revenues

Cost of Product Sales

Research and Development

Advertising Expenses

We expense the costs of advertising, including promotional expenses, as incurred.

Income Taxes

Foreign Currency

Deferred Financing Costs

Contingencies

Share-Based Compensation

Summary of Significant Accounting Policies - (Tables)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Schedule of New Accounting Pronouncements and Changes in Accounting Principles

The cumulative effect of the changes made to our consolidated balance sheet as of January 1, 2018 for the adoption of the above accounting standards was as follows (in thousands):



	Balance at December 31, 2017			Transition Adjustments			Balance at January 1, 2018
Assets:
Deferred tax assets, net	$	34,559		$	595		$	35,154
Liabilities:
Deferred revenue	8,618			(1,120		)	7,498
Deferred revenue, non-current	16,115			(1,120		)	14,995
Deferred tax liabilities, net	383,472			3,114			386,586
Shareholders' Equity:
Accumulated other comprehensive loss	(140,878		)	53			(140,825		)
Retained earnings	917,956			(332		)	917,624

Schedule of property and equipment

Estimated useful lives are as follows:



Buildings	40 years
Manufacturing equipment and machinery	5-10 years
Computer software and equipment	3 years
Furniture and fixtures	5 years

Property, plant and equipment consisted of the following (in thousands):



	December 31,
	2018			2017
Build-to-suit facility	$	52,067		$	51,721
Construction-in-progress	51,243			21,738
Land and buildings	46,650			46,729
Leasehold improvements	33,273			28,779
Manufacturing equipment and machinery	25,837			23,586
Computer software	19,062			19,969
Computer equipment	13,679			12,814
Furniture and fixtures	8,155			5,947
Subtotal	249,966			211,283
Less accumulated depreciation and amortization	(49,608		)	(41,203		)
Property, plant and equipment, net	$	200,358		$	170,080

Business Combination, Asset Acquisitions, and Disposition - (Tables)

12 Months Ended

Dec. 31, 2018

Business Combinations [Abstract]

Summary of assets and liabilities assumed in acquisition

The fair values of assets acquired and liabilities assumed at the closing date of the Celator Acquisition are summarized below (in thousands):



Cash and cash equivalents	$	26,137
Other receivables	386
Prepaid expenses and deposits	151
Property, plant and equipment	767
Intangible assets	1,811,250
Goodwill	252,825
Other non-current assets	43
Accrued liabilities	(19,076		)
Deferred tax liability, net, non-current	(542,901		)
Other non-current liabilities	(1,002		)
Total acquisition consideration - cash paid	$	1,528,580

Summary of pro forma financial information

The unaudited pro forma results do not assume any operating efficiencies as a result of the consolidation of operations and are as follows (in thousands, except per share data):



	Year Ended December 31, 2016
Revenues	$	1,488,118
Net income attributable to Jazz Pharmaceuticals plc	$	386,342
Net income attributable to Jazz Pharmaceuticals plc per ordinary share - basic	$	6.39
Net income attributable to Jazz Pharmaceuticals plc per ordinary share - diluted	$	6.24

Cash and Available-for-Sale Securities - (Tables)

12 Months Ended

Dec. 31, 2018

Cash and Cash Equivalents [Abstract]

Cash and Cash Equivalents and Investments

Cash and cash equivalents and investments consisted of the following (in thousands):



	December 31, 2018
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value		Cash and Cash Equivalents		Investments
Cash	$	215,606	$	—	$	—	$	215,606	$	215,606	$	—
Time deposits	515,000		—		—		515,000		—		515,000
Money market funds	94,016		—		—		94,016		94,016		—
Totals	$	824,622	$	—	$	—	$	824,622	$	309,622	$	515,000



	December 31, 2017
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value		Cash and Cash Equivalents		Investments
Cash	$	225,235	$	—	$	—	$	225,235	$	225,235	$	—
Time deposits	235,000		—		—		235,000		20,000		215,000
Money market funds	140,800		—		—		140,800		140,800		—
Totals	$	601,035	$	—	$	—	$	601,035	$	386,035	$	215,000

Fair Value Measurement - (Tables)

12 Months Ended

Dec. 31, 2018

Fair Value Disclosures [Abstract]

Assets and Liabilities Measured at Fair Value on Recurring Basis



	December 31, 2018						December 31, 2017
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Total Estimated Fair Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Total Estimated Fair Value
Assets:
Available-for-sale securities:
Time deposits	$	—	$	515,000	$	515,000	$	—	$	235,000	$	235,000
Money market funds	94,016		—		94,016		140,800		—		140,800
Interest rate contracts	—		4,070		4,070		—		2,138		2,138
Foreign exchange forward contracts	—		1,194		1,194		—		15,495		15,495
Totals	$	94,016	$	520,264	$	614,280	$	140,800	$	252,633	$	393,433
Liabilities:
Interest rate contracts	$	—	$	—	$	—	$	—	$	392	$	392
Foreign exchange forward contracts	—		1,460		1,460		—		5,017		5,017
Totals	$	—	$	1,460	$	1,460	$	—	$	5,409	$	5,409

Derivatives Instruments and Hedging Activities - (Tables)

12 Months Ended

Dec. 31, 2018

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of gains (losses) on derivative instruments

The impact on accumulated other comprehensive loss and earnings from derivative instruments that qualified as cash flow hedges was as follows (in thousands):



	Year Ended December 31,
Interest Rate Contracts:	2018			2017
Gain (loss) recognized in accumulated other comprehensive loss, net of tax	$	2,274		$	(213	)
Loss (gain) reclassified from accumulated other comprehensive loss to interest expense, net of tax	$	(252	)	$	1,695

Schedule of foreign exchange gain (loss) of outstanding derivatives



	Year Ended December 31,
Foreign Exchange Forward Contracts:	2018			2017
Gain (loss) recognized in foreign exchange gain (loss)	$	(14,648	)	$	17,902

Schedule of the fair value of outstanding derivatives

The following table summarizes the fair value of outstanding derivatives (in thousands):



	December 31, 2018
	Asset Derivatives			Liability Derivatives
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments:
Interest rate contracts	Other current assets	$	1,929	Accrued liabilities	$	—
	Other non-current assets	2,141
Derivatives not designated as hedging instruments:
Foreign exchange forward contracts	Other current assets	1,194		Accrued liabilities	1,460
Total fair value of derivative instruments		$	5,264		$	1,460



	December 31, 2017
	Asset Derivatives			Liability Derivatives
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments:
Interest rate contracts	Other non-current assets	$	2,138	Accrued liabilities	$	392
Derivatives not designated as hedging instruments:
Foreign exchange forward contracts	Other current assets	15,495		Accrued liabilities	5,017
Total fair value of derivative instruments		$	17,633		$	5,409

Schedule of offsetting assets

The following table summarizes the potential effect on our consolidated balance sheets of offsetting our interest rate contracts and foreign exchange forward contracts subject to such provisions (in thousands):



	December 31, 2018
	Gross Amounts of Recognized Assets/ Liabilities			Gross Amounts Offset in the Consolidated Balance Sheet		Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet			Gross Amounts Not Offset in the Consolidated Balance Sheet
Description	Gross Amounts of Recognized Assets/ Liabilities			Gross Amounts Offset in the Consolidated Balance Sheet					Derivative Financial Instruments			Cash Collateral Received (Pledged)		Net Amount
Derivative assets	$	5,264		$	—	$	5,264		$	(935	)	$	—	$	4,329
Derivative liabilities	$	(1,460	)	$	—	$	(1,460	)	$	935		$	—	$	(525	)



	December 31, 2017
	Gross Amounts of Recognized Assets/ Liabilities			Gross Amounts Offset in the Consolidated Balance Sheet		Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet			Gross Amounts Not Offset in the Consolidated Balance Sheet
Description	Gross Amounts of Recognized Assets/ Liabilities			Gross Amounts Offset in the Consolidated Balance Sheet					Derivative Financial Instruments			Cash Collateral Received (Pledged)		Net Amount
Derivative assets	$	17,633		$	—	$	17,633		$	(5,409	)	$	—	$	12,224
Derivative liabilities	$	(5,409	)	$	—	$	(5,409	)	$	5,409		$	—	$	—

Schedule of offsetting liabilities



	December 31, 2018
	Gross Amounts of Recognized Assets/ Liabilities			Gross Amounts Offset in the Consolidated Balance Sheet		Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet			Gross Amounts Not Offset in the Consolidated Balance Sheet
Description	Gross Amounts of Recognized Assets/ Liabilities			Gross Amounts Offset in the Consolidated Balance Sheet					Derivative Financial Instruments			Cash Collateral Received (Pledged)		Net Amount
Derivative assets	$	5,264		$	—	$	5,264		$	(935	)	$	—	$	4,329
Derivative liabilities	$	(1,460	)	$	—	$	(1,460	)	$	935		$	—	$	(525	)



	December 31, 2017
	Gross Amounts of Recognized Assets/ Liabilities			Gross Amounts Offset in the Consolidated Balance Sheet		Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet			Gross Amounts Not Offset in the Consolidated Balance Sheet
Description	Gross Amounts of Recognized Assets/ Liabilities			Gross Amounts Offset in the Consolidated Balance Sheet					Derivative Financial Instruments			Cash Collateral Received (Pledged)		Net Amount
Derivative assets	$	17,633		$	—	$	17,633		$	(5,409	)	$	—	$	12,224
Derivative liabilities	$	(5,409	)	$	—	$	(5,409	)	$	5,409		$	—	$	—

Inventories - (Tables)

12 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Components of inventories

Inventories consisted of the following (in thousands):



	December 31,
	2018		2017
Raw materials	$	2,774	$	3,542
Work in process	28,864		15,692
Finished goods	21,318		24,011
Total inventories	$	52,956	$	43,245

Property, Plant and Equipment - (Tables)

12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

Schedule of property and equipment

Estimated useful lives are as follows:



Buildings	40 years
Manufacturing equipment and machinery	5-10 years
Computer software and equipment	3 years
Furniture and fixtures	5 years

Property, plant and equipment consisted of the following (in thousands):



	December 31,
	2018			2017
Build-to-suit facility	$	52,067		$	51,721
Construction-in-progress	51,243			21,738
Land and buildings	46,650			46,729
Leasehold improvements	33,273			28,779
Manufacturing equipment and machinery	25,837			23,586
Computer software	19,062			19,969
Computer equipment	13,679			12,814
Furniture and fixtures	8,155			5,947
Subtotal	249,966			211,283
Less accumulated depreciation and amortization	(49,608		)	(41,203		)
Property, plant and equipment, net	$	200,358		$	170,080

Goodwill and Intangible Assets - (Tables)

12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of gross carrying amount of goodwill

The gross carrying amount of goodwill was as follows (in thousands):



Balance at December 31, 2017	$	947,537
Foreign exchange	(19,907		)
Balance at December 31, 2018	$	927,630

Schedule of gross carrying amounts and net book values of intangible assets

The gross carrying amounts and net book values of our intangible assets were as follows (in thousands):



	December 31, 2018								December 31, 2017
	Remaining Weighted- Average Useful Life (In years)	Gross Carrying Amount		Accumulated Amortization			Net Book Value		Gross Carrying Amount		Accumulated Amortization			Net Book Value
Acquired developed technologies	13.9	$	3,110,641	$	(632,413	)	$	2,478,228	$	3,392,832	$	(562,473	)	$	2,830,359
Priority review voucher		111,101		—			111,101		—		—			—
Manufacturing contracts	—	12,256		(12,256		)	—		12,824		(12,634		)	190
Trademarks	—	2,896		(2,896		)	—		2,910		(2,910		)	—
Total finite-lived intangible assets		3,236,894		(647,565		)	2,589,329		3,408,566		(578,017		)	2,830,549
Acquired IPR&D assets		142,005		—			142,005		148,578		—			148,578
Total intangible assets		$	3,378,899	$	(647,565	)	$	2,731,334	$	3,557,144	$	(578,017	)	$	2,979,127

Schedule of estimated future amortization costs



Year Ending December 31,	Estimated Amortization Expense
2019	242,953
2020	246,870
2021	198,956
2022	153,105
2023	153,105
Thereafter	1,483,239
Total	$	2,478,228

Accrued Liabilities - (Tables)

12 Months Ended

Dec. 31, 2018

Payables and Accruals [Abstract]

Schedule of accrued liabilities

Accrued liabilities consisted of the following (in thousands):



	December 31,
	2018		2017
Rebates and other sales deductions	$	86,495	$	81,368
Employee compensation and benefits	58,543		54,930
Estimated loss contingency	58,154		—
Inventory-related accruals	8,753		3,002
Accrued interest	7,407		7,297
Selling and marketing accruals	6,780		3,189
Clinical trial accruals	5,904		2,181
Royalties	2,679		8,058
Sales returns reserve	2,510		3,651
Professional fees	2,333		3,213
Derivative instrument liabilities	1,460		5,409
Other	23,869		26,481
Total accrued liabilities	$	264,887	$	198,779

Debt - (Tables)

12 Months Ended

Dec. 31, 2018

Debt Disclosure [Abstract]

Schedule of long-term debt

The following table summarizes the carrying amount of our indebtedness (in thousands):



	December 31,
	2018			2017
2021 Notes	$	575,000		$	575,000
Unamortized discount and debt issuance costs on 2021 Notes	(60,910		)	(81,627		)
2021 Notes, net	514,090			493,373

2024 Notes	575,000			575,000
Unamortized discount and debt issuance costs on 2024 Notes	(138,914		)	(158,680		)
2024 Notes, net	436,086			416,320

Term loan	646,236			671,345
Total debt	1,596,412			1,581,038
Less current portion	33,387			40,605
Total long-term debt	$	1,563,025		$	1,540,433

Schedule of maturities of long-term debt

Scheduled maturities with respect to our long-term debt are as follows (in thousands):



Year Ending December 31,	Scheduled Long-Term Debt Maturities
2019	$	33,387
2020	33,387
2021	608,387
2022	33,387
2023	517,493
Thereafter	575,000
Total	$	1,801,041

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Commitments and Contingencies - (Tables)

12 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Schedule of future minimum lease payments under noncancelable operating leases

Future minimum lease payments under our noncancelable operating leases as of December 31, 2018, were as follows (in thousands):



Year ending December 31,	Lease Payments
2019	$	8,404
2020	6,269
2021	5,771
2022	5,388
2023	5,168
Thereafter	8,794
Total	$	39,794

Future minimum lease payments under our noncancelable facility leases as of December 31, 2018, were as follows (in thousands):



Year Ending December 31,	Lease Payments
2019	$	9,881
2020	14,474
2021	14,908
2022	15,355
2023	15,816
Thereafter	119,409
Total	$	189,843

Schedule of lease expense under operating leases

Lease expense under our operating leases was as follows (in thousands):



	Year Ended December 31,
	2018		2017		2016
Lease expense	$	11,519	$	14,982	$	11,600

Shareholders' Equity - (Tables)

12 Months Ended

Dec. 31, 2018

Equity [Abstract]

Schedule of authorized but unissued ordinary shares

We had reserved the following shares of authorized but unissued ordinary shares (in thousands):



	December 31,
	2018	2017
2011 Equity Incentive Plan	17,729	16,026
2007 Employee Stock Purchase Plan	1,126	339
Amended and Restated 2007 Non-Employee Directors Stock Award Plan	453	481
Amended and Restated Directors Deferred Compensation Plan	178	178
2007 Equity Incentive Plan	13	17
Total	19,499	17,041

Comprehensive Income (Loss) - (Tables)

12 Months Ended

Dec. 31, 2018

Equity [Abstract]

Components of accumulated other comprehensive loss

The components of accumulated other comprehensive loss as of December 31, 2018 and December 31, 2017 were as follows (in thousands):



	Net Unrealized Gain From Hedging Activities			Foreign Currency Translation Adjustments			Total Accumulated Other Comprehensive Loss
Balance at December 31, 2017	$	1,482		$	(142,360	)	$	(140,878	)
Effect of adoption of ASU No. 2017-12	53			—			53
Balance at January 1, 2018	1,535			(142,360		)	(140,825		)
Other comprehensive income (loss) before reclassifications	2,274			(58,988		)	(56,714		)
Amounts reclassified from accumulated other comprehensive loss	(252		)	—			(252		)
Other comprehensive income (loss), net	2,022			(58,988		)	(56,966		)
Balance at December 31, 2018	$	3,557		$	(201,348	)	$	(197,791	)

Net Income per Ordinary Share - (Tables)

12 Months Ended

Dec. 31, 2018

Earnings Per Share [Abstract]

Basic and Diluted Net Income per Ordinary Share Computation

Basic and diluted net income per ordinary share attributable to Jazz Pharmaceuticals plc were computed as follows (in thousands, except per share amounts):



	Year Ended December 31,
	2018		2017		2016
Numerator:
Net income	$	447,098	$	487,848	$	396,831
Denominator:
Weighted-average ordinary shares used in per share calculations - basic	59,976		60,018		60,500
Dilutive effect of employee equity incentive and purchase plans	1,245		1,299		1,370
Weighted-average ordinary shares used in per share calculations - diluted	61,221		61,317		61,870

Net income per ordinary share :
Basic	$	7.45	$	8.13	$	6.56
Diluted	$	7.30	$	7.96	$	6.41

Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income per Share



	Year Ended December 31,
	2018	2017	2016
Exchangeable Senior Notes	5,504	3,805	2,878
Options to purchase ordinary shares and RSUs	3,101	3,319	3,010
Ordinary shares under ESPP	12	14	93

Segment and Other Information - (Tables)

12 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

Total long-lived assets by location

The following table presents total long-lived assets by location (in thousands):



	December 31,
	2018		2017
United States	$	126,941	$	95,570
Ireland	61,290		64,343
Italy	8,760		8,220
Other	3,367		1,947
Total long-lived assets (1)	$	200,358	$	170,080

_________________________


(1)	Long-lived assets consist of property, plant and equipment.

Revenues - (Tables)

12 Months Ended

Dec. 31, 2018

Revenue from Contract with Customer [Abstract]

Summary of Disaggregation of Revenue

The following table presents a summary of total revenues (in thousands):



	Year Ended December 31,
	2018		2017		2016
Xyrem	$	1,404,866	$	1,186,699	$	1,107,616
Erwinaze/Erwinase	174,739		197,340		200,678
Defitelio/defibrotide	149,448		133,650		108,952
Vyxeos	100,835		33,790		—
Prialt	20,839		27,361		29,120
Other	18,746		22,559		30,895
Product sales, net	1,869,473		1,601,399		1,477,261
Royalties and contract revenues	21,449		17,294		10,712
Total revenues	$	1,890,922	$	1,618,693	$	1,487,973

The following table presents a summary of total revenues attributed to geographic sources (in thousands):



	Year Ended December 31,
	2018		2017		2016
United States	$	1,727,576	$	1,463,457	$	1,355,921
Europe	125,911		125,624		108,301
All other	37,435		29,612		23,751
Total revenues	$	1,890,922	$	1,618,693	$	1,487,973

Summary of Revenues from Customers Representing More Than 10% of Total Revenues

The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues:



	Year Ended December 31,
	2018		2017		2016
Express Scripts	74	%	73	%	74	%
McKesson	17	%	16	%	15	%

Summary of a Reconciliation in Contract Liabilities from Contracts with Customer

The following table presents a reconciliation of our beginning and ending balances in contract liabilities from contracts with customers for the year ended December 31, 2018 (in thousands):



	Contract Liabilities
Balance as of December 31, 2017	$	24,733
Effect of adoption of ASU 2014-09	(2,240		)
Amount recognized within royalties and contract revenues	(7,498		)
Balance as of December 31, 2018	$	14,995

Share-Based Compensation - (Tables)

12 Months Ended

Dec. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of weighted-average assumptions used in Black-Scholes option pricing model and resulting weighted-average grant date fair value of share options granted



	Year Ended December 31,
	2018			2017			2016
Grant date fair value	$	47.17		$	42.72		$	40.45
Volatility	35		%	35		%	39		%
Expected term (years)	4.5			4.3			4.2
Range of risk-free rates	2.2-3.0%			1.6-2.1%			0.8-1.6%
Expected dividend yield	—		%	—		%	—		%

Schedule of share-based compensation expense related to share options, RSUs, and grants under ESPP

Share-based compensation expense related to share options, RSUs and grants under our ESPP was as follows (in thousands):



	Year Ended December 31,
	2018			2017			2016
Selling, general and administrative	$	76,770		$	83,218		$	79,037
Research and development	19,037			17,870			15,296
Cost of product sales	6,634			5,812			4,438
Total share-based compensation expense, pre-tax	102,441			106,900			98,771
Income tax benefit from share-based compensation expense	(17,230		)	(21,792		)	(30,022		)
Total share-based compensation expense, net of tax	$	85,211		$	85,108		$	68,749

Schedule of information and activity related to share option plans activity

The following table summarizes information as of December 31, 2018 and activity during 2018 related to our share option plans:



	Shares Subject to Outstanding Options (In thousands)		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In thousands)
Outstanding at January 1, 2018	5,145		$	121.06
Options granted	1,449		145.03
Options exercised	(772	)	107.45
Options forfeited	(424	)	139.36
Options expired	(118	)	169.18
Outstanding at December 31, 2018	5,280		127.08		6.8	$	78,389
Vested and expected to vest at December 31, 2018	5,027		126.32		6.7	78,332
Exercisable at December 31, 2018	3,070		117.08		5.5	77,725

Schedule of information and activity related to RSUs activity

The following table summarizes information as of December 31, 2018 and activity during 2018 related to our RSUs:



	Number of RSUs (in thousands)		Weighted- Average Grant-Date Fair Value		Weighted- Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In thousands)
Outstanding at January 1, 2018	1,063		$	140.46
RSUs granted	606		146.36
RSUs released	(374	)	145.31
RSUs forfeited	(193	)	140.10
Outstanding at December 31, 2018	1,102		142.13		1.4	$	136,614

Restructuring - (Tables)

12 Months Ended

Dec. 31, 2018

Restructuring and Related Activities [Abstract]

Schedule of restructuring amounts

The following table summarizes the amounts related to total restructuring through December 31, 2017 (in thousands):



	Termination Benefits
Balance at December 31, 2015	$	1,105
Expense	1,516
Payments	(2,590		)
Balance at December 31, 2016	31
Expense	14
Payments	(45		)
Balance at December 31, 2017	$	—

Income Taxes - (Tables)

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Components of income from continuing operations before income tax provision (benefit)

The components of income before the income tax provision (benefit) and equity in loss of investees were as follows (in thousands):



	Year Ended December 31,
	2018		2017		2016
Ireland	$	170,666	$	77,476	$	179,570
United States	294,621		271,440		312,904
Other	64,176		92,201		39,972
Total	$	529,463	$	441,117	$	532,446

Details of income tax provision (benefit)

The following table sets forth the details of the income tax provision (benefit) (in thousands):



	Year Ended December 31,
	2018			2017			2016
Current
Ireland	$	33,431		$	28,045		$	26,420
United States	95,143			135,608			140,061
Other	40,403			14,198			9,918
Total current tax expense	168,977			177,851			176,399
Deferred, exclusive of other components below
Ireland	(12,408		)	(19,709		)	(7,776		)
United States	(41,337		)	(27,559		)	(9,120		)
Other	(34,545		)	(19,108		)	(13,720		)
Total deferred, exclusive of other components	(88,290		)	(66,376		)	(30,616		)
Deferred, change in tax rates
United States	(538		)	(155,679		)	109
Other	13			(3,536		)	(10,656		)
Total deferred, change in tax rates	(525		)	(159,215		)	(10,547		)
Total deferred tax benefit	(88,815		)	(225,591		)	(41,163		)
Total income tax provision (benefit)	$	80,162		$	(47,740	)	$	135,236

Reconciliation of income taxes at the statutory income tax rate to effective income tax rate

The reconciliation between the statutory income tax rate applied to income before the income tax provision (benefit) and equity in loss of investees and our effective income tax rate was as follows:



	Year Ended December 31,
	2018		2017		2016
Statutory income tax rate	12.5	%	12.5	%	12.5	%
Foreign income tax rate differential	11.9	%	20.3	%	16.7	%
Investment in subsidiaries	(5.3	)%	(0.7	)%	(2.4	)%
Financing costs	(4.3	)%	(5.6	)%	(2.9	)%
Research and other tax credits	(3.9	)%	(2.6	)%	(2.8	)%
Change in valuation allowance	3.2	%	(2.8	)%	(0.1	)%
Impact of U.S. Tax Act	(1.4	)%	(33.7	)%	—	%
Non-deductible compensation	1.2	%	2.6	%	1.8	%
Change in unrecognized tax benefits	1.1	%	2.8	%	3.3	%
Change in estimates	(1.1	)%	(2.1	)%	—	%
Non-deductible loss contingency	0.8	%	—	%	—	%
Excess tax benefits from share-based compensation	(0.4	)%	(1.5	)%	(1.5	)%
Change in tax rate	(0.1	)%	(0.4	)%	(1.8	)%
Acquisition-related costs	—	%	—	%	2.1	%
Other	0.9	%	0.4	%	0.5	%
Effective income tax rate	15.1	%	(10.8	)%	25.4	%

Schedule of net deferred tax assets/(liabilities)

Significant components of our net deferred tax assets/(liabilities) were as follows (in thousands):



	December 31,
	2018			2017
Deferred tax assets:
Net operating loss carryforwards	$	106,128		$	125,966
Tax credit carryforwards	156,242			130,782
Intangible assets	23,469			23,536
Share-based compensation	24,592			23,128
Accruals	57,575			45,088
Indirect effects of unrecognized tax benefits	34,349			29,733
Investment in subsidiaries	25,585			—
Other	51,175			63,235
Total deferred tax assets	479,115			441,468
Valuation allowance	(61,237		)	(52,144		)
Net deferred tax assets	417,878			389,324
Deferred tax liabilities:
Intangible assets	(595,746		)	(655,347		)
Other	(73,350		)	(82,890		)
Total deferred tax liabilities	(669,096		)	(738,237		)
Net deferred tax liabilities	$	(251,218	)	$	(348,913	)

The following table presents the breakdown between deferred tax assets and liabilities (in thousands):



	Year Ended December 31,
	2018			2017
Deferred tax assets	$	57,879		$	34,559
Deferred tax liabilities	(309,097		)	(383,472		)
Net deferred tax liabilities	$	(251,218	)	$	(348,913	)

Reconciliation of unrecognized tax benefits

A reconciliation of our gross unrecognized tax benefits follows (in thousands):



	December 31,
	2018			2017			2016
Balance at the beginning of the year	$	106,162		$	90,910		$	66,385
Increases related to current year tax positions	22,649			27,875			26,873
Increases related to prior year tax positions	7,584			1,620			1,191
Decreases related to prior year tax positions	—			(1,075		)	(255		)
Lapse of the applicable statute of limitations	(18,182		)	(13,168		)	(3,284		)
Balance at the end of the year	$	118,213		$	106,162		$	90,910

Quarterly Financial Data (Unaudited) - (Tables)

12 Months Ended

Dec. 31, 2018

Quarterly Financial Information Disclosure [Abstract]

Schedule of interim financial results of operations on a quarterly basis

The following interim financial information presents our 2018 and 2017 results of operations on a quarterly basis (in thousands, except per share amounts):



	2018
	March 31		June 30		September 30		December 31
Revenues	$	444,613	$	500,479	$	469,373	$	476,457
Gross margin (1)	406,928		461,381		438,623		440,997
Net income	45,991		92,321		149,316		159,470
Net income per ordinary share, basic	0.77		1.53		2.47		2.69
Net income per ordinary share, diluted	0.75		1.50		2.41		2.64



	2017
	March 31		June 30		September 30		December 31
Revenues	$	376,053	$	394,386	$	411,855	$	436,399
Gross margin (1)	348,613		360,983		376,768		404,847
Net income	86,511		105,604		63,526		232,207
Net income per ordinary share, basic	1.44		1.76		1.06		3.87
Net income per ordinary share, diluted	1.41		1.72		1.03		3.79

__________________________


(1)	Gross margin is computed by subtracting cost of product sales (excluding amortization of intangible assets) from product sales, net.

Summary of Significant Accounting Policies - Cumulative Effect on the Consolidated Balance Sheet (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
ASSETS
Deferred tax assets, net	$ 57,879	$ 35,154	$ 34,559
Liabilities:
Deferred revenue	5,414	7,498	8,618
Deferred revenue, non-current	9,581	14,995	16,115
Deferred tax liabilities, net	309,097	386,586	383,472
Shareholders’ equity:
Accumulated other comprehensive loss	(197,791)	(140,825)	(140,878)
Retained earnings	$ 841,050	917,624	917,956
Previously Reported
ASSETS
Deferred tax assets, net			34,559
Liabilities:
Deferred revenue			8,618
Deferred revenue, non-current			16,115
Deferred tax liabilities, net			383,472
Shareholders’ equity:
Accumulated other comprehensive loss			(140,878)
Retained earnings			$ 917,956
Transition Adjustments
ASSETS
Deferred tax assets, net		595
Liabilities:
Deferred revenue		(1,120)
Deferred revenue, non-current		(1,120)
Deferred tax liabilities, net		3,114
Shareholders’ equity:
Accumulated other comprehensive loss		53
Retained earnings		$ (332)

Summary of Significant Accounting Policies - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jan. 01, 2019
Summary Of Significant Accounting Policies [Line Items]
Intangible asset amortization	$ 201,498,000	$ 152,065,000	$ 101,994,000
Advertising expenses	37,400,000	36,600,000	29,500,000
Adjustment to property and equipment due to adoption of new accounting guidance	(249,966,000)	(211,283,000)
Other non-current liabilities	$ 218,879,000	176,608,000
Acquired Developed Technologies
Summary Of Significant Accounting Policies [Line Items]
Intangible assets, useful life	13 years 11 months 6 days
Intangible asset amortization	$ 201,300,000	$ 149,100,000	$ 99,000,000
Minimum
Summary Of Significant Accounting Policies [Line Items]
Intangible assets, useful life	2 years
Maximum
Summary Of Significant Accounting Policies [Line Items]
Intangible assets, useful life	18 years
Customer concentration risk \| Accounts Receivable
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	89.00%	86.00%
Customer concentration risk \| Accounts Receivable \| Express Scripts
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	74.00%	71.00%
Customer concentration risk \| Accounts Receivable \| McKesson
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	15.00%	15.00%
Foreign exchange forward contracts \| Derivatives not designated as hedging instruments
Summary Of Significant Accounting Policies [Line Items]
Notional amount	$ 271,500,000	$ 511,400,000
Net asset (liability) fair value	(300,000)	10,500,000
Interest rate contracts \| Derivatives designated as hedging instruments
Summary Of Significant Accounting Policies [Line Items]
Notional amount	300,000,000	300,000,000.0
Net asset (liability) fair value	4,100,000	1,700,000
Accounting Standards Update 2016-02
Summary Of Significant Accounting Policies [Line Items]
Other non-current liabilities	110,000,000
Pro Forma \| Accounting Standards Update 2016-02
Summary Of Significant Accounting Policies [Line Items]
Right-of-use asset				$ 150,000,000
Finance and operating lease, liability				$ 170,000,000
Build-to-suit facility
Summary Of Significant Accounting Policies [Line Items]
Adjustment to property and equipment due to adoption of new accounting guidance	(52,067,000)	$ (51,721,000)
Build-to-suit facility \| Accounting Standards Update 2016-02
Summary Of Significant Accounting Policies [Line Items]
Adjustment to property and equipment due to adoption of new accounting guidance	$ 95,000,000

Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2018
Buildings
Property, Plant and Equipment [Line Items]
Estimated useful life of property and equipment	40 years
Manufacturing equipment and machinery \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life of property and equipment	5 years
Manufacturing equipment and machinery \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life of property and equipment	10 years
Computer software and equipment
Property, Plant and Equipment [Line Items]
Estimated useful life of property and equipment	3 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Estimated useful life of property and equipment	5 years

Business Combination, Asset Acquisitions, and Disposition - Celator Acquisition Narrative (Details) - USD ($)			12 Months Ended
	Jul. 12, 2016	Jun. 18, 2015	Dec. 31, 2018	Dec. 31, 2016	Jun. 07, 2018	Jul. 11, 2016	May 27, 2016
Credit Agreement June 2015 Amendment \| Borrowings under revolving credit facility
Business Acquisition [Line Items]
Line of credit, maximum borrowing capacity	$ 1,250,000,000				$ 1,600,000,000
Proceeds from revolving credit facility	1,000,000,000
Credit Agreement June 2015 \| Term Loan
Business Acquisition [Line Items]
Face amount	$ 750,000,000	$ 750,000,000			$ 667,700,000	$ 750,000,000
Credit Agreement June 2015 \| Borrowings under revolving credit facility
Business Acquisition [Line Items]
Line of credit, maximum borrowing capacity		750,000,000				$ 750,000,000
Proceeds from revolving credit facility		$ 160,000,000
Celator Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Share price (in dollars per share)	$ 30.25						$ 30.25
Number of shares tendered during offer period in accordance with merger agreement (in shares)	36,516,173
Percentage of acquiree shares tendered during offer period (as a percent)	81.00%
Offer condition, percentage of common shares tendered (as a percent)	50.00%
Number of acquiree shares delivered via notices of guaranteed delivery in accordance with merger agreement (in shares)	2,016,237
Percentage of acquiree shares delivered via notices of guaranteed delivery in accordance with merger agreement (as a percent)	4.00%
Total acquisition consideration	$ 1,500,000,000
Acquisition-related costs				$ 10,000,000
Intangible assets	1,811,250,000
Celator Pharmaceuticals, Inc. \| Acquired IPR&D assets
Business Acquisition [Line Items]
Acquired IPR&D assets	$ 1,800,000,000
Acquired developed technologies
Business Acquisition [Line Items]
Intangible assets, useful life			13 years 11 months 6 days
Acquired developed technologies \| Vyxeos
Business Acquisition [Line Items]
Intangible assets, useful life			18 years

Business Combination, Asset Acquisitions, and Disposition - Summary of Fair Values of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Jul. 12, 2016
Business Acquisition [Line Items]
Goodwill	$ 927,630	$ 947,537
Celator Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Cash and cash equivalents			$ 26,137
Other receivables			386
Prepaid expenses and deposits			151
Property, plant and equipment			767
Intangible assets			1,811,250
Goodwill			252,825
Other non-current assets			43
Accrued liabilities			(19,076)
Deferred tax liability, net, non-current			(542,901)
Other non-current liabilities			(1,002)
Total acquisition consideration - cash paid			$ 1,528,580

Business Combination, Asset Acquisitions, and Disposition - Summary of Pro Forma Financial Information (Details) - Celator Pharmaceuticals, Inc. $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($) $ / shares
Business Acquisition [Line Items]
Pro forma adjustment, transaction-related expense	$ 13,600
Pro forma adjustment, interest expense	13,700
Revenues	1,488,118
Net income attributable to Jazz Pharmaceuticals plc	$ 386,342
Net income attributable to Jazz Pharmaceuticals plc per ordinary share - basic (in dollars per share) \| $ / shares	$ 6.39
Net income attributable to Jazz Pharmaceuticals plc per ordinary share - diluted (in dollars per share) \| $ / shares	$ 6.24

Business Combination, Asset Acquisitions, and Disposition - Prialt Disposition (Details) - USD ($) $ in Thousands				12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Sep. 27, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jun. 29, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net proceeds from sale of assets				$ 47,898	$ 0	$ 0
Impairment charges				42,896	0	0
Loss on disposition				655	$ 473	$ 47
Prialt Asset Sale \| Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total purchase price of assets held for sale							$ 80,000
Proceeds from sale of productive assets before legal and other expenses			$ 50,000
Impairment charges				42,900
Loss on disposition				$ 500
Prialt Asset Sale \| Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations \| Forecast
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net proceeds from sale of assets	$ 15,000	$ 15,000

Business Combination, Asset Acquisitions, and Disposition - Collaboration and Option Agreement (Details) $ in Thousands	1 Months Ended	12 Months Ended
	Aug. 31, 2017 USD ($) product program	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non-refundable upfront payment		$ 0	$ 85,000	$ 23,750
ImmunoGen, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Initial number of programs under agreement \| program	2
Number of programs under agreement \| program	3
Non-refundable upfront payment	$ 75,000
Development funding term	7 years
Number of projects subject to right to co-commercialize \| product	1
Number of projects subject to right to co-commercialize under certain limited circumstances \| product	2
Maximum \| ImmunoGen, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Additional development funding	$ 100,000

Business Combination, Asset Acquisitions, and Disposition - License and Option Agreement (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jul. 31, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Research and development		$ 226,616	$ 198,442	$ 162,297
Pfenex
Business Acquisition [Line Items]
Research and development			$ 19,500	800
Licensing expenses				15,800
Acquired IPR&D expense				$ 15,000
Upfront Payment \| Pfenex
Business Acquisition [Line Items]
Upfront and option payments	$ 35,300
Milestone Payment \| Pfenex
Business Acquisition [Line Items]
Potential payments under agreement for certain, development, regulatory, and sales related milestones	$ 189,000

Business Combination, Asset Acquisitions, and Disposition - Acquisition of Alize Pharma II S.A.S. (Details) $ in Thousands, € in Millions	1 Months Ended		12 Months Ended
	Mar. 31, 2016 USD ($)	Mar. 31, 2016 EUR (€)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Business Acquisition [Line Items]
Acquired in-process research and development			$ 0	$ 85,000	$ 23,750
Alize Pharma II S.A.S \| Upfront Payment
Business Acquisition [Line Items]
Acquired in-process research and development	$ 8,800
Alize Pharma II S.A.S \| Milestone Payment
Business Acquisition [Line Items]
Potential payments under agreement for certain development, regulatory, and sales related milestones \| €		€ 10

Cash and Available-for-Sale Securities - Summary of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 824,622	$ 601,035
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	824,622	601,035
Cash and Cash Equivalents	309,622	386,035	$ 365,963	$ 988,785
Investments	515,000	215,000
Cash
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	215,606	225,235
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	215,606	225,235
Cash and Cash Equivalents	215,606	225,235
Investments	0	0
Time deposits
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	515,000	235,000
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	515,000	235,000
Cash and Cash Equivalents	0	20,000
Investments	515,000	215,000
Money market funds
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	94,016	140,800
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	94,016	140,800
Cash and Cash Equivalents	94,016	140,800
Investments	$ 0	$ 0

Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Available-for-sale securities:
Available-for-sale securities	$ 824,622	$ 601,035
Recurring
Available-for-sale securities:
Totals	614,280	393,433
Liabilities:
Totals	1,460	5,409
Recurring \| Time deposits
Available-for-sale securities:
Available-for-sale securities	515,000	235,000
Recurring \| Money market funds
Available-for-sale securities:
Available-for-sale securities	94,016	140,800
Recurring \| Interest rate contracts
Available-for-sale securities:
Derivative asset	4,070	2,138
Liabilities:
Derivative Liability	0	392
Recurring \| Foreign exchange forward contracts
Available-for-sale securities:
Derivative asset	1,194	15,495
Liabilities:
Derivative Liability	1,460	5,017
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Available-for-sale securities:
Totals	94,016	140,800
Liabilities:
Totals	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring \| Time deposits
Available-for-sale securities:
Available-for-sale securities	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring \| Money market funds
Available-for-sale securities:
Available-for-sale securities	94,016	140,800
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring \| Interest rate contracts
Available-for-sale securities:
Derivative asset	0	0
Liabilities:
Derivative Liability	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring \| Foreign exchange forward contracts
Available-for-sale securities:
Derivative asset	0	0
Liabilities:
Derivative Liability	0	0
Significant Other Observable Inputs (Level 2) \| Recurring
Available-for-sale securities:
Totals	520,264	252,633
Liabilities:
Totals	1,460	5,409
Significant Other Observable Inputs (Level 2) \| Recurring \| Time deposits
Available-for-sale securities:
Available-for-sale securities	515,000	235,000
Significant Other Observable Inputs (Level 2) \| Recurring \| Money market funds
Available-for-sale securities:
Available-for-sale securities	0	0
Significant Other Observable Inputs (Level 2) \| Recurring \| Interest rate contracts
Available-for-sale securities:
Derivative asset	4,070	2,138
Liabilities:
Derivative Liability	0	392
Significant Other Observable Inputs (Level 2) \| Recurring \| Foreign exchange forward contracts
Available-for-sale securities:
Derivative asset	1,194	15,495
Liabilities:
Derivative Liability	$ 1,460	$ 5,017

Fair Value Measurement - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2018	Sep. 30, 2017	Aug. 31, 2014
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Equity securities without readily determinable value, fair value	$ 4.5
Convertible Debt \| 2021 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest rate (as a percent)			1.875%
Convertible Debt \| 2024 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest rate (as a percent)		1.50%
Significant Other Observable Inputs (Level 2) \| Convertible Debt \| 2021 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of exchangeable senior notes	558.0
Significant Other Observable Inputs (Level 2) \| Convertible Debt \| 2024 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of exchangeable senior notes	$ 521.0

Derivatives Instruments and Hedging Activities - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Derivative [Line Items]
Gains recognized in AOCI to be reclassified over the next 12 months	$ 1,700,000
Derivatives designated as hedging instruments \| Interest rate contracts
Derivative [Line Items]
Notional amount	$ 300,000,000	$ 300,000,000.0
Derivatives not designated as hedging instruments \| Interest rate contracts
Derivative [Line Items]
Fixed interest rate	1.895%	1.895%
Derivatives not designated as hedging instruments \| Foreign exchange forward contracts
Derivative [Line Items]
Notional amount	$ 271,500,000	$ 511,400,000
Maximum \| Derivatives not designated as hedging instruments \| Foreign exchange forward contracts
Derivative [Line Items]
Contract term	12 months

Derivatives Instruments and Hedging Activities - Gains on Derivative Instruments (Details) - Interest rate contracts - Cash Flow Hedges - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in accumulated other comprehensive loss, net of tax	$ 2,274	$ (213)
Loss (gain) reclassified from accumulated other comprehensive loss to interest expense, net of tax	$ (252)	$ 1,695

Derivatives Instruments and Hedging Activities - Foreign Exchange Gain (Loss) Derivative Instruments (Details) - Derivatives not designated as hedging instruments - Foreign exchange forward contracts - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Derivative [Line Items]
Loss recognized in other income expense	$ (14,648)
Gain recognized in other income and expense		$ 17,902

Derivatives Instruments and Hedging Activities - Fair Value of Outstanding Derivatives (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Derivatives, Fair Value [Line Items]
Asset Derivatives	$ 5,264	$ 17,633
Liability Derivatives	1,460	5,409
Derivatives designated as hedging instruments \| Interest rate contracts \| Other current assets
Derivatives, Fair Value [Line Items]
Asset Derivatives	1,929
Derivatives designated as hedging instruments \| Interest rate contracts \| Accrued liabilities
Derivatives, Fair Value [Line Items]
Liability Derivatives	0	392
Derivatives designated as hedging instruments \| Interest rate contracts \| Other non-current assets
Derivatives, Fair Value [Line Items]
Asset Derivatives	2,141	2,138
Derivatives not designated as hedging instruments \| Foreign exchange forward contracts \| Other current assets
Derivatives, Fair Value [Line Items]
Asset Derivatives	1,194	15,495
Derivatives not designated as hedging instruments \| Foreign exchange forward contracts \| Accrued liabilities
Derivatives, Fair Value [Line Items]
Liability Derivatives	$ 1,460	$ 5,017

Derivatives Instruments and Hedging Activities - Offsetting Assets and Liabilities (Details) - Pro Forma - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Derivative assets
Gross Amounts of Recognized Assets/ Liabilities	$ 5,264	$ 17,633
Gross Amounts Offset in the Consolidated Balance Sheet	0	0
Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet	5,264	17,633
Gross Amounts Not Offset in the Consolidated Balance Sheet
Derivative Financial Instruments	(935)	(5,409)
Cash Collateral Received (Pledged)	0	0
Net Amount	4,329	12,224
Derivative liabilities
Gross Amounts of Recognized Assets/ Liabilities	(1,460)	(5,409)
Gross Amounts Offset in the Consolidated Balance Sheet	0	0
Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet	(1,460)	(5,409)
Gross Amounts Not Offset in the Consolidated Balance Sheet
Derivative Financial Instruments	935	5,409
Cash Collateral Received (Pledged)	0	0
Net Amount	$ (525)	$ 0

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Components of Inventories
Raw materials	$ 2,774	$ 3,542
Work in process	28,864	15,692
Finished goods	21,318	24,011
Total inventories	$ 52,956	$ 43,245

Property, Plant and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 249,966	$ 211,283
Less accumulated depreciation and amortization	(49,608)	(41,203)
Property and equipment, net	200,358	170,080
Depreciation and amortization expense	15,200	13,100	$ 11,800
Build-to-suit facility
Property, Plant and Equipment [Line Items]
Property and equipment, gross	52,067	51,721
Construction-in-progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	51,243	21,738
Land and buildings
Property, Plant and Equipment [Line Items]
Property and equipment, gross	46,650	46,729
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	33,273	28,779
Manufacturing equipment and machinery
Property, Plant and Equipment [Line Items]
Property and equipment, gross	25,837	23,586
Computer software
Property, Plant and Equipment [Line Items]
Property and equipment, gross	19,062	19,969
Computer equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	13,679	12,814
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 8,155	$ 5,947

Goodwill and Intangible Assets - Schedule of Gross Carrying Amount of Goodwill (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018 USD ($)
Goodwill [Roll Forward]
Balance at December 31, 2017	$ 947,537
Foreign exchange	(19,907)
Balance at December 31, 2018	$ 927,630

Goodwill and Intangible Assets - Schedule of Gross Carrying Amounts and Net Book Values of Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived and Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 3,236,894	$ 3,408,566
Accumulated Amortization	(647,565)	(578,017)
Total	2,589,329	2,830,549
Intangible assets, gross	3,378,899	3,557,144
Intangible assets, net	2,731,334	2,979,127
Acquired IPR&D assets
Finite-Lived and Indefinite Lived Intangible Assets [Line Items]
Acquired IPR&D assets	$ 142,005	148,578
Acquired developed technologies
Finite-Lived and Indefinite Lived Intangible Assets [Line Items]
Remaining Weighted- Average Useful Life (In years)	13 years 11 months 6 days
Gross Carrying Amount	$ 3,110,641	3,392,832
Accumulated Amortization	(632,413)	(562,473)
Total	2,478,228	2,830,359
Contract-Based Intangible Assets
Finite-Lived and Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	111,101	0
Accumulated Amortization	0	0
Total	$ 111,101	0
Manufacturing contracts
Finite-Lived and Indefinite Lived Intangible Assets [Line Items]
Remaining Weighted- Average Useful Life (In years)	0 years
Gross Carrying Amount	$ 12,256	12,824
Accumulated Amortization	(12,256)	(12,634)
Total	$ 0	190
Trademarks
Finite-Lived and Indefinite Lived Intangible Assets [Line Items]
Remaining Weighted- Average Useful Life (In years)	0 years
Gross Carrying Amount	$ 2,896	2,910
Accumulated Amortization	(2,896)	(2,910)
Total	$ 0	$ 0

Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Costs (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Total	$ 2,589,329	$ 2,830,549
Acquired developed technologies
Finite-Lived Intangible Assets [Line Items]
2019	242,953
2020	246,870
2021	198,956
2022	153,105
2023	153,105
Thereafter	1,483,239
Total	$ 2,478,228	$ 2,830,359

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Rebates and other sales deductions	$ 86,495	$ 81,368
Employee compensation and benefits	58,543	54,930
Estimated loss contingency	58,154	0
Inventory-related accruals	8,753	3,002
Accrued interest	7,407	7,297
Selling and marketing accruals	6,780	3,189
Clinical trial accruals	5,904	2,181
Royalties	2,679	8,058
Sales returns reserve	2,510	3,651
Professional fees	2,333	3,213
Derivative instrument liabilities	1,460	5,409
Other	23,869	26,481
Total accrued liabilities	$ 264,887	$ 198,779

Debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Principal amount	$ 1,801,041
Total debt	1,596,412	$ 1,581,038
Less current portion	33,387	40,605
Total long-term debt	1,563,025	1,540,433
Convertible Debt \| 2021 Notes
Debt Instrument [Line Items]
Principal amount	575,000	575,000
Unamortized discount and debt issuance costs	(60,910)	(81,627)
Total debt	514,090	493,373
Convertible Debt \| 2024 Notes
Debt Instrument [Line Items]
Principal amount	575,000	575,000
Unamortized discount and debt issuance costs	(138,914)	(158,680)
Total debt	436,086	416,320
Term loan
Debt Instrument [Line Items]
Total debt	$ 646,236	$ 671,345

Debt - Credit Agreement (Details) - USD ($)				12 Months Ended
Debt - Credit Agreement (Details) - USD ($)	Jun. 07, 2018	Jul. 12, 2016	Jun. 18, 2015	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jul. 11, 2016
Debt Instrument [Line Items]
Long-term debt outstanding				$ 1,801,041,000
Loss on extinguishment and modification of debt				1,425,000	$ 0	$ 638,000
Borrowings under revolving credit facility \| Credit Agreement June 2015
Debt Instrument [Line Items]
Line of credit, maximum borrowing capacity			$ 750,000,000				$ 750,000,000
Proceeds from revolving credit facility			160,000,000
Borrowings under revolving credit facility \| Credit Agreement June 2015 Amendment
Debt Instrument [Line Items]
Line of credit, maximum borrowing capacity	$ 1,600,000,000	$ 1,250,000,000
Proceeds from revolving credit facility		1,000,000,000
Undrawn revolving credit facilities				1,600,000,000
Borrowings under revolving credit facility \| Credit Agreement June 2015 Amendment \| Minimum
Debt Instrument [Line Items]
Commitment fee percentage (as a percent)	0.25%
Borrowings under revolving credit facility \| Credit Agreement June 2015 Amendment \| Maximum
Debt Instrument [Line Items]
Commitment fee percentage (as a percent)	0.35%
Term Loan \| Credit Agreement June 2015
Debt Instrument [Line Items]
Face amount	$ 667,700,000	$ 750,000,000	750,000,000				$ 750,000,000
Long-term debt outstanding	$ 667,700,000
Loss on extinguishment and modification of debt				1,400,000		$ 600,000
Term Loan \| Credit Agreement 2012
Debt Instrument [Line Items]
Extinguishment of debt			$ 893,100,000
Term Loan \| Credit Agreement June 2015 Amendment
Debt Instrument [Line Items]
Long-term debt outstanding				$ 651,000,000
Interest rate during the period				3.90%
Effective interest rate (as a percent)				3.66%
Percentage of principal repayment	5.00%
Term Loan \| Credit Agreement June 2015 Amendment \| London Interbank Offered Rate (LIBOR) \| Minimum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	1.375%
Term Loan \| Credit Agreement June 2015 Amendment \| London Interbank Offered Rate (LIBOR) \| Maximum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	1.75%
Term Loan \| Credit Agreement June 2015 Amendment \| Prime Rate \| Minimum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	0.375%
Term Loan \| Credit Agreement June 2015 Amendment \| Prime Rate \| Maximum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	0.75%

Debt - Exchangeable Senior Notes (Details)	1 Months Ended	3 Months Ended	12 Months Ended
Debt - Exchangeable Senior Notes (Details)	Aug. 31, 2014 USD ($) d $ / shares	Sep. 30, 2017 USD ($) d $ / shares	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Debt Instrument [Line Items]
Repayments under revolving credit facility			$ 0	$ 850,000,000	$ 150,000,000
Interest expense, net			56,700,000	37,800,000	$ 27,500,000
2024 Notes \| Convertible Debt
Debt Instrument [Line Items]
Face amount		$ 575,000,000
Interest rate (as a percent)		1.50%
Percentage of conversion price		130.00%
Number of trading days \| d		20
Number of consecutive days in trading period \| d		30
Conversion rate of shares (in shares per dollar)		0.0045659
Debt conversion price (in dollars per share) \| $ / shares		$ 219.02
Effective interest rate (as a percent)		6.80%
Debt term		7 years
Debt issuance cost		$ 15,600,000
Carrying value of the equity component			149,800,000	149,800,000
2021 Notes \| Convertible Debt
Debt Instrument [Line Items]
Interest rate (as a percent)	1.875%
Percentage of conversion price	130.00%
Number of trading days \| d	20
Number of consecutive days in trading period \| d	30
Conversion rate of shares (in shares per dollar)	0.0050057
Debt conversion price (in dollars per share) \| $ / shares	$ 199.77
Effective interest rate (as a percent)	6.40%
Debt term	7 years
Debt issuance cost	$ 16,100,000
Carrying value of the equity component			$ 126,900,000	$ 126,900,000
Borrowings under revolving credit facility
Debt Instrument [Line Items]
Repayments under revolving credit facility		$ 500,000,000
Jazz Investments I Limited \| Convertible Debt
Debt Instrument [Line Items]
Ownership percentage (as a percent)			100.00%

Debt - Schedule of Debt Maturities (Details) $ in Thousands	Dec. 31, 2018 USD ($)
Long-term Debt, Fiscal Year Maturity [Abstract]
2019	$ 33,387
2020	33,387
2021	608,387
2022	33,387
2023	517,493
Thereafter	575,000
Long-term debt outstanding	$ 1,801,041

Commitments and Contingencies - Leases and Other Commitments (Details) $ in Thousands	1 Months Ended			12 Months Ended
	Sep. 30, 2017 renewal_term	Aug. 31, 2016 USD ($)	Jan. 31, 2015 renewal_term	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Other Commitments [Line Items]
Other non-current liabilities				$ 218,879	$ 176,608
Lease expense				11,519	14,982	$ 11,600
Total future lease payments				39,794
Noncancelable purchase commitments due within one year				65,100
Buildings \| Palo Alto
Other Commitments [Line Items]
Operating lease, term	12 years		12 years
Financing obligation				62,500	62,900
Lease expense				4,000	$ 2,400	$ 1,900
Buildings \| Palo Alto \| Property, Plant and Equipment
Other Commitments [Line Items]
Construction-in-progress				47,300
Buildings \| Palo Alto \| Other Non-current Liabilities
Other Commitments [Line Items]
Other non-current liabilities				$ 47,300
Buildings \| Palo Alto \| Lease Agreements
Other Commitments [Line Items]
Number of renewal option terms \| renewal_term	2		2
Operating lease, extended term option	5 years		5 years
Buildings \| Dublin
Other Commitments [Line Items]
Operating lease, term		20 years
Early termination, lease term option 1		8 years
Notice of termination period		1 year
Early termination, lease term option 2		15 years
Total future lease payments		$ 16,900

Commitments and Contingencies - Schedule Of Future Minimum Lease Payments Under Noncancelable Operating Leases (Details) $ in Thousands	Dec. 31, 2018 USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2019	$ 8,404
2020	6,269
2021	5,771
2022	5,388
2023	5,168
Thereafter	8,794
Total	39,794
Facility
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2019	9,881
2020	14,474
2021	14,908
2022	15,355
2023	15,816
Thereafter	119,409
Total	$ 189,843

Commitments and Contingencies - Legal Proceedings and Other Contingencies Narrative (Details) $ in Millions	1 Months Ended	12 Months Ended
	Apr. 30, 2018 USD ($)	Dec. 31, 2018 USD ($) lawsuit
Xyrem
Loss Contingencies [Line Items]
Loss contingency claims previously settled number \| lawsuit		8
DOJ Investigation
Loss Contingencies [Line Items]
Proposed settlement amount	$ 57.0
Estimated loss contingency		$ 58.2

Shareholders' Equity - Narrative (Details) $ / shares in Units, shares in Millions	12 Months Ended
	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Nov. 30, 2018 USD ($)	Nov. 30, 2016 USD ($)	Nov. 30, 2015 USD ($)
Stockholders' Equity Note [Line Items]
Cash dividends declared or paid	$ 0	$ 0
Maximum allowable dividend and restricted payments	30,000,000
Maximum allowable restricted payments	$ 100,000,000
Maximum secured leverage ratio, for restricted payments to be allowed	3
Minimum total leverage ratio, allowable restricted payments	2
Ordinary Shares
Stockholders' Equity Note [Line Items]
Total amount authorized for repurchase of shares under share repurchase program	$ 1,020,000,000
Stock repurchased	$ 523,700,000	$ 98,800,000
Stock repurchased (in shares) \| shares	3.5	0.7
Treasury stock acquired, average cost per share (in dollars per share) \| $ / shares	$ 148.33	$ 140.34
Ordinary Shares \| November 2015 Share Repurchase Program
Stockholders' Equity Note [Line Items]
Total amount authorized for repurchase of shares under share repurchase program					$ 300,000,000
Remaining amount authorized for repurchase of shares	$ 379,100,000
Ordinary Shares \| November 2016 Share Repurchase Program
Stockholders' Equity Note [Line Items]
Total amount authorized for repurchase of shares under share repurchase program				$ 300,000,000
Additional amount authorized for repurchase of shares under the share repurchase program	$ 400,000,000		$ 320,000,000

Shareholders' Equity - Schedule of Authorized But Unissued Ordinary Shares (Details) - shares shares in Thousands	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized but unissued ordinary shares reserved (in shares)	19,499	17,041
2011 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized but unissued ordinary shares reserved (in shares)	17,729	16,026
2007 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized but unissued ordinary shares reserved (in shares)	1,126	339
Amended and Restated 2007 Non-Employee Directors Stock Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized but unissued ordinary shares reserved (in shares)	453	481
Amended and Restated Directors Deferred Compensation Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized but unissued ordinary shares reserved (in shares)	178	178
2007 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized but unissued ordinary shares reserved (in shares)	13	17

Comprehensive Income (Loss) - Components of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	$ 2,713,097
Effect of adoption of ASU No. 2017-12		$ (279)		$ 107,687
Other comprehensive income (loss) before reclassifications	(56,714)
Amounts reclassified from accumulated other comprehensive loss	(252)
Other comprehensive income (loss), net	(56,966)	176,455	$ (49,861)
Ending balance	2,757,422	2,713,097
Net Unrealized Gain From Hedging Activities
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	1,535
Other comprehensive income (loss) before reclassifications	2,274
Amounts reclassified from accumulated other comprehensive loss	(252)
Other comprehensive income (loss), net	2,022
Ending balance	3,557	1,535
Foreign Currency Translation Adjustments
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(142,360)
Other comprehensive income (loss) before reclassifications	(58,988)
Amounts reclassified from accumulated other comprehensive loss	0
Other comprehensive income (loss), net	(58,988)
Ending balance	(201,348)	(142,360)
Total Accumulated Other Comprehensive Loss
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(140,825)
Effect of adoption of ASU No. 2017-12		53
Ending balance	(197,791)	(140,825)
ASU No. 2017-12 \| Net Unrealized Gain From Hedging Activities
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Effect of adoption of ASU No. 2017-12		53
ASU No. 2017-12 \| Foreign Currency Translation Adjustments
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Effect of adoption of ASU No. 2017-12		0
ASU No. 2017-12 \| Total Accumulated Other Comprehensive Loss
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Effect of adoption of ASU No. 2017-12		53
Previously Reported \| Net Unrealized Gain From Hedging Activities
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	1,482
Ending balance		1,482
Previously Reported \| Foreign Currency Translation Adjustments
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(142,360)
Ending balance		(142,360)
Previously Reported \| Total Accumulated Other Comprehensive Loss
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	$ (140,878)
Ending balance		$ (140,878)

Net Income per Ordinary Share - Basic and Diluted Net Income (Loss) per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Numerator:
Net income	$ 159,470	$ 149,316	$ 92,321	$ 45,991	$ 232,207	$ 63,526	$ 105,604	$ 86,511	$ 447,098	$ 487,848	$ 396,831
Denominator:
Weighted-average ordinary shares used in per share calculations - basic (in shares)									59,976	60,018	60,500
Dilutive effect of employee equity incentive and purchase plans (in shares)									1,245	1,299	1,370
Weighted-average ordinary shares used in per share calculations - diluted (in shares)									61,221	61,317	61,870
Net income per ordinary share :
Basic (in dollars per share)	$ 2.69	$ 2.47	$ 1.53	$ 0.77	$ 3.87	$ 1.06	$ 1.76	$ 1.44	$ 7.45	$ 8.13	$ 6.56
Diluted (in dollars per share)	$ 2.64	$ 2.41	$ 1.50	$ 0.75	$ 3.79	$ 1.03	$ 1.72	$ 1.41	$ 7.30	$ 7.96	$ 6.41

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Net Income per Ordinary Share - Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income per Share (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Exchangeable Senior Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Ordinary shares (in shares)	5,504	3,805	2,878
Options to purchase ordinary shares and RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Ordinary shares (in shares)	3,101	3,319	3,010
Ordinary shares under ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Ordinary shares (in shares)	12	14	93

Segment and Other Information - Narrative (Details)	12 Months Ended
Segment and Other Information - Narrative (Details)	Dec. 31, 2018 Segment
Segment Reporting [Abstract]
Number of operating business segments	1

Segment and Other Information - Total Long-Lived Assets by Location (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 200,358	$ 170,080
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	126,941	95,570
Ireland
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	61,290	64,343
Italy
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	8,760	8,220
Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 3,367	$ 1,947

Revenues - Summary of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disaggregation of Revenue [Line Items]
Total revenues	$ 1,890,922	$ 1,618,693	$ 1,487,973
United States
Disaggregation of Revenue [Line Items]
Total revenues	1,727,576	1,463,457	1,355,921
Europe
Disaggregation of Revenue [Line Items]
Total revenues	125,911	125,624	108,301
All other
Disaggregation of Revenue [Line Items]
Total revenues	37,435	29,612	23,751
Product sales, net
Disaggregation of Revenue [Line Items]
Total revenues	1,869,473	1,601,399	1,477,261
Xyrem
Disaggregation of Revenue [Line Items]
Total revenues	1,404,866	1,186,699	1,107,616
Erwinaze/Erwinase
Disaggregation of Revenue [Line Items]
Total revenues	174,739	197,340	200,678
Defitelio/defibrotide
Disaggregation of Revenue [Line Items]
Total revenues	149,448	133,650	108,952
Vyxeos
Disaggregation of Revenue [Line Items]
Total revenues	100,835	33,790	0
Prialt
Disaggregation of Revenue [Line Items]
Total revenues	20,839	27,361	29,120
Other
Disaggregation of Revenue [Line Items]
Total revenues	18,746	22,559	30,895
Royalties and contract revenues
Disaggregation of Revenue [Line Items]
Total revenues	$ 21,449	$ 17,294	$ 10,712

Revenues - Summary of the Percentage of Total Revenues from Customers (Details) - Total Revenues - Customer concentration risk	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Express Scripts
Concentration Risk [Line Items]
Concentration risk, percentage	74.00%	73.00%	74.00%
McKesson
Concentration Risk [Line Items]
Concentration risk, percentage	17.00%	16.00%	15.00%

Revenues - Narrative (Details) $ in Thousands	12 Months Ended
Revenues - Narrative (Details) $ in Thousands	Dec. 31, 2018 USD ($) agreement
Summary Of Deferred Revenue [Line Items]
Contract revenue recognized	$ 7,498
Nippon Shinyaku
Summary Of Deferred Revenue [Line Items]
Number of license, development, and commercialization agreements \| agreement	2
Contract revenue recognized	$ 7,500
Revenue, performance obligation, description of timing	The deferred revenue balances are being recognized over an average of four years representing the period we expect to perform our research and developments obligations under each agreement.
Minimum
Summary Of Deferred Revenue [Line Items]
Payment terms, range	30 days
Maximum
Summary Of Deferred Revenue [Line Items]
Payment terms, range	45 days

Revenues - Summary of Contract Liabilities (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018 USD ($)
Change In Contract With Customer, Liability [Roll Forward]
Balance as of December 31, 2017	$ 24,733
Effect of adoption of ASU 2014-09	(2,240)
Amount recognized within royalties and contract revenues	(7,498)
Balance as of December 31, 2018	$ 14,995

Share-Based Compensation - Narrative (Details)				1 Months Ended		9 Months Ended	12 Months Ended			13 Months Ended
Share-Based Compensation - Narrative (Details)	Jan. 01, 2019 shares	Jan. 18, 2012 shares	Oct. 24, 2011	Dec. 31, 2011 period shares	Aug. 31, 2010 shares	Sep. 30, 2011	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Jan. 17, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recognized tax benefits related to share options exercised \| $							$ 7,700,000	$ 8,900,000	$ 8,300,000
Aggregate intrinsic value of share options exercised \| $							43,400,000	38,900,000	36,100,000
Share Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to unvested stock options \| $							$ 76,100,000
Unrecognized compensation cost, weighted-average period of recognition (in years)							2 years 6 months 20 days
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)							4 years
Unrecognized compensation cost, weighted-average period of recognition (in years)							2 years 5 months 15 days
RSUs weighted-average grant date fair value (in dollars per share) \| $ / shares							$ 146.36
Number of RSUs released (in shares)							374,000
Shares issued (in shares)							253,000
Shares withheld for tax purposes (in shares)							121,000
Total fair value of shares vested \| $							$ 55,800,000	53,200,000	59,200,000
Unrecognized compensation cost related to unvested RSUs \| $							$ 94,800,000
2011 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service periods (in years)				4 years
Shares authorized for issuance (in shares)							24,424,669
2011 Equity Incentive Plan \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants expiration period (in years)				10 years
2011 Equity Incentive Plan, Option One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance, annual automatic increase, maximum percentage of outstanding shares				4.50%
2011 Equity Incentive Plan, Option Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in shares reserved under plan (in shares)				5,000,000
2007 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance (in shares)		1,000,000
2007 Equity Incentive Plan \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service periods (in years)		1 year								3 years
2007 Equity Incentive Plan \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service periods (in years)		3 years								5 years
Grants expiration period (in years)		10 years								10 years
2007 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance (in shares)							3,558,471
ESPP discount rate (as a percent)				15.00%
ESPP offering period (in months)				24 months
Number of purchase periods within each ESPP offering period \| period				4
Number of shares available for issuance (in shares)				175,000
Unrecognized compensation cost related to grants under the ESPP \| $							$ 6,000,000
2007 Employee Stock Purchase Plan \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost, weighted-average period of recognition (in years)							1 year 2 months
2007 Employee Stock Purchase Plan Option One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance, annual automatic increase, maximum percentage of outstanding shares				1.50%
2007 Employee Stock Purchase Plan Option Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in shares reserved under plan (in shares)				1,000,000
2007 Directors Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance under deferred compensation plan (in shares)							903,938
2007 Directors Award Plan \| Initial Grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)						3 years
2007 Directors Award Plan \| Annual Automatic Grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)						1 year
2007 Directors Award Plan \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service periods (in years)			1 year
2007 Directors Award Plan \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service periods (in years)			3 years
Grants expiration period (in years)			10 years
Directors Deferred Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in shares reserved under plan (in shares)					200,000
Recorded expense related to retainer fees earned and deferred \| $							$ 0	$ 0	$ 0
Deferred compensation arrangement with individuals, shares unissued (in shares)							14,499
Subsequent Event \| 2011 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in shares reserved under plan (in shares)	2,587,659
Subsequent Event \| 2007 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in shares reserved under plan (in shares)	862,553

Share-Based Compensation - Schedule of Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model and Resulting Weighted-Average Grant Date Fair Value of Share Options Granted (Details) - Share Options - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value (in dollars per share)	$ 47.17	$ 42.72	$ 40.45
Volatility (as a percent)	35.00%	35.00%	39.00%
Expected term (in years)	4 years 6 months	4 years 3 months	4 years 2 months
Range of risk-free rates, minimum (as a percent)	2.20%	1.60%	0.80%
Range of risk-free rates, maximum (as a percent)	3.00%	2.10%	1.60%
Expected dividend yield (as a percent)	0.00%	0.00%	0.00%

Share-Based Compensation - Schedule of Stock-Based Compensation Expense Related to Stock Options, RSUs, Ordinary Shares Credited to Directors' Phantom Share Accounts and Grants under ESPP (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense, pre-tax	$ 102,441	$ 106,900	$ 98,771
Income tax benefit from share-based compensation expense	(17,230)	(21,792)	(30,022)
Total share-based compensation expense, net of tax	85,211	85,108	68,749
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense, pre-tax	76,770	83,218	79,037
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense, pre-tax	19,037	17,870	15,296
Cost of product sales
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense, pre-tax	$ 6,634	$ 5,812	$ 4,438

Share-Based Compensation - Schedule of Share Option Plans Activity (Details) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018 USD ($) $ / shares shares
Shares Subject to Outstanding Options [Roll Forward]
Outstanding, beginning balance (in shares) \| shares	5,145
Options granted (in shares) \| shares	1,449
Options exercised (in shares) \| shares	(772)
Options forfeited (in shares) \| shares	(424)
Options expired (in shares) \| shares	(118)
Outstanding, ending balance (in shares) \| shares	5,280
Vested and expected to vest (in shares) \| shares	5,027
Exercisable, balance (in shares) \| shares	3,070
Weighted Average Exercise Price (in dollars per share) [Roll Forward]
Outstanding, beginning balance (in dollars per share) \| $ / shares	$ 121.06
Options granted (in dollars per share) \| $ / shares	145.03
Options exercised (in dollars per share) \| $ / shares	107.45
Options forfeited (in dollars per share) \| $ / shares	139.36
Options expired (in dollars per share) \| $ / shares	169.18
Outstanding, ending balance (in dollars per share) \| $ / shares	127.08
Vested and expected to vest (in dollars per share) \| $ / shares	126.32
Exercisable (in dollars per share) \| $ / shares	$ 117.08
Weighted- Average Remaining Contractual Term (Years)
Weighted-average remaining contractual term, outstanding (in years)	6 years 9 months 2 days
Weighted-average remaining contractual term, vested and expected to vest, exercisable (in years)	6 years 8 months 20 days
Weighted-average remaining contractual term, exercisable (in years)	5 years 6 months
Aggregate Intrinsic Value
Aggregate intrinsic value, outstanding \| $	$ 78,389
Aggregate intrinsic value, vested and expected to vest \| $	78,332
Aggregate intrinsic value, exercisable \| $	$ 77,725

Share-Based Compensation - Schedule of RSUs Activity (Details) - Restricted Stock Units (RSUs) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018 USD ($) $ / shares shares
Number of RSUs [Roll Forward]
Number of RSUs, outstanding, beginning balance (in shares) \| shares	1,063
Number of RSUs granted (in shares) \| shares	606
Number of RSUs released (in shares) \| shares	(374)
Number of RSUs forfeited (in shares) \| shares	(193)
Number of RSUs, outstanding, ending balance (in shares) \| shares	1,102
Weighted-Average Grant-Date Fair Value [Roll Forward]
Weighted-average grant-date fair value, outstanding, beginning balance (in dollars per share) \| $ / shares	$ 140.46
Weighted-average grant-date fair value, RSUs granted (in dollars per share) \| $ / shares	146.36
Weighted-average grant-date fair value, RSUs released (in dollars per share) \| $ / shares	145.31
Weighted-average grant-date fair value, RSUs forfeited (in dollars per share) \| $ / shares	140.10
Weighted-average grant-date fair value, outstanding, ending balance (in dollars per share) \| $ / shares	$ 142.13
Weighted-average remaining contractual term, outstanding	1 year 4 months 15 days
Aggregate intrinsic value, outstanding \| $	$ 136,614

Employee Benefit Plans - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Defined Contribution Plan Disclosure [Line Items]
Expenses related to defined contribution plans	$ 6.4	$ 5.5	$ 3.4
Ireland
Defined Contribution Plan Disclosure [Line Items]
Expenses related to defined contribution plans	$ 1.2	1.0	0.8
Defined contribution plans, employer matching percentage of employee's eligible contributions (as a percent)	8.00%
United States
Defined Contribution Plan Disclosure [Line Items]
Expenses related to defined contribution plans	$ 4.2	3.7	1.9
United Kingdom
Defined Contribution Plan Disclosure [Line Items]
Expenses related to defined contribution plans	$ 0.8	0.7	$ 0.6
Defined contribution plans, employer matching percentage of employee's eligible contributions (as a percent)	12.00%
France
Defined Contribution Plan Disclosure [Line Items]
Accrued retirement liability	$ 0.4	0.3
Italy
Defined Contribution Plan Disclosure [Line Items]
Accrued retirement liability	$ 0.3	$ 0.3

Restructuring - Narrative (Details) - One-time Termination Benefits - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017
Restructuring Cost and Reserve [Line Items]
Termination benefit costs incurred		$ 3.0
France, Italy, and the United Kingdom
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 1.5

Restructuring - Schedule of Restructuring (Details) - Termination Benefits - Accrued liabilities - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance	$ 31	$ 1,105
Expense	14	1,516
Payments	(45)	(2,590)
Restructuring reserve, ending balance	$ 0	$ 31

Income Taxes - Components of Income Before Income Tax Provision (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Components of Income from Continuing Operations before Income Tax Provision (Benefit)
Ireland	$ 170,666	$ 77,476	$ 179,570
United States	294,621	271,440	312,904
Other	64,176	92,201	39,972
Income before income tax provision (benefit) and equity in loss of investees	$ 529,463	$ 441,117	$ 532,446

Income Taxes - Details of Income Tax Provision (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Current
Ireland	$ 33,431	$ 28,045	$ 26,420
United States	95,143	135,608	140,061
Other	40,403	14,198	9,918
Total current tax expense	168,977	177,851	176,399
Deferred, exclusive of other components below
Ireland	(12,408)	(19,709)	(7,776)
United States	(41,337)	(27,559)	(9,120)
Other	(34,545)	(19,108)	(13,720)
Total deferred, exclusive of other components	(88,290)	(66,376)	(30,616)
Deferred, change in tax rates
United States	(538)	(155,679)	109
Other	13	(3,536)	(10,656)
Total deferred, change in tax rates	(525)	(159,215)	(10,547)
Total deferred tax benefit	(88,815)	(225,591)	(41,163)
Total income tax provision (benefit)	$ 80,162	$ (47,740)	$ 135,236

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended			12 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2012
Operating Loss Carryforwards [Line Items]
Tax Cuts and Jobs Act of 2017 - change in tax rate, provisional income tax benefit				$ (5,900)	$ (155,100)
Tax Cuts and Jobs Act of 2017 - provisional transition tax expense				2,900	6,300
Tax Cuts And Jobs Act of 2017 - provisional transition tax benefit				(10,300)
Tax Cuts and Jobs Act of 2017 - net expense (benefit) of the impacts	$ (10,300)	$ 2,900	$ (148,800)	(7,500)	(148,800)
Tax Cuts and Jobs Act of 2017 - provisional deferred tax asset related to deductibility of certain executive compensation			7,500		7,500
Income tax provision (benefit)				$ 80,162	$ (47,740)	$ 135,236
Effective income tax rate (as a percent)				15.10%	(10.80%)	25.40%
Tax Cuts and Jobs Act of 2017 - effective income tax rate excluding impact of the U.S. Tax Act (as a percent)					33.70%
Statutory income tax rate (as a percent)				12.50%	12.50%	12.50%
Increase (decrease) in valuation allowance				$ 9,100	$ (1,000)	$ 19,200
Deferred tax assets, valuation allowance	61,237		52,144	61,237	52,144
Cumulated unremitted earnings of overseas subsidiaries	1,200,000		1,700,000	1,200,000	1,700,000
Unrecognized tax benefits, accrued interest and penalties	6,300		3,600	6,300	3,600
Unrecognized tax benefits that would impact the effective tax rate	78,500		$ 73,500	$ 78,500	$ 73,500
Ireland
Operating Loss Carryforwards [Line Items]
Statutory income tax rate (as a percent)				12.50%	12.50%	12.50%
U.S. Federal
Operating Loss Carryforwards [Line Items]
NOL carryforwards	324,800			$ 324,800
Tax credit carryforwards	137,300			137,300
U.S. Federal \| 2019
Operating Loss Carryforwards [Line Items]
Annual limitation on utilization of certain acquired federal NOLs	445,600			445,600
U.S. Federal \| 2020
Operating Loss Carryforwards [Line Items]
Annual limitation on utilization of certain acquired federal NOLs	27,800			27,800
U.S. Federal \| 2021 to 2032
Operating Loss Carryforwards [Line Items]
Annual limitation on utilization of certain acquired federal NOLs	283,200			283,200
U.S. Federal \| EUSA Pharma Acquisition
Operating Loss Carryforwards [Line Items]
NOL carryforwards							$ 53,600
U.S. Federal \| Celator Pharmaceuticals, Inc.
Operating Loss Carryforwards [Line Items]
NOL carryforwards						$ 211,500
U.S. State
Operating Loss Carryforwards [Line Items]
NOL carryforwards	83,500			83,500
Tax credit carryforwards	12,700			12,700
Foreign Tax Authorities
Operating Loss Carryforwards [Line Items]
Increase (decrease) in valuation allowance				25,700
Tax credit carryforwards	8,700			8,700
Foreign Tax Authorities \| Luxembourg
Operating Loss Carryforwards [Line Items]
NOL carryforwards	80,200			80,200
Foreign Tax Authorities \| United Kingdom
Operating Loss Carryforwards [Line Items]
NOL carryforwards	$ 51,900			51,900
Valuation Allowance, Operating Loss Carryforwards
Operating Loss Carryforwards [Line Items]
Increase (decrease) in valuation allowance				11,200	$ (6,600)	$ (17,900)
Tax Cuts And Jobs Act Of 2017, Foreign Tax Credits
Operating Loss Carryforwards [Line Items]
Increase (decrease) in valuation allowance					5,900
Utilization Of NOL Carryforwards Which Previously Carried Valuation Allowance
Operating Loss Carryforwards [Line Items]
Increase (decrease) in valuation allowance					$ (9,100)
Tax Year 2012 And 2013 \| French Tax Authorities
Operating Loss Carryforwards [Line Items]
Proposed additional tax including interest and penalties				43,000
Tax Year 2015 \| French Tax Authorities
Operating Loss Carryforwards [Line Items]
Proposed additional tax including interest and penalties				4,000
Her Majesty's Revenue and Customs (HMRC) \| Foreign Tax Authorities
Operating Loss Carryforwards [Line Items]
Increase (decrease) in valuation allowance				$ (10,900)

Income Taxes - Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Effective Income Tax Rate Reconciliation [Abstract]
Statutory income tax rate	12.50%	12.50%	12.50%
Foreign income tax rate differential	11.90%	20.30%	16.70%
Investment in subsidiaries	(5.30%)	(0.70%)	(2.40%)
Financing costs	(4.30%)	(5.60%)	(2.90%)
Research and other tax credits	(3.90%)	(2.60%)	(2.80%)
Change in valuation allowance	3.20%	(2.80%)	(0.10%)
Impact of U.S. Tax Act	(1.40%)	(33.70%)	0.00%
Non-deductible compensation	1.20%	2.60%	1.80%
Change in unrecognized tax benefits	1.10%	2.80%	3.30%
Change in estimates	(1.10%)	(2.10%)	0.00%
Non-deductible loss contingency	0.80%	0.00%	0.00%
Excess tax benefits from share-based compensation	(0.40%)	(1.50%)	(1.50%)
Change in tax rate	(0.10%)	(0.40%)	(1.80%)
Acquisition-related costs	0.00%	0.00%	2.10%
Other	0.90%	0.40%	0.50%
Effective income tax rate	15.10%	(10.80%)	25.40%

Income Taxes - Schedule of Net Deferred Tax Assets/(Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Net operating loss carryforwards	$ 106,128	$ 125,966
Tax credit carryforwards	156,242	130,782
Intangible assets	23,469	23,536
Share-based compensation	24,592	23,128
Accruals	57,575	45,088
Indirect effects of unrecognized tax benefits	34,349	29,733
Investment in subsidiaries	25,585	0
Other	51,175	63,235
Total deferred tax assets	479,115	441,468
Valuation allowance	(61,237)	(52,144)
Net deferred tax assets	417,878	389,324
Deferred tax liabilities:
Intangible assets	(595,746)	(655,347)
Other	(73,350)	(82,890)
Total deferred tax liabilities	(669,096)	(738,237)
Net deferred tax liabilities	$ (251,218)	$ (348,913)

Income Taxes - Current and Non-current Deferred Assets/(Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Deferred tax assets	$ 57,879	$ 35,154	$ 34,559
Deferred tax liabilities	(309,097)	$ (386,586)	(383,472)
Net deferred tax liabilities	$ (251,218)		$ (348,913)

Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits
Balance at the beginning of the year	$ 106,162	$ 90,910	$ 66,385
Increases related to current year tax positions	22,649	27,875	26,873
Increases related to prior year tax positions	7,584	1,620	1,191
Decreases related to prior year tax positions	0	(1,075)	(255)
Lapse of the applicable statute of limitations	(18,182)	(13,168)	(3,284)
Balance at the end of the year	$ 118,213	$ 106,162	$ 90,910

Subsequent Event - Narrative (Details) $ in Thousands		1 Months Ended	12 Months Ended
Subsequent Event - Narrative (Details) $ in Thousands	Jan. 02, 2019 USD ($) product target	Jan. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Subsequent Event [Line Items]
Upfront and milestone payments paid			$ 0	$ 85,000	$ 23,750
Milestone payment not yet paid			$ 226,616	$ 198,442	$ 162,297
Codiak Biosciences Inc \| Subsequent Event
Subsequent Event [Line Items]
Number of targets \| target	5
Number of projects subject to right to co-commercialize \| product	2
Upfront Payment \| Codiak Biosciences Inc \| Subsequent Event
Subsequent Event [Line Items]
Upfront and milestone payments paid		$ 56,000
Forecast \| Preclinical Development Milestone Payment \| Codiak Biosciences Inc \| Subsequent Event
Subsequent Event [Line Items]
Milestone payment not yet paid	$ 20,000
Forecast \| Milestone Payment \| Codiak Biosciences Inc \| Subsequent Event
Subsequent Event [Line Items]
Milestone payment not yet paid	$ 200,000

Quarterly Financial Data (Unaudited) - Schedule Of Interim Financial Information Presents Results Of Operations On Quarterly Basis (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Revenues	$ 476,457	$ 469,373	$ 500,479	$ 444,613	$ 436,399	$ 411,855	$ 394,386	$ 376,053
Gross margin	440,997	438,623	461,381	406,928	404,847	376,768	360,983	348,613
Net income	$ 159,470	$ 149,316	$ 92,321	$ 45,991	$ 232,207	$ 63,526	$ 105,604	$ 86,511	$ 447,098	$ 487,848	$ 396,831
Net income per ordinary share, basic (in dollars per share)	$ 2.69	$ 2.47	$ 1.53	$ 0.77	$ 3.87	$ 1.06	$ 1.76	$ 1.44	$ 7.45	$ 8.13	$ 6.56
Net income per ordinary share, diluted (in dollars per share)	$ 2.64	$ 2.41	$ 1.50	$ 0.75	$ 3.79	$ 1.03	$ 1.72	$ 1.41	$ 7.30	$ 7.96	$ 6.41
Estimated loss contingency				$ 57,000
Impairment charges and disposal costs			$ 44,000
Upfront and milestone payments expense				$ 11,000	$ 26,500	$ 75,000
Legal proceedings and restructuring expense								$ 6,000
Tax Cuts and Jobs Act of 2017 - net expense (benefit) of the impacts	$ (10,300)	$ 2,900			$ (148,800)				$ (7,500)	$ (148,800)

Schedule II Valuation and Qualifying Accounts - (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Allowance for doubtful accounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	$ 396	$ 287	$ 489
Additions charged to costs and expenses	20	231	168
Other Additions	0	0	0
Deductions	(366)	(122)	(370)
Balance at end of period	50	396	287
Allowance for sales discounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	103	118	181
Additions charged to costs and expenses	811	1,087	1,334
Other Additions	0	0	0
Deductions	(838)	(1,102)	(1,397)
Balance at end of period	76	103	118
Allowance for chargebacks
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	3,663	4,749	3,023
Additions charged to costs and expenses	41,387	41,941	41,991
Other Additions	0	0	0
Deductions	(44,642)	(43,027)	(40,265)
Balance at end of period	408	3,663	4,749
Deferred tax asset valuation allowance
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	52,144	53,184	33,949
Additions charged to costs and expenses	35,500	7,509	19,328
Other Additions	0	5,581	5,544
Deductions	(26,407)	(14,130)	(5,637)
Balance at end of period	$ 61,237	$ 52,144	$ 53,184